<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004094.pub2" GROUP_ID="ENDOC" ID="126702051321195105" MERGED_FROM="" MODIFIED="2008-11-03 12:34:34 +0100" MODIFIED_BY="Gudrun Paletta" REVIEW_NO="PR07" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2008-11-03 12:34:34 +0100" MODIFIED_BY="Gudrun Paletta">
<TITLE>Long-term pharmacotherapy for obesity and overweight</TITLE>
<CONTACT MODIFIED="2008-11-03 12:34:34 +0100" MODIFIED_BY="Gudrun Paletta"><PERSON ID="14725" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Raj</FIRST_NAME><MIDDLE_INITIALS>S</MIDDLE_INITIALS><LAST_NAME>Padwal</LAST_NAME><EMAIL_1>rpadwal@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>2E3.22 WMHSC</DEPARTMENT><ORGANISATION>University of Alberta Hospital</ORGANISATION><CITY>Edmonton, AB</CITY><ZIP>T6G 2B7</ZIP><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 780 4077290</PHONE_1><FAX_1>+1 780 4072680</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-03 12:34:34 +0100" MODIFIED_BY="Gudrun Paletta"><PERSON ID="14725" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Raj</FIRST_NAME><MIDDLE_INITIALS>S</MIDDLE_INITIALS><LAST_NAME>Padwal</LAST_NAME><EMAIL_1>rpadwal@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>2E3.22 WMHSC</DEPARTMENT><ORGANISATION>University of Alberta Hospital</ORGANISATION><CITY>Edmonton, AB</CITY><ZIP>T6G 2B7</ZIP><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 780 4077290</PHONE_1><FAX_1>+1 780 4072680</FAX_1></ADDRESS></PERSON><PERSON ID="D9DCE1D082E26AA201079724FB0F30A5" ROLE="AUTHOR"><FIRST_NAME>Diana</FIRST_NAME><LAST_NAME>Rucker</LAST_NAME><POSITION>Fellow</POSITION><EMAIL_1>drucker@ualberta.ca</EMAIL_1><ADDRESS><DEPARTMENT>Internal Medicine </DEPARTMENT><ORGANISATION>University of Alberta</ORGANISATION><ADDRESS_1>8440-112 St</ADDRESS_1><CITY>Edmonton, AB</CITY><ZIP>T6G 2B7</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 180 4078153</PHONE_1><FAX_1>+1 180 4072680</FAX_1></ADDRESS></PERSON><PERSON ID="14697" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Stephanie</FIRST_NAME><MIDDLE_INITIALS>K</MIDDLE_INITIALS><LAST_NAME>Li</LAST_NAME><EMAIL_1>skli20@yahoo.ca</EMAIL_1><ADDRESS><DEPARTMENT>Internal Medicine (PGY4)</DEPARTMENT><ORGANISATION>University of Alberta </ORGANISATION><ADDRESS_1>10820-85 Ave</ADDRESS_1><CITY>Edmonton, AB</CITY><ZIP>T6E 2L1 </ZIP><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 780 9891842</PHONE_1><PHONE_2>+1 780 4452212</PHONE_2></ADDRESS></PERSON><PERSON ID="C30FDE5A82E26AA2016B340A33BEA8EB" ROLE="AUTHOR"><FIRST_NAME>Cintia</FIRST_NAME><LAST_NAME>Curioni</LAST_NAME><POSITION>Assistant Professor</POSITION><EMAIL_1>c_curioni@uol.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Instituto de Medicina Social</DEPARTMENT><ORGANISATION>Universidade do Estado do Rio de Janeiro</ORGANISATION><ADDRESS_1>Rua São Francisco Xavier, 524 / 7º andar / bloco D - Maracanã</ADDRESS_1><CITY>Rio de Janeiro</CITY><ZIP>20559-900</ZIP><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 21 2548-3616</PHONE_1><FAX_1>+55 21 2548-3616</FAX_1></ADDRESS></PERSON><PERSON ID="14692" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>David</FIRST_NAME><MIDDLE_INITIALS>CW</MIDDLE_INITIALS><LAST_NAME>Lau</LAST_NAME><POSITION>Professor of Medicine, Biochemistry &amp; Molecular Biology</POSITION><EMAIL_1>dcwlau@ucalgary.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>University of Calgary</ORGANISATION><ADDRESS_1>2501-3330 Hospital Drive NW</ADDRESS_1><CITY>Calgary</CITY><ZIP>T2N 4N1</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 403 220 2261</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-03 12:17:14 +0100" MODIFIED_BY="Gudrun Paletta">
<UP_TO_DATE>
<DATE DAY="24" MONTH="12" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="24" MONTH="12" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="24" MONTH="2" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2003"/>
</DATES>
<WHATS_NEW MODIFIED="2008-11-01 15:44:08 +0100" MODIFIED_BY="Gudrun Paletta">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="1" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-11-01 15:43:59 +0100" MODIFIED_BY="Gudrun Paletta">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-11-01 15:43:59 +0100" MODIFIED_BY="Gudrun Paletta">
<DATE DAY="14" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>This is an update of the Cochrane review first published in issue 4, 2003. Major changes include:<BR/>The previous search included head-to-head clinical trials but, due to the length of this review and large number of placebo-controlled studies, the decision was made to focus on placebo-controlled trials only.<BR/>
<BR/>
<BR/>In contrast to the previous version of this review we analysed separately published weight loss and weight maintenance trials together.<BR/>
<BR/>From the date of the last search (December 2002) to December 2006, 29 potentially relevant trials were identified and five orlistat, five sibutramine and four rimonabant studies met final inclusion criteria. These were added to the 11 orlistat and five sibutramine trials previously identified.<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Department of Medicine, University of Alberta</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-03 12:32:27 +0100" MODIFIED_BY="Gudrun Paletta">
<SUMMARY MODIFIED="2008-11-03 12:23:42 +0100" MODIFIED_BY="Gudrun Paletta">
<TITLE MODIFIED="2008-11-03 12:23:42 +0100" MODIFIED_BY="Gudrun Paletta">Long-term drug pharmacotherapy for obesity and overweight</TITLE>
<SUMMARY_BODY>
<P>This review assessed the long-term benefits and risks of approved anti-obesity drugs in clinical trials of 1 to 4 years duration. Sixteen orlistat (10,631 patients), 10 sibutramine (2623 patients) and four rimonabant (6635 patients) studies were examined. High drop-out rates (30% to 40%) were a limitation of nearly all studies. Compared to placebo, all three drugs reduced weight by around five kg or less and orlistat reduced the number of high-risk patients who developed diabetes. No data to show that any of the three drugs lowers the risk of death or cardiovascular disease were found. The most prominent side effects were gastrointestinal for orlistat, cardiovascular for sibutramine (raised blood pressure and/or pulse rate) and psychiatric for rimonabant (mood disorders). In Europe, rimonabant is contraindicated for patients with severe depression and/or patients who are treated with antidepressive medications. Rimonabant is furthermore not recommended for patients with other untreated psychiatric conditions.<BR/>We conclude that: 1. average weight losses with current anti-obesity agents appear modest but may be of clinical benefit, and 2. better studies designed to examine mortality and cardiovascular morbidity are required to fully evaluate any potential benefit of such agents.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-11-03 12:23:07 +0100" MODIFIED_BY="Gudrun Paletta">
<ABS_BACKGROUND>
<P>Obesity is a highly and increasingly prevalent chronic condition for which drugs are commonly prescribed to improve health. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the long-term effects of approved anti-obesity medications in clinical trials of at least one-year duration. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>MEDLINE, EMBASE, <I>The Cochrane Library</I>, the Current Science Meta-register of Controlled Trials and reference lists were searched. Drug manufacturers and two obesity experts were contacted. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Double-blind, randomised placebo-controlled trials of approved anti-obesity agents that 1) included patients over 18 years, 2) used an intention-to-treat analysis, and 3) had follow-up of one year or more. Both weight loss and weight maintenance trials were included. Abstracts, pseudo-randomised trials, head-to-head trials and open-label studies were excluded.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-11-03 12:16:12 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Two reviewers independently assessed all potentially relevant reports for inclusion and methodological quality. Data were extracted using double data entry. The primary outcome measure was weight loss.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-11-03 12:23:07 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Sixteen orlistat (n = 10,631), 10 sibutramine (n = 2623) and four rimonabant trials (n = 6365) met inclusion criteria. Attrition rates averaged 30% to 40%. Compared to placebo, orlistat reduced weight by 2.9 kg (95% confidence interval (CI) 2.5 to 3.2 kg), sibutramine by 4.2 kg (95% CI 3.6 to 4.7 kg), and rimonabant by 4.7 kg (95% CI 4.1 to 5.3 kg). Patients on active drug therapy were significantly more likely to achieve 5% and 10% weight loss thresholds. Placebo-controlled weight losses were consistently lower in patients with diabetes. Orlistat reduced diabetes incidence, improved total cholesterol, LDL-cholesterol, blood pressure, and glycaemic control in patients with diabetes but increased rates of gastrointestinal side effects and slightly lowered HDL levels. Sibutramine improved HDL and triglyceride levels but raised blood pressure and pulse rate. Rimonabant improved HDL-cholesterol, triglyceride and blood pressure levels and glycaemic control in patients with diabetes but increased the risk of mood disorders.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Orlistat, sibutramine and rimonabant have been studied in trials of one year or longer. Internal validity of studies was limited by high attrition rates. All three antiobesity agents are modestly effective in reducing weight and have differing effects on cardiovascular risk and adverse effects profiles. Longer and more methodologically rigorous studies of anti-obesity drugs that are powered to examine endpoints such as mortality and cardiovascular morbidity are required. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-03 12:30:41 +0100" MODIFIED_BY="Gudrun Paletta">
<BACKGROUND MODIFIED="2008-11-03 12:26:35 +0100" MODIFIED_BY="Gudrun Paletta">
<CONDITION MODIFIED="2008-11-03 12:25:25 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Obesity is a highly and increasingly prevalent chronic condition that is associated with significant morbidity and mortality. Globally, over 300 million individuals are obese and an additional 800 million are overweight (<LINK REF="REF-Haslam-2005" TYPE="REFERENCE">Haslam 2005</LINK>). In many countries, the adult prevalence of obesity has risen above 20% (<LINK REF="REF-IOTF-2007" TYPE="REFERENCE">IOTF 2007</LINK>). In the United States, Eastern Mediterranean, and Pacific Islands, the prevalence ranges from approximately 30% to over 70% (<LINK REF="REF-Flegal-2002" TYPE="REFERENCE">Flegal 2002</LINK>; <LINK REF="REF-IOTF-2007" TYPE="REFERENCE">IOTF 2007</LINK>). Prevalence rises with age and is higher in females and certain ethnic populations, such as American Indians, Hispanic Americans and Pacific Islanders (<LINK REF="REF-Flegal-2002" TYPE="REFERENCE">Flegal 2002</LINK>; <LINK REF="REF-Kopelman-2000" TYPE="REFERENCE">Kopelman 2000</LINK>; <LINK REF="REF-WHO-1998" TYPE="REFERENCE">WHO 1998</LINK>). Obesity and overweight are also becoming a major concern in children and adolescents (<LINK REF="REF-Haslam-2005" TYPE="REFERENCE">Haslam 2005</LINK>; <LINK REF="REF-Ogden-2002" TYPE="REFERENCE">Ogden 2002</LINK>).</P>
<P>In addition to increased total mortality, obesity is associated with a number of chronic conditions including coronary artery disease, stroke, type 2 diabetes, heart failure, dyslipidaemia, hypertension, reproductive and gastrointestinal cancers, gallstones, fatty liver disease, osteoarthritis, and sleep apnea (<LINK REF="REF-Birmingham-1999" TYPE="REFERENCE">Birmingham 1999</LINK>; <LINK REF="REF-Calle-1999" TYPE="REFERENCE">Calle 1999</LINK>; <LINK REF="REF-Kenchaiah-2002" TYPE="REFERENCE">Kenchaiah 2002</LINK>; <LINK REF="REF-Manson-1995" TYPE="REFERENCE">Manson 1995</LINK>; <LINK REF="REF-UTD-2001" TYPE="REFERENCE">UTD 2001</LINK>; <LINK REF="REF-Williamson-1993" TYPE="REFERENCE">Williamson 1993</LINK>). There is also a significant psychosocial stigma associated with being obese (<LINK REF="REF-Bray-1998" TYPE="REFERENCE">Bray 1998</LINK>). In many countries, the economic burden of obesity-related illness is substantial, with estimates ranging from 2% to 7% of total health care expenditures and billions of dollars in direct and indirect costs to society (<LINK REF="REF-Birmingham-1999" TYPE="REFERENCE">Birmingham 1999</LINK>; <LINK REF="REF-Seidell-1996" TYPE="REFERENCE">Seidell 1996</LINK>).</P>
<P>Body mass index (BMI) is the most widely used measurement to quantify degree of overweight and obesity because it is easily calculated (weight in kilograms divided by the square of the height in meters) and available in many epidemiological studies. According to the World Health Organization (WHO) criteria, overweight is defined as a BMI of 25 to 29.9 kg/m<SUP>2</SUP> and obesity as 30 kg/m<SUP>2</SUP> or greater. Obesity is further subdivided into mild (30 to 34.9 kg/m<SUP>2</SUP>), moderate (35 to 39.9 kg/m<SUP>2</SUP>) and severe (40 kg/m<SUP>2</SUP> or greater) categories. Mortality rates and risk of cardiovascular disease rise with increasing degrees of overweight and obesity; marked increases in risk of death occur when BMI levels reach 29 to 30 kg/m<SUP>2</SUP> or greater (<LINK REF="REF-Calle-1999" TYPE="REFERENCE">Calle 1999</LINK>; <LINK REF="REF-Manson-1995" TYPE="REFERENCE">Manson 1995</LINK>; <LINK REF="REF-Stevens-1998" TYPE="REFERENCE">Stevens 1998</LINK>). In non-smokers with BMI levels greater than 40 kg/m<SUP>2</SUP>, the 14-year relative risk of death is 2.6 times higher for men and 2.0 times higher for women compared to non-smokers with BMI levels between 23.5 and 24.9 kg/m<SUP>2</SUP> (<LINK REF="REF-Calle-1999" TYPE="REFERENCE">Calle 1999</LINK>). Obesity is a particularly strong risk factor for the development of type 2 diabetes. Compared to a baseline BMI of less than 22 kg/m<SUP>2</SUP>, a BMI greater than 35 kg/m<SUP>2</SUP> increases the 10-year odds ratio of developing type 2 diabetes by 41 in men and 30 in women (<LINK REF="REF-Field-2001" TYPE="REFERENCE">Field 2001</LINK>). The pattern of fat deposition is also an important prognostic factor, particularly in the elderly, with increased cardiovascular risk observed in those with central or visceral fat accumulation (typically measured by the waist circumference or waist-hip ratio) (<LINK REF="REF-Kissebah-1994" TYPE="REFERENCE">Kissebah 1994</LINK>; <LINK REF="REF-Rexrode-1998" TYPE="REFERENCE">Rexrode 1998</LINK>; <LINK REF="REF-Rimm-1995" TYPE="REFERENCE">Rimm 1995</LINK>; <LINK REF="REF-Visscher-2002" TYPE="REFERENCE">Visscher 2002</LINK>). In fact, central measures of adiposity may be more strongly associated with cardiovascular events than BMI (<LINK REF="REF-INTERHEART-2005" TYPE="REFERENCE">INTERHEART 2005</LINK>).</P>
<P>Before-after case series, cohort studies and randomised controlled trials have demonstrated that weight loss in overweight and obese participants - even as little as 5% to 10% of initial body weight - is associated with an improvement in cardiovascular risk factors (<LINK REF="REF-Blackburn-1995" TYPE="REFERENCE">Blackburn 1995</LINK>; <LINK REF="REF-Colditz-1995" TYPE="REFERENCE">Colditz 1995</LINK>; <LINK REF="REF-Goldstein-1992" TYPE="REFERENCE">Goldstein 1992</LINK>; <LINK REF="REF-Wadden-1993" TYPE="REFERENCE">Wadden 1993</LINK>) and a reduction in the incidence of type 2 diabetes in high-risk individuals (<LINK REF="REF-DPP-2002" TYPE="REFERENCE">DPP 2002</LINK>). Cohort studies examining the relationship between weight loss and long-term mortality have shown mixed results (<LINK REF="REF-Andres-1993" TYPE="REFERENCE">Andres 1993</LINK>; <LINK REF="REF-Williamson-1993" TYPE="REFERENCE">Williamson 1993</LINK>). Many studies have failed to distinguish between voluntary and involuntary weight loss or fat loss and overall weight loss. Those studies making such distinctions have generally found that voluntary weight loss or fat loss in overweight or obese participants leads to decreased mortality rates (<LINK REF="REF-Allison-1999" TYPE="REFERENCE">Allison 1999</LINK>; <LINK REF="REF-French-1999" TYPE="REFERENCE">French 1999</LINK>; <LINK REF="REF-Williamson-1995" TYPE="REFERENCE">Williamson 1995</LINK>). To date, no randomised controlled trial has been performed that confirms these findings, although studies examining hard cardiovascular endpoints and mortality are underway ( <LINK REF="REF-Look-AHEAD" TYPE="REFERENCE">Look AHEAD</LINK>; <LINK REF="REF-Padwal-2007" TYPE="REFERENCE">Padwal 2007</LINK>).</P>
<P>Non-pharmacological methods of obesity therapy, which include dietary modification, exercise and behavioural modification, have demonstrated short-term effectiveness. Unfortunately, long-term recidivism rates are high (<LINK REF="REF-NIH-1993" TYPE="REFERENCE">NIH 1993</LINK>) and effectiveness is also limited by a compensatory slowing of the metabolic rate (<LINK REF="REF-Leibel-1995" TYPE="REFERENCE">Leibel 1995</LINK>). Surgical procedures such as gastric bypass and banding have the greatest long-term success rates (approximately 20% weight loss after ten years) but are currently indicated only for the very obese (BMI greater than 40 kg/m<SUP>2</SUP> or BMI 35 to 40 kg/m<SUP>2</SUP> with an obesity-related disorder) (<LINK REF="REF-SOS-2004" TYPE="REFERENCE">SOS 2004</LINK>). Operative mortality rates are generally less than one percent in appropriate patients and high-volume centres, but long-term gastrointestinal adverse effects and other complications may occur (<LINK REF="REF-Greenway-2000" TYPE="REFERENCE">Greenway 2000</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2008-11-03 12:26:35 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Obesity guidelines currently recommend that drug therapy be considered for patients with a BMI greater than or equal to 30 kg/m<SUP>2</SUP> or a BMI of 27 to 30 kg/m<SUP>2</SUP> with one or more obesity-related disorders (<LINK REF="REF-Lau-D-2007" TYPE="REFERENCE">Lau D 2007</LINK>; <LINK REF="REF-Lau-DC-2007" TYPE="REFERENCE">Lau DC 2007</LINK>; <LINK REF="REF-Padwal-2007" TYPE="REFERENCE">Padwal 2007</LINK>; <LINK REF="REF-US-Guidelines-1998" TYPE="REFERENCE">US Guidelines 1998</LINK>). Drugs should be used in conjunction with non-pharmacological therapy. Approved anti-obesity medications can be divided into three broad categories:<BR/>1. Inhibitors of intestinal fat absorption. Orlistat, a drug that inhibits pancreatic and other lipases, is the only agent currently available in this class. Side effects are related to malabsorption of fat within the gastrointestinal tract and include steatorhea, bloating, and oily discharge. Fecal incontinence and malabsorption of fat-soluble vitamins, such as vitamin A, D, E, and K, have also been reported (<LINK REF="REF-McNeely-1998" TYPE="REFERENCE">McNeely 1998</LINK>).<BR/>2. Medications that act to suppress appetite, increase satiety, or increase thermogenesis, primarily by modifying central nervous system neurotransmission of norepinephrine, dopamine and serotonin. This category includes sibutramine, phentermine, mazindol, diethylpropion, benzphetamine, phendimetrazine, fenfluramine, and dexfenfluramine. The latter two agents have been associated with a higher risk of cardiac valvulopathy and pulmonary hypertension and are no longer available (<LINK REF="REF-Abenhaim-1996" TYPE="REFERENCE">Abenhaim 1996</LINK>; <LINK REF="REF-Connolly-1997" TYPE="REFERENCE">Connolly 1997</LINK>; <LINK REF="REF-Jick-1998" TYPE="REFERENCE">Jick 1998</LINK>;<LINK REF="REF-Khan-1998" TYPE="REFERENCE">Khan 1998</LINK>; <LINK REF="REF-Weissman-1998" TYPE="REFERENCE">Weissman 1998</LINK>).<BR/>Sibutramine, which inhibits re-uptake of serotonin and norepinephrine, is the most widely used agent in this category and primarily acts to suppress appetite. The most common adverse effects of sibutramine are related to increased adrenergic activity and include dry mouth, headache, insomnia, and constipation (<LINK REF="REF-Luque-1999" TYPE="REFERENCE">Luque 1999</LINK>). Sibutramine may also cause increases in blood pressure and heart rate. Potential concerns regarding cardiac arrhythmias and cardiac mortality have been raised and the drug has been reviewed by several regulatory agencies and deemed safe to remain on the market (<LINK REF="REF-Health-Canada-2002" TYPE="REFERENCE">Health Canada 2002</LINK>; <LINK REF="REF-Wooltorton-2002" TYPE="REFERENCE">Wooltorton 2002</LINK>).<BR/>3. Inhibitors of the endocannabinoid system. Rimonabant, the first of this class of drugs, is approved in the European Union and other countries. Rimonabant acts by both central and peripheral mechanisms to reduce food intake and body weight (<LINK REF="REF-Padwal-2007" TYPE="REFERENCE">Padwal 2007</LINK>). An increased incidence of mood disorders is the major adverse effect. In Europe, rimonabant is contraindicated for patients with severe depression and/or patients who are treated with antidepressive medications; it is not recommended for patients with other untreated psychiatric conditions.</P>
<P>Orlistat, sibutramine and rimonabant are the three medications approved for long-term use.</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2008-11-03 12:19:22 +0100" MODIFIED_BY="Gudrun Paletta">
<P>It has been suggested that obesity be considered a chronic illness requiring long-term therapy similar to hypertension or dyslipidaemia (<LINK REF="REF-Bray-2000" TYPE="REFERENCE">Bray 2000</LINK>; <LINK REF="REF-NTF-1994" TYPE="REFERENCE">NTF 1994</LINK>). The majority of randomised-controlled trials (RCTs) evaluating anti-obesity medications have been of short duration. However, short-term efficacy is clearly a sub-optimal endpoint, especially if most patients regain weight over the long term when therapy is stopped. A meta-analysis of 108 primarily short-term studies published up to December 1999 found that average antiobesity drug-induced weight losses compared to placebo were modest, never exceeding four kg for any one agent (<LINK REF="REF-Haddock-2002" TYPE="REFERENCE">Haddock 2002</LINK>).</P>
<P>This review of obesity pharmacotherapy focuses on 'long-term' studies, which we define as one-year or greater. For a chronic illness like obesity, it is more relevant to evaluate drug efficacy over the long-term. In addition, since weight losses achieved with lifestyle intervention are modest and recidivism rates are high (<LINK REF="REF-Lau-2007" TYPE="REFERENCE">Lau 2007</LINK>; <LINK REF="REF-Lau-DC-2007" TYPE="REFERENCE">Lau DC 2007</LINK>), there is potential for even greater use of drug therapy, particularly given rising obesity prevalence rates. It is also important to determine if the modest weight reductions associated with drug therapy translate into a reduced cardiovascular morbidity, cardiovascular mortality and overall mortality. In addition, it is important to quantify the degree of improvement in cardiovascular risk factors (that is blood pressure, lipid profiles and glycaemic control) reported with antiobesity drug therapy.</P>
<P>This review represents an update of a previous Cochrane review (<LINK REF="REF-Padwal-2003" TYPE="REFERENCE">Padwal 2003</LINK>). Major changes can be inspected in <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>.</P>
<P>Other systematic reviews and Health Technology Assessments in this area may also be of interest to the reader (<LINK REF="REF-Arterburn-2004" TYPE="REFERENCE">Arterburn 2004</LINK>; <LINK REF="REF-Li-2005" TYPE="REFERENCE">Li 2005</LINK>; <LINK REF="REF-Norris-2005" TYPE="REFERENCE">Norris 2005</LINK>; <LINK REF="REF-O_x0027_Meara-2001" TYPE="REFERENCE">O'Meara 2001</LINK>; <LINK REF="REF-O_x0027_Meara-2002" TYPE="REFERENCE">O'Meara 2002</LINK>). A Cochrane review specifically on rimonabant has also recently been published (<LINK REF="REF-Curioni-2006" TYPE="REFERENCE">Curioni 2006</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-11-01 15:56:28 +0100" MODIFIED_BY="Gudrun Paletta">
<P>To assess the effects of Long-term pharmacotherapy for obesity and overweight.</P>
<SUBSECTION>
<HEADING LEVEL="2">Primary Objective</HEADING>
<P>In placebo-controlled clinical trials of at least one year duration, to determine the efficacy of single or combination anti-obesity drug therapy in reducing weight, cardiovascular morbidity (stroke, myocardial infarction), cardiovascular mortality and overall mortality.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Secondary Objectives</HEADING>
<P>In placebo-controlled clinical trials of at least one year duration, to determine:</P>
<UL>
<LI>The efficacy of antiobesity drugs in reducing waist circumference and body mass index (BMI) levels.</LI>
<LI>The impact of antiobesity drug therapy on cardiovascular risk factors. These include blood pressure, lipid parameters and glycaemic control.</LI>
<LI>The efficacy of anti-obesity drug therapy in reducing weight and improving glycaemic control in patients with type 2 diabetes.</LI>
<LI>The major adverse events associated with each antiobesity agent.</LI>
</UL>
</SUBSECTION>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-03 12:27:15 +0100" MODIFIED_BY="Gudrun Paletta">
<SELECTION_CRITERIA MODIFIED="2008-11-03 12:27:15 +0100" MODIFIED_BY="Gudrun Paletta">
<CRIT_STUDIES>
<P>Only double-blind (blinding of participants and care providers) RCTs of anti-obesity agents were considered for inclusion. Quasi-randomised, open-label, and cross-over trials were not included. Studies had to 1) enroll overweight or obese patients (defined below), 2) include a placebo control group, 3) report an intention-to-treat analysis and 4) have a minimum follow-up period of one year (from the point of randomizations). Studies published in abstract form only were not included. No language or publication restrictions were applied. Previously, our search included head-to-head clinical trials but, due to the length of this review and large number of placebo-controlled studies, the decision was made to focus on placebo-controlled trials only.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Adults (age 18 or over) with either:<BR/>
</P>
<UL>
<LI>body mass index (BMI) 30 kg/m<SUP>2</SUP> or greater;</LI>
<LI>BMI 27 kg/m<SUP>2</SUP> or greater plus one or more obesity-related co-morbidity.</LI>
</UL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Weight loss and weight maintenance studies evaluating the pharmacologic therapy of obesity including the following medications: sibutramine, phentermine, mazindol, diethylpropion, benzphetamine, phendimetrazine, benzocaine rimonabant and orlistat. <BR/>Drugs excluded from this review include off-label therapy (e.g. fluoxetine, sertraline, bupropion, topiramate, metformin), those with high addiction potentials that preclude long-term use (amphetamine/dexamphetamine and methamphetamine), investigational/herbal/alternative compounds, and drugs withdrawn from the market due to unacceptable side effect profiles (fenfluramine, dexfenfluramine, phenylpropanolamine).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-11-03 12:27:15 +0100" MODIFIED_BY="Gudrun Paletta">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-11-01 15:58:10 +0100" MODIFIED_BY="Gudrun Paletta">
<UL>
<LI>weight loss, expressed as number of kilograms lost, percentage of baseline weight lost, or both.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-11-01 15:58:14 +0100" MODIFIED_BY="Gudrun Paletta">
<UL>
<LI>weight loss expressed as the proportion of patients achieving 5% and 10% weight loss (5% and 10% responders), change in BMI and change in waist circumference;</LI>
<LI>total and cardiovascular mortality;</LI>
<LI>myocardial infarction (fatal and nonfatal);</LI>
<LI>stroke (fatal and nonfatal);</LI>
<LI>medication intolerance (percentage withdrawn from therapy due to adverse events);</LI>
<LI>change in blood pressure;</LI>
<LI>change in lipid profile (total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, triglycerides);</LI>
<LI>change in glycosylated haemoglobin concentration (Hb A1C);</LI>
<LI>side effects of therapy.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-01 16:00:24 +0100" MODIFIED_BY="Gudrun Paletta">
<ELECTRONIC_SEARCHES MODIFIED="2008-11-01 16:00:24 +0100" MODIFIED_BY="Gudrun Paletta">
<UL>
<LI>
<I>The Cochrane Library </I>(issue 4, 2006);</LI>
<LI>MEDLINE (until December Week 3, 2006);</LI>
<LI>EMBASE (until week 51, 2006);</LI>
<LI>metaRegister of Controlled Trials (www.controlled-trials.com; until December 2006).</LI>
</UL>
<P>
<BR/>Electronic searches were performed with the aid of a medical librarian. Search strategy available upon request.</P>
<P>The described search strategy (see for a detailed search strategy under <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) were used for MEDLINE. For use with EMBASE, The Cochrane Library and the other databases this strategy will be slightly adapted.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-11-01 15:58:51 +0100" MODIFIED_BY="Gudrun Paletta">
<UL>
<LI>reference lists of original studies, narrative reviews and systematic reviews;</LI>
<LI>drug manufacturers and two experts in the field of obesity were contacted in an effort to identify unpublished studies.</LI>
</UL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-11-01 16:43:18 +0100" MODIFIED_BY="Gudrun Paletta">
<STUDY_SELECTION MODIFIED="2008-11-01 16:01:16 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Two reviewers (RP or DR) performed electronic searches and screened the initial results. Articles that clearly did not meet the inclusion criteria were rejected on initial review. If uncertainty existed, the full text of the article was reviewed. Two reviewers (RP and SL or DR) independently assessed all potentially relevant studies for inclusion using pre-designed data abstraction forms. Disagreements were resolved by consensus. Reviewers were not blinded to the journal, author, or institution of publication. Inter-rater agreement was assessed using Cohen's kappa coefficient (<LINK REF="REF-Cohen-1960" TYPE="REFERENCE">Cohen 1960</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-11-01 16:01:25 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Two reviewers (RP or SL/DR) independently extracted and recorded data. Discrepancies were rechecked twice more. Data not presented in written form were extrapolated from graphs if possible. If the published article provided inadequate information for a given endpoint, the primary author was contacted by e-mail at least twice. An additional request was made to the pharmaceutical company if data elements were still missing.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-11-01 16:01:38 +0100" MODIFIED_BY="Gudrun Paletta">
<P>The Verhagen Delphi list for quality assessment of RCTs was used as a guide to assess study quality (<LINK REF="REF-Verhagen-1998" TYPE="REFERENCE">Verhagen 1998</LINK>) and was independently judged by two authors (RP and SL or DR). The nine criteria are as follows:<BR/>1. Was a method of randomizations performed?<BR/>2. Was the treatment allocation concealed?<BR/>3. Were the groups similar at baseline regarding the most important prognostic indicators?<BR/>4. Were the eligibility criteria specified?<BR/>5. Was the outcome assessor blinded?<BR/>6. Was the care provider blinded?<BR/>7. Was the patient blinded?<BR/>8. Were point estimates and measures of variability presented for the primary outcome variables?<BR/>9. Did the analysis include an intention-to-treat analysis (ITT)?</P>
<P>The assessment of ITT analysis included an assessment of the study attrition rate (<LINK REF="REF-Hollis-1999" TYPE="REFERENCE">Hollis 1999</LINK>) for the primary endpoint of weight loss . Although an acceptable attrition rate is difficult to define and depends both on the study and outcome in question, to conveniently define a specific threshold, we arbitrarily deemed an attrition rate of less than 15% per study arm as acceptable. We have reported methodological quality in a descriptive fashion rather than using a numeric quality score, as such scores can be inaccurate and poorly reproducible when used to differentiate between high and low quality studies (<LINK REF="REF-Juni-2001" TYPE="REFERENCE">Juni 2001</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2008-11-01 16:01:51 +0100" MODIFIED_BY="Gudrun Paletta">
<P>We calculated a risk difference for dichotomous outcomes and a weighted mean difference for continuous outcomes. This calculation was performed using data at the end of follow-up for each individual study.</P>
<P>Two different types of study designs are generally used in obesity pharmacotherapy - so called 'weight loss' and 'weight maintenance' studies. The latter type of study examines the impact of the drug on weight after a weight loss induction phase that uses a low or very-low calorie diet. This induction phase typically lasts between 1 to 6 months and is performed in all patients. Weight maintenance studies consistently tend to include the weight losses achieved during the induction phase in the overall weight changes reported for each study arm. Because randomization typically occurs after the induction phase and the weight loss achieved during this phase, when reported, appears equivalent between study arms, the effect of this practice on the overall placebo-subtracted mean difference in weight tends to be negligible. In addition, many weight loss trials included a short 'run-in' phase during which patients are treated with placebo and diet. This is performed to either stratify randomizations by the degree of weight loss achieved during the run-in phase or exclude patients not able to achieve a predefined amount of weight. Accordingly, this practice blurs the distinction between weight loss and weight maintenance trials. Therefore, in contrast to our previous version of this review (<LINK REF="REF-Padwal-2003" TYPE="REFERENCE">Padwal 2003</LINK>), we analysed separately published weight loss and weight maintenance trials together.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2008-11-01 16:43:18 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Quantitative analyses of outcomes were based on intention-to-treat (ITT) results. In studies with high attrition rates, we preferentially abstracted results reported in a last-observation-carried-forward (LOCF) fashion, in which the last observation on record was used as a surrogate for the final value. This is a commonly reported, more conservative analysis than an analysis involving completers only. When quantitative pooling was not possible or deemed inappropriate, results were presented in narrative fashion.</P>
<P>If studies reported mean baseline and mean final values in the control or intervention groups (with associated standard errors or deviations), but did not report the standard deviation associated with this difference, we computed this as follows (for the control and intervention arms separately):<BR/>1. We took the difference between mean final and mean initial measurements as the mean change in the variable (delta V).<BR/>2. The standard deviation (SD) associated with change in delta V was calculated using the following formula: square root of [(SDpre)<SUP>2 </SUP>+ (SDpost)<SUP>2</SUP> - 2r(SDpre*SDpost)], where SDpre was the standard deviation of the mean baseline measurement, SDpost was the standard deviation of the mean follow-up measurement, and was the correlation between the baseline and follow-up values. As studies did not report r, and its true value is unknown (ranging between 0 and 1), we used 0.5 as an estimation of its value. We tested this assumption by performing sensitivity analyses on the outcomes of systolic blood pressure, total cholesterol, and fasting glucose using 0.25 and 0.75 as values for r.</P>
<P>If the study reported only the mean change in a variable for the treatment and control groups and its associated P-value, we computed the standard deviations for delta V for each study arm by assuming that both study arms had equal variances. If the P-value was reported as less than a certain value, we used 1/100 less than that value as a conservative estimate of the true P-value. For example, if the reported P-value was less than 0.01, we estimated the true P-value to be 0.0099. Z-scores were estimated by assuming a normal distribution. If the sample size of the study arm was less than 100, we assumed a t-distribution instead of a normal distribution.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2008-11-01 16:02:36 +0100" MODIFIED_BY="Gudrun Paletta">
<P>A chi-squared test for heterogeneity was performed and the I<SUP>2</SUP> statistic calculated for each outcome. A random-effects model was preferentially used, partly to incorporate any observed heterogeneity among trials. If the I<SUP>2 </SUP>statistic demonstrated significant heterogeneity (over 50%), we did not quantitatively pool the results unless the observed statistical heterogeneity was judged to be of little clinical relevance (that is clinically insignificant between-study differences and consistently concordant results across studies).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2008-11-01 16:02:52 +0100" MODIFIED_BY="Gudrun Paletta">
<P>If the number of studies was greater than 10 for a given drug, a funnel plot was used to assess for small study bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-11-01 16:02:26 +0100" MODIFIED_BY="Gudrun Paletta">
<P>A random-effects model was employed using the RevMan 4.2.9 program.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-11-01 16:03:07 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Planned subgroup analyses (for cardiovascular morbidity/mortality endpoints and weight loss) included:<BR/>
</P>
<UL>
<LI>patients with type 2 diabetes;</LI>
<LI>body mass index (BMI) strata (less than 30 kg/m<SUP>2</SUP>, 30 to 34.9 kg/m<SUP>2</SUP>, 35 to 39.9 kg/m<SUP>2</SUP>, 40 kg/m<SUP>2</SUP> or greater);</LI>
<LI>patients at high cardiovascular risk (that is known cardiovascular disease or risk factors).</LI>
</UL>
<P>
<BR/>If significant statistical heterogeneity was present <U>and</U> deemed clinically significant, we planned to assess the impact of study size, study length, baseline BMI and baseline cardiovascular risk on this heterogeneity. In the absence of individual patient data, we knew a priori that meta-regression analysis would not be possible.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-11-01 16:03:20 +0100" MODIFIED_BY="Gudrun Paletta">
<P>We performed separate analyses using a fixed-effect model and by varying the correlation coefficient r (as noted above).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-03 12:30:41 +0100" MODIFIED_BY="Gudrun Paletta">
<STUDY_DESCRIPTION MODIFIED="2008-11-03 12:28:00 +0100" MODIFIED_BY="Gudrun Paletta">
<SEARCH_RESULTS MODIFIED="2008-11-03 12:28:00 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Search results are summarized in the Quality of Reporting of Meta-analyses (QUORUM) flow diagram (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="REF-Moher-1999" TYPE="REFERENCE">Moher 1999</LINK>). From the date of the last search (December 2002) to December 2006, 27 potentially relevant trials were identified and five orlistat, five sibutramine and four rimonabant studies met final inclusion criteria. These were added to the 11 orlistat and five sibutramine trials previously identified. Cohen's kappa coefficient for inter-rater agreement measured 0.95 for trial selection and 0.85 for study quality.</P>
<SUBSECTION>
<HEADING LEVEL="4">Orlistat</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Population and setting</HEADING>
<P>The 16 trials included 10 631 participants with an average body mass index (BMI) of 36.3 kg/m<SUP>2</SUP>, weight of 104 kg, and age of 47 years ( <LINK REF="STD-Bakris-2002" TYPE="STUDY">Bakris 2002</LINK>; <LINK REF="STD-Berne-2004" TYPE="STUDY">Berne 2004</LINK>; <LINK REF="STD-Broom-2002" TYPE="STUDY">Broom 2002</LINK>; <LINK REF="STD-Davidson-1999" TYPE="STUDY">Davidson 1999</LINK>; <LINK REF="STD-Derosa-2003" TYPE="STUDY">Derosa 2003</LINK>; <LINK REF="STD-Finer-2000" TYPE="STUDY">Finer 2000</LINK>; <LINK REF="STD-Hauptman-2000" TYPE="STUDY">Hauptman 2000</LINK>; <LINK REF="STD-Hollander-1998" TYPE="STUDY">Hollander 1998</LINK>; <LINK REF="STD-Kelley-2002" TYPE="STUDY">Kelley 2002</LINK>; Krempf 2003; <LINK REF="STD-Lindgarde-2000" TYPE="STUDY">Lindgarde 2000</LINK>; <LINK REF="STD-Miles-2002" TYPE="STUDY">Miles 2002</LINK>; <LINK REF="STD-Rossner-2000" TYPE="STUDY">Rossner 2000</LINK>; <LINK REF="STD-Sjostrom-1998" TYPE="STUDY">Sjostrom 1998</LINK>; <LINK REF="STD-Swinburn-2005" TYPE="STUDY">Swinburn 2005</LINK>; <LINK REF="STD-XENDOS" TYPE="STUDY">XENDOS</LINK>). Study size ranged from 50 to 3305 participants, 66% of whom were female and 89% Caucasian. The country of origin for each study is listed in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>Nine studies limited enrolment to higher risk populations: four recruited patients with type 2 diabetes on stable doses of oral hypoglycaemic agents or insulin (<LINK REF="STD-Berne-2004" TYPE="STUDY">Berne 2004</LINK>; <LINK REF="STD-Hollander-1998" TYPE="STUDY">Hollander 1998</LINK>; <LINK REF="STD-Kelley-2002" TYPE="STUDY">Kelley 2002</LINK>; <LINK REF="STD-Miles-2002" TYPE="STUDY">Miles 2002</LINK>) and five enrolled obese patients with at least one cardiovascular risk factor (hypertension, dyslipidaemia, type 2 diabetes, or impaired glucose tolerance) (<LINK REF="STD-Bakris-2002" TYPE="STUDY">Bakris 2002</LINK>; <LINK REF="STD-Broom-2002" TYPE="STUDY">Broom 2002</LINK>; <LINK REF="STD-Derosa-2003" TYPE="STUDY">Derosa 2003</LINK>; <LINK REF="STD-Lindgarde-2000" TYPE="STUDY">Lindgarde 2000</LINK>; <LINK REF="STD-Swinburn-2005" TYPE="STUDY">Swinburn 2005</LINK>). In the XENDOS trial, the largest study, 21% of patients had impaired glucose tolerance (<LINK REF="STD-XENDOS" TYPE="STUDY">XENDOS</LINK>).</P>
<P>Exclusion criteria common to most studies were obesity of endocrine origin, uncontrolled hypertension, treatment with drugs affecting body weight, pregnant or lactating women, women of childbearing potential not on contraceptives, significant psychiatric or medical illness, previous bariatric surgery, and weight loss of greater than 3 to 4 kg in the three months prior to screening.</P>
<P>Most trials included a single-blind, placebo run-in phase, which varied in duration from 2 to 5 weeks and many required a compliance rate of 75% or greater during the run-in phase before randomizations into the actual trial.</P>
<P>The four orlistat weight maintenance studies represented continuations of weight loss trials in which patients were placed on a weight maintenance diet during their second year (<LINK REF="STD-Davidson-1999" TYPE="STUDY">Davidson 1999</LINK>; <LINK REF="STD-Hauptman-2000" TYPE="STUDY">Hauptman 2000</LINK>; <LINK REF="STD-Rossner-2000" TYPE="STUDY">Rossner 2000</LINK>; <LINK REF="STD-Sjostrom-1998" TYPE="STUDY">Sjostrom 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Interventions</HEADING>
<P>The dose of orlistat used in all trials was 120 mg tid, which is the standard dose recommended for use in clinical practice. Two studies also included 60 mg tid study arms, showing efficacy and tolerability that was intermediate between that of placebo and 120 mg tid study arms (<LINK REF="STD-Hauptman-2000" TYPE="STUDY">Hauptman 2000</LINK>; <LINK REF="STD-Rossner-2000" TYPE="STUDY">Rossner 2000</LINK>). The remainder of this review will focus on results obtained using 120 mg tid dosage regimen.</P>
<P>A standardized, low fat (less than 30% of caloric intake), hypocaloric diet and encouragement to exercise were the main co-interventions (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). A typical diet derived 30% of calories from fat, 50% from carbohydrates, and 20% from protein, with maximum cholesterol content of 300 mg/day.</P>
<P>During the second year of weight maintenance, diets differed between trials but, in general, were increased by approximately 200 to 300 kcal/day in those patients still losing weight and remained unaltered in those patients in whom weight remained stable. At the beginning of the weight maintenance phase, patients in the orlistat group were re-randomised to receive placebo, 60 mg tid and 120 mg tid in one study (<LINK REF="STD-Davidson-1999" TYPE="STUDY">Davidson 1999</LINK>). In a second study, all patients completing year one were re-randomised to orlistat 120 mg tid or placebo (<LINK REF="STD-Sjostrom-1998" TYPE="STUDY">Sjostrom 1998</LINK>). In the final two studies, patients remained in the same groups to which they were assigned during year one (orlistat 60 mg, 120 mg and placebo) (<LINK REF="STD-Hauptman-2000" TYPE="STUDY">Hauptman 2000</LINK>; <LINK REF="STD-Rossner-2000" TYPE="STUDY">Rossner 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Outcomes</HEADING>
<P>Fourteen trials reported weight change as the primary outcome. This was commonly reported as the percentage of baseline weight lost, absolute number of kilograms lost and the percentage of patients losing 5% and 10% of initial body weight. In the remaining two trials, diabetes incidence (<LINK REF="STD-XENDOS" TYPE="STUDY">XENDOS</LINK>) and change in the Framingham cardiovascular risk score (<LINK REF="STD-Swinburn-2005" TYPE="STUDY">Swinburn 2005</LINK>) were the primary endpoints. Other commonly reported outcomes included change in cholesterol, fasting glucose and blood pressure levels and gastrointestinal side effects.</P>
<P>Total mortality, cardiovascular morbidity, and cardiovascular mortality were not reported as outcomes in any of the trials. Other endpoints are summarized in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sibutramine</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Population and setting</HEADING>
<P>The 10 sibutramine studies included 2623 participants (range 86 to 485) with an average BMI of 35.1 kg/m<SUP>2</SUP>, weight of 97 kg, and age of 45 years (see table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). Seven weight loss trials (<LINK REF="STD-Hauner-2004" TYPE="STUDY">Hauner 2004</LINK>; <LINK REF="STD-McMahon-2000" TYPE="STUDY">McMahon 2000</LINK>; <LINK REF="STD-McMahon-2002" TYPE="STUDY">McMahon 2002</LINK>; <LINK REF="STD-McNulty-2003" TYPE="STUDY">McNulty 2003</LINK>; <LINK REF="STD-Sanchez_x002d_Reyes-2004" TYPE="STUDY">Sanchez-Reyes 2004</LINK>; <LINK REF="STD-Smith-2001" TYPE="STUDY">Smith 2001</LINK>) and three weight maintenance trials (<LINK REF="STD-Apfelbaum-1999" TYPE="STUDY">Apfelbaum 1999</LINK>; <LINK REF="STD-James-2000" TYPE="STUDY">James 2000</LINK>; <LINK REF="STD-Mathus_x002d_Vliegen-2005" TYPE="STUDY">Mathus-Vliegen 2005</LINK>) were identified, with follow-up periods for the randomizations phase ranging between 1 to 1.5 years. Seventy-three percent of the participants were female and 95% were Caucasian. Most non-Caucasian participants came from two trials, in which 26% of participants were African American (<LINK REF="STD-McMahon-2000" TYPE="STUDY">McMahon 2000</LINK>; <LINK REF="STD-McMahon-2002" TYPE="STUDY">McMahon 2002</LINK>). Two studies limited enrolment to hypertensive patients with controlled blood pressure (<LINK REF="STD-McMahon-2000" TYPE="STUDY">McMahon 2000</LINK>; <LINK REF="STD-McMahon-2002" TYPE="STUDY">McMahon 2002</LINK>) and three enrolled patients with type 2 diabetes (<LINK REF="STD-Kaukua-2003" TYPE="STUDY">Kaukua 2003</LINK>; <LINK REF="STD-McNulty-2003" TYPE="STUDY">McNulty 2003</LINK>; <LINK REF="STD-Sanchez_x002d_Reyes-2004" TYPE="STUDY">Sanchez-Reyes 2004</LINK>). Exclusion criteria were similar to ones described above for the orlistat studies.</P>
<P>Further details regarding the study populations and settings are reported in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Interventions and outcomes</HEADING>
<P>The dose of sibutramine ranged between 10 to 20 mg, with the most common dose being 15 mg. If results for both 15 and 20 mg arms were reported, we used the 15 mg results because the 20 mg dose is no longer used. Dietary modification with or without advice to exercise were common co-interventions.</P>
<P>Four weight loss trials included a single-blind, placebo run-in phase, which varied from 2 to 10 weeks in duration (<LINK REF="STD-McMahon-2000" TYPE="STUDY">McMahon 2000</LINK>; <LINK REF="STD-McMahon-2002" TYPE="STUDY">McMahon 2002</LINK>; <LINK REF="STD-Smith-2001" TYPE="STUDY">Smith 2001</LINK>; <LINK REF="STD-Kaukua-2003" TYPE="STUDY">Kaukua 2003</LINK>). Randomizations were restricted to those participants that could follow dietary advice (<LINK REF="STD-Smith-2001" TYPE="STUDY">Smith 2001</LINK>) or those that achieved 75% compliance during the run-in phase (<LINK REF="STD-McMahon-2000" TYPE="STUDY">McMahon 2000</LINK>).</P>
<P>The weight maintenance studies included initial calorie-restricted induction phases that varied from 1 to 6 months (see table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). Patients able to lose a pre-defined amount of weight entered the randomizations phase of the study.</P>
<P>Specific outcomes for each study are summarized in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and were similar to those presented in orlistat studies. All studies reported either percent or absolute weight loss. Blood pressure and pulse rate were also commonly reported. No data on cardiovascular morbidity or mortality were found. In addition to reporting overall weight loss, the weight maintenance studies reported the proportion of patients achieving successful weight maintenance, defined as maintenance of 80% to 100% of the weight lost during the induction phase.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Rimonabant</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Population and setting</HEADING>
<P>The four rimonabant studies included 6635 participants (range 1036 to 3045) with an average BMI of 36.5 kg/m<SUP>2</SUP>, weight of 102 kg, and age of 48 years (see table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). All studies reported results for a one-year weight loss phase; one study also reported outcomes for a second year of weight maintenance in which rimonabant-treated patients were re-randomised to continue taking rimonabant or switch to placebo (<LINK REF="STD-RIO_x002d_North-America" TYPE="STUDY">RIO-North America</LINK>). Seventy-three percent of the participants were female and 87% were Caucasian.</P>
<P>Further details regarding the study populations and settings are reported in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. One study enrolled patients with dyslipidaemia (<LINK REF="STD-RIO_x002d_Lipids" TYPE="STUDY">RIO-Lipids</LINK>), one enrolled patients with diabetes (<LINK REF="STD-RIO_x002d_Diabetes" TYPE="STUDY">RIO-Diabetes</LINK>), and the other two commonly included patients with dyslipidaemia or hypertension (<LINK REF="STD-RIO_x002d_Europe" TYPE="STUDY">RIO-Europe</LINK>; <LINK REF="STD-RIO_x002d_North-America" TYPE="STUDY">RIO-North America</LINK>). Exclusion criteria were similar to ones described above for the orlistat studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Interventions and outcomes</HEADING>
<P>All studies included a placebo arm, a rimonabant 5 mg arm and a rimonabant 20 mg arm. The 20 mg dose is the one used in clinical practice; therefore all abstracted outcomes reflect this dose. Dietary modification with or without advice to exercise were common co-interventions.</P>
<P>All trials included a 4-week single-blind, placebo run-in phase, and restricted randomizations to those participants completed the run-in phase and were adherent.</P>
<P>Specific outcomes for each study are summarized in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. All studies reported either percent or absolute weight loss. No data on cardiovascular morbidity or mortality were found.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ongoing studies</HEADING>
<P>The major ongoing studies in this area are summarized in the table <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>. CRESCENDO and SCOUT, involving rimonabant and sibutramine, respectively, are the largest antiobesity studies to-date and are designed to evaluate the effect of these agents on cardiovascular morbidity and mortality.</P>
</SUBSECTION>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2008-11-01 16:05:02 +0100" MODIFIED_BY="Gudrun Paletta">
<P>A total of 30 double-blind, placebo-controlled RCTs, including 16 orlistat (n = 10,631), 10 sibutramine (n = 2623) and four rimonabant studies (n = 6635) were included in the final review and are detailed below. Twenty-seven studies were financially supported by the drug manufacturer.</P>
<P>Twenty-seven studies (16 orlistat, seven sibutramine and four rimonabant) were weight loss trials, in which drug therapy was used in conjunction with a weight loss diet for 1 to 4 years. One rimonabant and four orlistat weight loss trials also contained a second weight maintenance year. The three remaining sibutramine trials were weight maintenance studies with follow-up periods of one and 1.5 years from the point of randomizations.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2008-11-01 16:36:52 +0100" MODIFIED_BY="Gudrun Paletta">
<P>The most pertinent excluded trials are summarized in the table <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.The degree of weight loss reported in all excluded studies was similar to that of studies included in this review. No excluded studies examined the effect of a given drug on cardiovascular morbidity or mortality.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-11-03 12:29:51 +0100" MODIFIED_BY="Gudrun Paletta">
<SUBSECTION>
<HEADING LEVEL="3">All studies</HEADING>
<P>Methodological quality is summarized in the corresponding tables of methodological quality for each drug (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>). A "?" in the table indicates that the study did not mention this quality indicator in sufficient detail to confirm that it was done. Studies were all of similar quality.</P>
<SUBSECTION>
<HEADING LEVEL="4">Allocation, blinding and baseline similarity</HEADING>
<P>Eligibility criteria were reported in all studies. In all studies, co-interventions appeared to be equally applied to intervention and control arms. "Double-blinding" was assumed to refer to blinding of patients and blinding of care providers, although this was not explicitly stated in any of the trials. Blinding of outcome assessors was not specifically mentioned in any study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective reporting</HEADING>
<P>Secondary endpoints were inconsistently reported, and sometimes reported in only a subgroup of patients or were not reported in an extractable manner. Given these limitations, our analysis includes only those data which were extractable from a given study. Readers should keep this in mind, as, in particular, studies may have only reported full results for endpoints that significantly differed from placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Follow-up and exclusions</HEADING>
<P>The major methodological limitation was high attrition rates, as detailed below.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3"/>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Orlistat</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Weight loss studies</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Allocation, blinding and baseline similarity</HEADING>
<P>Five trials adequately described methods of randomizations and allocation concealment (<LINK REF="STD-Berne-2004" TYPE="STUDY">Berne 2004</LINK>; <LINK REF="STD-Derosa-2003" TYPE="STUDY">Derosa 2003</LINK>; <LINK REF="STD-Finer-2000" TYPE="STUDY">Finer 2000</LINK>; <LINK REF="STD-Sjostrom-1998" TYPE="STUDY">Sjostrom 1998</LINK>; <LINK REF="STD-XENDOS" TYPE="STUDY">XENDOS</LINK>). The remaining studies merely stated that randomizations was performed without giving further details. Five studies reported baseline similarity from the point of entry into the run-in phase and not from the point of randomizations (<LINK REF="STD-Broom-2002" TYPE="STUDY">Broom 2002</LINK>; <LINK REF="STD-Davidson-1999" TYPE="STUDY">Davidson 1999</LINK>; <LINK REF="STD-Hollander-1998" TYPE="STUDY">Hollander 1998</LINK>; <LINK REF="STD-Krempf--2003" TYPE="STUDY">Krempf 2003</LINK>; <LINK REF="STD-Lindgarde-2000" TYPE="STUDY">Lindgarde 2000</LINK>). In the remaining studies, the groups were similar at baseline. All studies reported point estimates and measures of variability for the primary outcome of weight loss.</P>
<P>In many studies, baseline weight was defined as the weight measured at the beginning of the run-in period, rather than at the point of randomizations. Thus, the absolute change in weight (mean final weight minus mean baseline weight) in both study arms was inflated because weight lost during the run-in period was included in this calculation. However, both study arms lost similar amounts of weight during the run-in phase of each trial. Therefore, the overall mean difference in weight between treatment and control arms was not affected.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Selective reporting</HEADING>
<P>All trials reported some measure of variability for the primary endpoint of weight loss.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Follow-up and exclusions</HEADING>
<P>Only two trials met the definition of true intention-to-treat (ITT) analysis (<LINK REF="STD-Berne-2004" TYPE="STUDY">Berne 2004</LINK>; <LINK REF="STD-Derosa-2003" TYPE="STUDY">Derosa 2003</LINK>); the remaining 14 studies reported attrition rates of over 20% (range for all studies 0% to 66%; approximate average for all 16 trials was 30%). In the largest and longest trial, nearly 60% of patients dropped out over the four year follow-up period (<LINK REF="STD-XENDOS" TYPE="STUDY">XENDOS</LINK>). The most common reasons for premature withdrawal were treatment refusal, loss to follow-up, and adverse effects.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Weight maintenance studies</HEADING>
<P>Patients entering year two of the study already represented a highly select population because of the high attrition rates observed during the first year of each study. For example, in the two trials that did not re-randomise patients, only 52% and 60% of patients were followed for the full two years (<LINK REF="STD-Hauptman-2000" TYPE="STUDY">Hauptman 2000</LINK>; <LINK REF="STD-Rossner-2000" TYPE="STUDY">Rossner 2000</LINK>). A last-observation-carried-forward (LOCF) ITT analysis was again used in the weight loss maintenance phase of each trial. No study reported the baseline characteristics of patients entering the second year of the trial.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3"/>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sibutramine</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Allocation, blinding and baseline similarity</HEADING>
<P>Three of ten trials reported methods of randomizations and allocation concealment in adequate detail (<LINK REF="STD-James-2000" TYPE="STUDY">James 2000</LINK>; ; <LINK REF="STD-Mathus_x002d_Vliegen-2005" TYPE="STUDY">Mathus-Vliegen 2005</LINK>; <LINK REF="STD-Smith-2001" TYPE="STUDY">Smith 2001</LINK>). Study groups were similar at baseline in all studies. Two studies included weight loss achieved during the 6-month run-in phase in the analysis (<LINK REF="STD-James-2000" TYPE="STUDY">James 2000</LINK>; <LINK REF="STD-Mathus_x002d_Vliegen-2005" TYPE="STUDY">Mathus-Vliegen 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective reporting</HEADING>
<P>One trial did not provide any measures of variability for weight loss (<LINK REF="STD-McMahon-2000" TYPE="STUDY">McMahon 2000</LINK>). We were able to obtain this from the drug manufacturer.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Follow-up and exclusions</HEADING>
<P>Similar to the orlistat studies described above, all trials reported a LOCF ITT analysis for weight loss. Attrition rates were high in nine of ten studies (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>), ranging from 11% to 51% per study arm and averaging almost 40%. Therefore, only one study was deemed to have fully met criteria for a true ITT analysis (that is an acceptable drop-out rate) (<LINK REF="STD-Kaukua-2003" TYPE="STUDY">Kaukua 2003</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3"/>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Rimonabant</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Allocation, blinding and baseline similarity</HEADING>
<P>Two of four trials reported methods of randomizations and allocation concealment in adequate detail (<LINK REF="STD-RIO_x002d_Diabetes" TYPE="STUDY">RIO-Diabetes</LINK>; <LINK REF="STD-RIO_x002d_Europe" TYPE="STUDY">RIO-Europe</LINK>). Study groups were similar at baseline in all studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective reporting</HEADING>
<P>All trials reported some measure of variability for the primary endpoint of weight loss.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Follow-up and exclusions</HEADING>
<P>Similar to orlistat and sibutramine studies, all trials reported a LOCF ITT analysis for weight loss. Attrition rates were high in all studies (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>), ranging from 32% to 49% per study arm and averaging 40%. Therefore, no study was deemed to fully meet criteria for a true ITT analysis (that is an acceptable drop-out rate).</P>
</SUBSECTION>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-11-03 12:30:41 +0100" MODIFIED_BY="Gudrun Paletta">
<SUBSECTION>
<HEADING LEVEL="3">General comments</HEADING>
<P>The number of patients included in a given endpoint analysis may be lower than the overall number of patients studied and varies according to study attrition rates, lack of endpoint reporting, and our ability to abstract data for that endpoint. The <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> contains a list of the endpoints reported for each study. If an endpoint is reported in this table but is not included in the meta-analysis section, it is because the endpoint was not reported in an extractable manner or was not reported in a manner that facilitated inclusion (e.g., reported as an on-treatment rather than an intention-to-treat result or reported only in a subset of patients).</P>
<P>Studies did not report results by body mass index (BMI) strata. Therefore, this analysis was not performed.</P>
<P>The results of our two sensitivity analyses (using a fixed-effect model and by varying the correlation coefficient r) were essentially identical to the main results and, for the sake of brevity, are not detailed below.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Heterogeneity</HEADING>
<P>Statistical heterogeneity (I<SUP>2</SUP> of 50% or greater) was present in several anthropometric outcomes but was not judged to be clinically relevant (see Methods section). Substantial statistical heterogeneity was also present when analysing the effects of orlistat and rimonabant on glycaemic control in patients with and without diabetes. For orlistat, this heterogeneity was attenuated and did not appear clinically relevant when limiting pooling to patients with diabetes alone. For rimonabant, glycaemic control results are reported only for the single trial involving patients with type 2 diabetes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3"/>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Orlistat</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Body weight</HEADING>
<P>All sixteen studies reported greater reductions in weight in the orlistat group compared to the placebo group. Orlistat-treated patients lost 2.9 kg (95% confidence interval (CI) 2.5 to 3.2 kg; 15 studies) or 2.9% (95% CI 2.5 to 3.4%; 13 studies) more weight than placebo-treated patients. Placebo-subtracted absolute weight losses were slightly greater in patients with lower baseline cardiovascular (CV) risk (3.0 kg, 95% CI 2.4 to 3.6 kg; 7 studies) compared to patients with higher baseline risk (2.8 kg, 95% CI 2.4 to 3.1 kg; 8 studies). Similar results were obtained for percentage weight loss as the outcome: 3.4% (95% CI 2.8 to 4.0%; 6 studies) for lower risk patients versus 2.7% (95% CI 2.1 to 3.3%; 7 studies) for higher risk patients.</P>
<P>In patients with diabetes, orlistat reduced weight by 2.6% (95% CI 2.2 to 3.1%; 5 studies) or 2.3 kg (95% CI 1.6 to 3.0 kg; 4 studies) compared to placebo therapy (<LINK REF="STD-Berne-2004" TYPE="STUDY">Berne 2004</LINK>; <LINK REF="STD-Hollander-1998" TYPE="STUDY">Hollander 1998</LINK>; <LINK REF="STD-Kelley-2002" TYPE="STUDY">Kelley 2002</LINK>; <LINK REF="STD-Lindgarde-2000" TYPE="STUDY">Lindgarde 2000</LINK>; <LINK REF="STD-Miles-2002" TYPE="STUDY">Miles 2002</LINK>).</P>
<P>All trials reported that a greater percentage of participants in the orlistat group achieved 5% and 10% weight loss compared to placebo. Pooling results from 14 trials showed that 21% (95% CI 18% to 24%) more participants in the orlistat group achieved 5% weight loss. Pooled data from 13 studies demonstrated that 12% (95% CI 9% to 14%) more orlistat-treated patients achieved 10% weight loss.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Waist circumference and body mass index</HEADING>
<P>Orlistat significantly reduced waist circumference (2.1 cm, 95% CI 1.3 to 2.9 cm; 9 studies) and BMI (1.1 kg/m<SUP>2</SUP>, 95% CI 0.7 to 1.4 kg/m<SUP>2</SUP> ; 3 studies) compared to placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blood pressure</HEADING>
<P>Orlistat resulted in placebo-subtracted systolic blood pressure reductions of 1.5 mm Hg (95% CI 0.9 to 2.2 mm Hg; 13 studies) and diastolic blood pressure reductions of 1.4 mm Hg (95% CI 0.7 to 2.0 mm Hg; 12 studies).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Glycaemic parameters</HEADING>
<P>Orlistat reduced the incidence of type 2 diabetes from 9.0% to 6.2% (hazard ratio 0.63, 95% CI 0.46 to 0.86) in the <LINK REF="STD-XENDOS" TYPE="STUDY">XENDOS</LINK> trial (<LINK REF="STD-XENDOS" TYPE="STUDY">XENDOS</LINK>). This benefit was primarily observed in the patients with impaired glucose tolerance at baseline.</P>
<P>In trials that included patients with and without diabetes, orlistat reduced fasting glucose levels by 0.1 to 0.5 mmol/L (statistically significant in 4 of 6 studies). In patients with diabetes, orlistat reduced fasting glucose and Hb A1C levels by 1.0 mmol/L (95% CI 0.6 mmol/L to 1.5 mmol/L; 5 studies) and 0.4% (95% CI 0.2 to 0.6%; 5 studies), respectively.</P>
<P>A more detailed analysis of obesity pharmacotherapy in patients with type 2 diabetes is provided in a separate Cochrane review (<LINK REF="REF-Norris-2005" TYPE="REFERENCE">Norris 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Lipid parameters</HEADING>
<P>Compared to placebo, orlistat reduced total cholesterol levels by 0.32 mmol/L (95% CI 0.28 to 0.37 mmol/L; 13 studies), LDL-cholesterol levels by 0.26 mmol/L (95% CI 0.22 to 0.30 mmol/L; 13 studies) and HDL cholesterol levels by 0.03 mmol/L (95% CI 0.02 to 0.04 mmol/L; 11 studies). The change in triglyceride levels were not significantly different from placebo (-0.03 mmol/L, 95% CI +0.07 mmol/L to -0.12 mmol/L; 11 studies).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Change in Framingham risk score</HEADING>
<P>One study evaluated the effect of orlistat on the change in Framingham cardiovascular risk score and found nearly identical changes to that of placebo with no significant difference between study arms (<LINK REF="STD-Swinburn-2005" TYPE="STUDY">Swinburn 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Orlistat weight maintenance studies</HEADING>
<P>During the weight maintenance phase of each study, both orlistat and placebo study arms showed similar amounts of weight regain, but the weight differential observed after the weight loss phase was preserved. Changes in serum lipids and glucose values during the weight maintenance phase were similar to those described for the weight loss phase of each trial (<LINK REF="STD-Hauptman-2000" TYPE="STUDY">Hauptman 2000</LINK>; <LINK REF="STD-Rossner-2000" TYPE="STUDY">Rossner 2000</LINK>; <LINK REF="STD-Sjostrom-1998" TYPE="STUDY">Sjostrom 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects</HEADING>
<P>Gastrointestinal (GI) events were the predominant side effect associated with orlistat therapy. The categorization of outcomes and detail of reporting of GI adverse events varied between trials. Over 80% of orlistat-treated patients experienced at least one GI side effect, with an absolute frequency that was 24% (95% CI 20% to 29%; 14 studies) higher than patients on placebo. The most commonly reported GI events were fatty/oily stool, fecal urgency and oily spotting, each occurring at frequency rates of 15% to 30% in most studies. Approximately 5% of orlistat-treated patients discontinued therapy due to GI side effects, which was 2% (95% CI 1% to 3%; 12 studies) higher than patients taking placebo.</P>
<P>Fecal incontinence was a reported side effect of orlistat therapy but only three trials reported this complication as a separate endpoint (<LINK REF="STD-Hauptman-2000" TYPE="STUDY">Hauptman 2000</LINK>; <LINK REF="STD-Rossner-2000" TYPE="STUDY">Rossner 2000</LINK>; <LINK REF="STD-Sjostrom-1998" TYPE="STUDY">Sjostrom 1998</LINK>), with an incidence rate of 7%. This was 6% (95% CI 5% to 8%) higher than the frequency of fecal incontinence in patients on placebo. Levels of fat-soluble vitamins (A, D, E) and beta-carotene were reportedly lowered by orlistat therapy, with vitamin D the most frequently affected (<LINK REF="STD-Finer-2000" TYPE="STUDY">Finer 2000</LINK>; <LINK REF="STD-Hauptman-2000" TYPE="STUDY">Hauptman 2000</LINK>; <LINK REF="STD-Hollander-1998" TYPE="STUDY">Hollander 1998</LINK>; <LINK REF="STD-Sjostrom-1998" TYPE="STUDY">Sjostrom 1998</LINK>). However, no study reported the occurrence of clinically significant vitamin deficiency, although patients were routinely advised to take a multivitamin pill daily.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3"/>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sibutramine</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Weight loss</HEADING>
<P>Patients on sibutramine therapy lost 4.2 kg (95% CI 3.6 to 4.7 kg; 8 studies) or 4.3% (95% CI 3.7% to 5.0%; 10 studies) more weight than those taking placebo. Placebo-subtracted weight loss for patients at higher CV risk was 4.3 kg (95% CI 3.6 to 5.0 kg; 5 studies) or 4.5% (95% CI 3.8 to 5.2%; 5 studies). Corresponding values for lower risk patients were 4.0 kg (95% CI 3.0 to 5.0 kg; 5 studies) or 3.9% (95% CI 2.1% to 5.7%; 3 studies). In addition, sibutramine treatment increase the frequency of successful 5% responders by 32% (95% CI 27% to 37%; 7 studies) and 10% responders by 18% (95% CI 11% to 25%; 7 studies) compared to placebo.</P>
<P>In patients with diabetes, sibutramine reduced weight by 5.0% (95% CI 3.8 to 6.2%; 3 studies) or 4.9 kg (95% CI 3.6 kg to 6.2 kg; 3 studies) compared to placebo therapy (<LINK REF="STD-Kaukua-2003" TYPE="STUDY">Kaukua 2003</LINK>; <LINK REF="STD-McNulty-2003" TYPE="STUDY">McNulty 2003</LINK>; <LINK REF="STD-Sanchez_x002d_Reyes-2004" TYPE="STUDY">Sanchez-Reyes 2004</LINK>).</P>
<P>The three weight maintenance studies reported that 10% to 30% more sibutramine-treated patients achieved successful weight maintenance compared to placebo (successful weight maintenance defined as maintaining 80% to 100% of the initial weight loss). This achieved statistical significance (P&lt;0.05) in all three studies (<LINK REF="STD-Apfelbaum-1999" TYPE="STUDY">Apfelbaum 1999</LINK>; <LINK REF="STD-James-2000" TYPE="STUDY">James 2000</LINK>; <LINK REF="STD-Mathus_x002d_Vliegen-2005" TYPE="STUDY">Mathus-Vliegen 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Waist circumference and body mass index</HEADING>
<P>Sibutramine-treated patients demonstrated placebo-subtracted reductions in BMI of 1.5 kg/m<SUP>2</SUP> (95% CI 1.3 kg/m<SUP>2</SUP> to 1.8 kg/m<SUP>2</SUP>; 5 studies) and waist circumference by 4.0 cm (95% CI 3.3 cm to 4.7 cm; 8 studies).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Glycaemic parameters</HEADING>
<P>Overall, changes in glycaemic parameters were inconsistently reported and, when reported, were not significantly different from placebo in any study even in patients with diabetes. Data were commonly not reported in an extractable format, which limited quantitative pooling.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Lipid parameters</HEADING>
<P>Compared to placebo, sibutramine increased HDL cholesterol levels by 0.04 mmol/L (95% CI 0.01 to 0.08 mmol/L; 5 studies) and reduced triglyceride levels by 0.18 mmol/L (95% CI 0.07 to 0.30 mmol/L; 4 studies).</P>
<P>Data for total cholesterol and LDL-cholesterol were not consistently reported or extractable in the majority of studies. Placebo-subtracted changes in these two endpoints were not statistically significant in any study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Blood pressure and pulse rate</HEADING>
<P>Sibutramine increased systolic blood pressure by 1.7 mm Hg (95% CI 0.1 to 3.3 mm Hg; 7 studies), diastolic blood pressure by 2.4 mm Hg (95% CI 1.5 to 3.3 mm Hg; 7 studies) and pulse rate by 4.5 beats/min (95% CI 3.5 to 5.6 beats/min; 7 studies) compared to placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other adverse effects</HEADING>
<P>Insomnia, nausea, dry mouth, and constipation were more common in patients on sibutramine therapy, occurring at frequency rates of 7% to 20%.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3"/>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Rimonabant</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Weight loss</HEADING>
<P>Patients on rimonabant therapy lost 4.7 kg (95% CI 4.1 to 5.3 kg; 4 studies) more weight than those taking placebo. All studies enrolled patients with cardiovascular risk factors; therefore, sensitivity analysis according to baseline CV risk was not performed. Rimonabant treatment increased the number of 5% weight-loss responders by 33% (95% CI 29% to 37%; 4 studies) and 10% responders by 19% (95% CI 15% to 23%; 7 studies) compared to placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Waist circumference</HEADING>
<P>Rimonabant reduced waist circumference by 3.9 cm (95% CI 3.3 to 4.5 cm; 4 studies) compared to placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blood pressure</HEADING>
<P>Rimonabant reduced placebo-subtracted systolic blood pressure by 1.8 mm Hg (95% CI 0.8 to 2.8 mm Hg; 3 studies) and diastolic blood pressure by 1.2 mm Hg (95% CI 0.5 to 1.9 mm Hg; 3 studies) more than placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Glycaemic parameters</HEADING>
<P>Fasting glucose levels were reduced in <LINK REF="STD-RIO_x002d_Diabetes" TYPE="STUDY">RIO-Diabetes</LINK> by 1 mmol/L (95% CI 0.6 to 1.3 mmol/L) and haemoglobin A1C levels reduced by 0.7% (95% CI 0.6 to 0.8). When reported, no clinically or statistically significant reductions were demonstrated in the other studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Lipid parameters</HEADING>
<P>Compared to placebo, rimonabant increased HDL cholesterol levels by 0.1 mmol/L (95% CI 0.08 to 0.11 mmol/L; 4 studies) and reduced triglyceride levels by 0.24 mmol/L (95% CI 0.17 to 0.30 mmol/L; 4 studies). Non-significant changes in LDL (-0.05 mmol/L, 95% CI -0.12 to +0.01 mmol/L; 4 studies) and total cholesterol (-0.04 mmol/L, 95% CI -0.11 to +0.03; 4 studies) levels were demonstrated after quantitative pooling of data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects</HEADING>
<P>The frequency of serious adverse effects was 6% in rimonabant-treated patients, which was 2% (95% CI 0% to 3%; 4 studies) higher than those taking placebo. Fourteen percent of patients on rimonabant discontinued therapy due to adverse events, which was 6% (95% CI 5% to 8%; 4 studies) greater than placebo. The most concerning adverse effect was an increased incidence of psychiatric disorders (depression, anxiety, irritability, aggression), which occurred in 6% of patients receiving rimonabant and was 3% (95% CI 2% to 5%; 4 studies) more likely in patients receiving rimonabant compared to placebo.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-11-01 16:14:01 +0100" MODIFIED_BY="Gudrun Paletta">
<P>In summary, meta-analysis of long-term RCTs involving orlistat, sibutramine and rimonabant demonstrates that each drug results in average placebo-subtracted weight reductions of approximately 5 kg or less. No data on the effect of these agents on mortality or cardiovascular morbidity were found. Weight maintenance studies for each agent report similar amounts of weight regain in both active treatment and placebo study arms, such that the original weight differential between groups is maintained. Orlistat reduces total cholesterol, LDL-cholesterol, blood pressure, diabetes incidence and improves glycaemic control but increases the risk of gastrointestinal side effects and slightly lowers HDL levels. Sibutramine improves HDL-cholesterol and triglyceride levels but increases blood pressure and pulse rate. Rimonabant improves HDL, triglyceride and blood pressure levels and glycemic control in patients with diabetes but increases the risk of mood disorders.</P>
<P>Previous studies have demonstrated that weight loss is more difficult to achieve in patients with diabetes, possibly because of the underlying disease state or because medications used to treat diabetes tend to increase weight (<LINK REF="REF-Wing-1987" TYPE="REFERENCE">Wing 1987</LINK>). We found that studies enrolling patients with diabetes reported slightly smaller amounts of weight loss with orlistat and rimonabant therapy, a finding that was not seen with sibutramine therapy. Despite this finding, both orlistat and rimonabant improved glycaemic parameters in patients with diabetes whereas sibutramine did not. The underlying reasons for and the clinical significance of these findings are unclear. One potential contributor to improved glycaemic control with rimonabant therapy is an increase in adiponectin levels (<LINK REF="STD-RIO_x002d_North-America" TYPE="STUDY">RIO-North America</LINK>). Further data are needed, ideally from head-to-head clinical trials of all three agents, before more definitive conclusions can be made.</P>
<P>High attrition rates in both treatment and control groups compromise the internal validity of many studies. Authors attempt to address this limitation by using a last-observation-carried-forward (LOCF) analysis. Such an analysis can bias results in either direction, depending on the differential dropout rates in treatment and control arms and the reasons for withdrawal. It is difficult to compensate for such high attrition rates by using any form of analysis. Bias may be introduced into the results of these studies, and should be kept in mind when interpreting the results of this review. A recent study using administrative data from British Columbia, Canada found poor persistence rates with orlistat and sibutramine in a 'real world' setting (<LINK REF="REF-Padwal-R-2007" TYPE="REFERENCE">Padwal R 2007</LINK>). In nearly 3500 users of sibutramine and 17,000 users of orlistat, persistence rates at one year were less than 10% and at two years, less than 2%. Overall, data from within and outside of the clinical trial setting suggest that a lack of adherence to therapy is a major limiting factor to the efficacy and effectiveness of antiobesity drug therapy.</P>
<P>Gastrointestinal side effects were the predominant side effect of orlistat therapy, with most studies reporting that side effects were mild and transient and decreased as patients adjusted to a low fat diet. However, high study attrition rates may reflect a differential drop-out of patients unable to tolerate the medication and may partly explain the improved tolerance of patients remaining in the study.</P>
<P>The increase in blood pressure and heart rate observed with sibutramine therapy are of potential concern, particularly on a population-wide basis where even mild increases in blood pressure can be expected to result in an increase in cardiovascular events in a population already at risk. A small rise blood pressure may have a detrimental effect on patients with pre-existing cardiovascular disease, a patient population excluded from these trials. This further underscores the need for studies examining mortality and cardiovascular morbidity and the ongoing SCOUT trial should provide further information (<LINK REF="STD-SCOUT-2005" TYPE="STUDY">SCOUT 2005</LINK>). If sibutramine is prescribed, careful blood pressure monitoring is recommended.</P>
<P>The increased incidence of mood disorders with rimonabant mandates careful post-marketing surveillance, particularly because psychiatric illness commonly coexists with obesity (<LINK REF="REF-Lau-DC-2007" TYPE="REFERENCE">Lau DC 2007</LINK>; <LINK REF="REF-NIH-1993" TYPE="REFERENCE">NIH 1993</LINK>). As the patient population enrolled in the RIO studies was carefully screened to exclude patients with major psychiatric disease, the risk of mood disorders with rimonabant therapy may have been underestimated. In Europe, rimonabant is contraindicated for patients with severe depression and/or patients who are treated with antidepressive medications; moreover it is not recommended for patients with other untreated psychiatric conditions.</P>
<P>If one assumes that the observed results of this review are valid and reproducible outside of the clinical trial setting, is the mild degree of weight loss achieved of clinical benefit? Current evidence suggests that it may be, particularly in high-risk subgroups, but more definitive data are needed. Weight reduction of approximately 5% to 10% of initial body weight is associated with improvements in blood pressure, lipid and glucose parameters (<LINK REF="REF-Blackburn-1995" TYPE="REFERENCE">Blackburn 1995</LINK>; <LINK REF="REF-Goldstein-1992" TYPE="REFERENCE">Goldstein 1992</LINK>) but RCT data examining the impact of weight reduction on cardiovascular events and mortality are lacking and studies are ongoing (<LINK REF="STD-CRESCENDO-2005" TYPE="STUDY">CRESCENDO 2005</LINK>; ; <LINK REF="REF-Look-AHEAD" TYPE="REFERENCE">Look AHEAD</LINK>; <LINK REF="STD-SCOUT-2005" TYPE="STUDY">SCOUT 2005</LINK>). Recently, RCTs involving treatments such as intensive lifestyle modification (diet plus exercise), acarbose, metformin, orlistat, troglitazone and rosiglitazone have reduced diabetes incidence in high risk patients, the majority of whom were overweight or obese (<LINK REF="REF-Buchanan-2002" TYPE="REFERENCE">Buchanan 2002</LINK>; <LINK REF="REF-Chiasson-2002" TYPE="REFERENCE">Chiasson 2002</LINK>; <LINK REF="REF-DPP-2002" TYPE="REFERENCE">DPP 2002</LINK>; <LINK REF="REF-DREAM-2006" TYPE="REFERENCE">DREAM 2006</LINK>; <LINK REF="REF-Tuomilehto-2001" TYPE="REFERENCE">Tuomilehto 2001</LINK>). Intensive lifestyle modification led to the largest reduction in risk of 58% in two studies (<LINK REF="REF-DPP-2002" TYPE="REFERENCE">DPP 2002</LINK>; <LINK REF="REF-Tuomilehto-2001" TYPE="REFERENCE">Tuomilehto 2001</LINK>). Although these studies are not directly comparable due to differences in patient populations and treatment regimens, weight loss for all trials was modest, ranging from 0.8 to 5.6 kg greater in the intervention arms compared to control arms. These data suggest that small amounts of weight loss in this high-risk population are associated with a significant reduction in the incidence of diabetes. Whether this benefit is sustained over longer follow-up periods remains to be seen. It should also be noted that the observed results can only be attributed to the entire randomised intervention (diet/exercise +/- drug therapy), rather than just the observed reduction in weight.</P>
<P>Studying morbidity/mortality endpoints is vital to confirming a favourable benefit/risk ratio for antiobesity drugs as drugs that improve surrogate endpoints (such as weight loss) may not ultimately improve more clinically relevant outcomes (<LINK REF="REF-Padwal-2007" TYPE="REFERENCE">Padwal 2007</LINK>; <LINK REF="REF-Padwal-RS-2007" TYPE="REFERENCE">Padwal RS 2007</LINK>). Similarly, the clinical significance of the reduction in diabetes incidence observed with pharmacotherapy, including orlistat in the <LINK REF="STD-XENDOS" TYPE="STUDY">XENDOS</LINK> trial, is uncertain at this time. The reduction in diabetes incidence wanes when the drug is stopped, suggesting a masking/delaying effect rather than a true preventive effect (<LINK REF="REF-Padwal-2005" TYPE="REFERENCE">Padwal 2005</LINK>). RCTs examining the effect of pharmacotherapy on diabetes-related microvascular and macrovascular endpoints as well as mortality are required. Trials such as SCOUT and CRESCENDO will provide much needed information on the effect of antiobesity agents on hard morbidity and mortality endpoints (<LINK REF="STD-CRESCENDO-2005" TYPE="STUDY">CRESCENDO 2005</LINK>; <LINK REF="STD-SCOUT-2005" TYPE="STUDY">SCOUT 2005</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="2">Limitations </HEADING>
<P>The major methodological issues have been discussed above. All studies in this review showed a positive treatment effect. We did not find any negative or neutral studies. This raises the possibility of publication bias. The vast majority of trials were funded by pharmaceutical companies and this may increase the potential for positive results (<LINK REF="REF-Lexchin-2003" TYPE="REFERENCE">Lexchin 2003</LINK>). We were unable to locate unpublished data by contacting study authors and drug manufacturers. We generated a funnel plot of orlistat studies (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) to assess for publication or small study bias (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>; <LINK REF="REF-Sterne-2001" TYPE="REFERENCE">Sterne 2001</LINK>). This shows a scattering of points near the midpoint and apex of the pyramid and a paucity of points at the bottom. This indicates that the impact of all types of small studies (positive, negative or neutral) may be underestimated in this meta-analysis. However, the limited number of studies included in this review may limit overall interpretation and accuracy of the funnel plot. The number of sibutramine and rimonabant studies was too small to warrant generation of funnel plots.</P>
<P>Statistical heterogeneity was present when quantitative pooling was performed for several outcomes. This was addressed by using a random-effects meta-analysis and by not combining outcomes when the heterogeneity was felt to be clinically significant. As we did not have access to individual patient data, we could not perform meta-regression analysis to further investigate the cause of the observed heterogeneity. It is likely that differences in patient populations, cointerventions, trial duration and drug dose all were contributing factors.</P>
<P>The majority of the patients in this review were middle-aged and Caucasian. Extrapolation to patients of different ethnic background and to the elderly should be made with caution.</P>
<P>Due to the lack of data, we were not able to draw any conclusions regarding the relative efficacy of antiobesity agents in different ranges of BMI levels and in patients with pre-existing cardiovascular disease. As mentioned above, the effect of antiobesity drugs on cardiovascular morbidity and mortality is unknown. The role of combination anti-obesity therapy was not reviewed, nor was the role of anti-obesity pharmacotherapy in children and adolescents. Effects on health-related quality of life were not reviewed.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-11-01 16:23:14 +0100" MODIFIED_BY="Gudrun Paletta">
<IMPLICATIONS_PRACTICE MODIFIED="2008-11-01 16:23:14 +0100" MODIFIED_BY="Gudrun Paletta">
<P>The following issues should be considered before prescribing an antiobesity agent:<BR/>1. The available evidence is limited in two major ways. Internal validity is limited by high attrition rates. External validity is limited by the enrolment of highly selected patient populations into clinical trials and also by data showing poor long-term persistence in 'real world' settings.<BR/>2. The decision to prescribe involves a careful assessment of the risks and benefits. The average amount of weight lost is modest and most patients will remain significantly obese or overweight even with drug therapy. Current antiobesity agents are costly, each drug has associated adverse effects, and the ultimate effect on cardiovascular morbidity and mortality remains unknown. Balanced against these factors are the potential for modest improvements in the cardiovascular risk profile that varies according to each agent and the possibility that the patient will have a good response (that is 10% weight loss or more). In addition, realistic minimum weight loss goals of 5% to 10% should be set and it should be noted that there is accumulating evidence that even such modest amounts of weight loss are beneficial.<BR/>3. A minority of patients (10% to 20%) do achieve weight loss of 10% or more, although it is difficult to predict which patients will respond to this extent. Since near-maximal weight loss was achieved by three to six months in most trials, one should discontinue therapy at this point if significant weight loss and/or improvement in comorbidity has not occurred.<BR/>4. Drug therapy should be used in conjunction with lifestyle modification.<BR/>5. Although we did not formally systematically review head-to-head trials, there appear to be no definitive data demonstrating that one particular agent is clearly more efficacious than another (<LINK REF="REF-Padwal-2007" TYPE="REFERENCE">Padwal 2007</LINK>).</P>
<P>Therefore, initial therapy can be guided by the following factors:<BR/>
</P>
<UL>
<LI>patient preference;</LI>
<LI>local costs, availability and drug plan coverage;</LI>
<LI>patient comorbidity and the adverse effect profiles.</LI>
</UL>
<P>A summary is provided in <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>. Orlistat reduces LDL levels, diabetes incidence, glucose levels and blood pressure and is not associated with major systemic toxicities. It is likely to be most useful in patients with prediabetes/diabetes, elevated LDL levels or pre-existing cardiovascular disease but should be avoided in patients with chronic gastrointestinal problems. Sibutramine acts primarily upon satiety and is useful when lack of satiety is a problem. It also may be preferentially used in patients with dyslipidaemia (high triglycerides/low HDL levels) but should be avoided in patients with a history of cardiovascular disease and poorly controlled hypertension until further data are available. Rimonabant might be particularly useful in patients with the metabolic syndrome, dyslipidaemia (high triglycerides/low HDL levels), diabetes (based on <LINK REF="STD-RIO_x002d_Diabetes" TYPE="STUDY">RIO-Diabetes</LINK>) and hypertension. Originally developed as a dual antiobesity drug and smoking cessation agent, rimonabant may also be of use in an obese patient who is <U>concurrently</U> trying to quit smoking. It should be noted that this latter developmental program has since been discontinued and the drug is not indicated solely for smoking cessation. Rimonabant should be avoided in patients with previous psychiatric disease, patients on antidepressants and individuals with significant liver dysfunction.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-11-01 16:14:54 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Further study is needed to evaluate:</P>
<UL>
<LI>the effectiveness, efficacy, and safety of existing antiobesity medications over longer follow-up periods, including their impact on mortality and cardiovascular morbidity. This needs to be done in a methodologically rigorous manner, with minimization of attrition rates.</LI>
<LI>the efficacy and effectiveness of combination drug therapy over the long-term.</LI>
<LI>which patients respond best to which agent.</LI>
<LI>newer, more effective, and better tolerated anti-obesity drugs.</LI>
<LI>the effect of anti-obesity therapy on other obesity-related comorbidites such as sleep apnea, arthritis, and cancer.</LI>
</UL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors would like to acknowledge the help of Ms. Jeannette Buckingham in helping to update our search and to study authors who provided supplemental data. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>R. Padwal: none known.<BR/>D. Rucker: none known.<BR/>S. Li: none known.<BR/>C.Curioni: none known.<BR/>D. Lau: David Lau owns common shares in GlaxoSmithKline and Eli Lilly. He is a consultant to Abbott Laboratories, Ltd., AstraZeneca Canada Inc., Merck Frosst Canada<BR/>Inc., Bristol-Myers Squibb Canada, Eli Lilly Canada Inc., Oryx Pharmaceuticals Inc., Pfizer Canada Inc., sanofi-aventis Canada Inc., Servier Canada Inc. and Solvay Pharma Inc.; and has received speaker fees from Abbott Laboratories, Ltd., AstraZeneca Canada Inc., GlaxoSmithKline, Merck Frosst Canada Inc., Merck/Schering, Eli Lilly Canada Inc., sanofi-aventis Canada Inc. and Novo Nordisk Canada Inc.; research grants from AstraZeneca Canada Inc., Bristol Myers Squibb, Dainippon Pharmaceuticals, GlaxoSmithKline, Pfizer Canada Inc., and Sanofi-Aventis Canada Inc.; and travel assistance to attend international meetings from Abbott Laboratories, Ltd., AstraZeneca Canada Inc. and Sanofi-Aventis Canada Inc. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-11-01 16:16:15 +0100" MODIFIED_BY="Gudrun Paletta">
<P>RAJ PADWAL: registered the topic, performed the literature search and collected articles, reviewed articles for inclusion and methodological quality, performed data entry and statistical calculations, and was the primary author for the initial and final drafts.</P>
<P>DIANA RUCKER: performed the literature search for the update, collected articles, reviewed articles for inclusion and quality, performed data entry and statistical calculations and co-authored the update.</P>
<P>STEPHANIE LI: collected articles, reviewed articles for inclusion and methodological quality, performed data entry and co-wrote the final draft.</P>
<P>CINTIA CURIONI and DAVID LAU: co-designed the review, provided expert advice and co-wrote the initial and final drafts.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-11-03 12:32:27 +0100" MODIFIED_BY="Gudrun Paletta"/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Apfelbaum-1999" NAME="Apfelbaum 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E</AU>
<TI>Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine</TI>
<SO>American Journal of Medicine</SO>
<YR>1999</YR>
<VL>106</VL>
<PG>179-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bakris-2002" NAME="Bakris 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I</AU>
<TI>Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension</TI>
<SO>Journal of Hypertension</SO>
<YR>2002</YR>
<VL>20</VL>
<PG>2257-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berne-2004" NAME="Berne 2004" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berne C</AU>
<TI>A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin</TI>
<SO>Diabet Med</SO>
<YR>2005</YR>
<VL>22</VL>
<PG>612-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Broom-2002" NAME="Broom 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Broom I, Wilding J, Stott P, Myers N</AU>
<TI>Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2002</YR>
<VL>56</VL>
<PG>494-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davidson-1999" NAME="Davidson 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D et al</AU>
<TI>Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1999</YR>
<VL>281</VL>
<PG>235-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Derosa-2003" NAME="Derosa 2003" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Derosa G, Mugellini A, Ciccarelli L, Fogari R</AU>
<TI>Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet</TI>
<SO>Clin Ther</SO>
<YR>2003</YR>
<VL>25</VL>
<PG>1107-1122</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Finer-2000" NAME="Finer 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Finer N, James WPT, Kopelman PG, Lean MEJ, Williams G</AU>
<TI>One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor</TI>
<SO>International Journal of Obesity and Related Metabolic Disorders</SO>
<YR>2000</YR>
<VL>24</VL>
<PG>306-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hauner-2004" NAME="Hauner 2004" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hauner H, Meier M, Wendland G, et al</AU>
<TI>Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT study</TI>
<SO>Exp Clin Endocrinol Diabetes</SO>
<YR>2004</YR>
<VL>112</VL>
<PG>201-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hauptman-2000" NAME="Hauptman 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hauptman J, Lucas C, Boldrin MN, Collins H, Segal K</AU>
<TI>Orlistat in the long-term treatment of obesity in primary care settings</TI>
<SO>Archives of Family Medicine</SO>
<YR>2000</YR>
<VL>9</VL>
<PG>160-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hollander-1998" NAME="Hollander 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T et al</AU>
<TI>Role of orlistat in the treatment of obese patients with type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>1998</YR>
<VL>21</VL>
<PG>1288-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-James-2000" NAME="James 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>James WPT, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, et al</AU>
<TI>Effect of sibutramine on weight maintenance after weight loss: a randomised trial</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>356</VL>
<PG>2119-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaukua-2003" NAME="Kaukua 2003" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaukua JK, Pekkarinen TA, Rissanen AM</AU>
<TI>Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes</TI>
<SO>Int J Obes Relat Metab Disord</SO>
<YR>2004</YR>
<VL>28</VL>
<PG>600-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kelley-2002" NAME="Kelley 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, Hollander P</AU>
<TI>Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2002</YR>
<VL>25</VL>
<PG>1033-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krempf--2003" NAME="Krempf  2003" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krempf M, Louvet JP, Allanic H, et al</AU>
<TI>Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity</TI>
<SO>Int J Obese Relat Met Disord</SO>
<YR>2003</YR>
<VL>27</VL>
<PG>591-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindgarde-2000" NAME="Lindgarde 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindgarde F</AU>
<TI>The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study</TI>
<SO>Journal of Internal Medicine</SO>
<YR>2000</YR>
<VL>248</VL>
<PG>245-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mathus_x002d_Vliegen-2005" NAME="Mathus-Vliegen 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mathus-Vliegen EM for the Balance Study Group</AU>
<TI>Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>2005</YR>
<VL>59(Suppl 1)</VL>
<PG>S31-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McMahon-2000" NAME="McMahon 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K et al</AU>
<TI>Efficacy and safety of sibutramine in obese white and African American patients with hypertension</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<PG>2185-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McMahon-2002" NAME="McMahon 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K</AU>
<TI>Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled by angiotensin converting enzyme inhibitors</TI>
<SO>Journal of Human Hypertension</SO>
<YR>2002</YR>
<VL>16</VL>
<PG>5-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McNulty-2003" NAME="McNulty 2003" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McNulty SJ, Ur E, Williams G, et al</AU>
<TI>A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin</TI>
<SO>Diabetes Care</SO>
<YR>2003</YR>
<VL>26</VL>
<PG>125-131</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miles-2002" NAME="Miles 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miles JM, Leiter L, Hollander P, et al</AU>
<TI>Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin</TI>
<SO>Diabetes Care</SO>
<YR>2002</YR>
<VL>25</VL>
<PG>1123-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RIO_x002d_Diabetes" NAME="RIO-Diabetes" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF</AU>
<TI>Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>368</VL>
<PG>1660-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RIO_x002d_Europe" NAME="RIO-Europe" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S</AU>
<TI>Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>365</VL>
<PG>1389-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RIO_x002d_Lipids" NAME="RIO-Lipids" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Despres JP, Golay A, Sjostrom L</AU>
<TI>Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia</TI>
<SO>N Engl J Med</SO>
<YR>2005</YR>
<VL>353</VL>
<PG>2121-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RIO_x002d_North-America" NAME="RIO-North America" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J</AU>
<TI>Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>295</VL>
<PG>761-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rossner-2000" NAME="Rossner 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G</AU>
<TI>Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity</TI>
<SO>Obesity Research</SO>
<YR>2000</YR>
<VL>8</VL>
<PG>49-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanchez_x002d_Reyes-2004" NAME="Sanchez-Reyes 2004" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez-Reyes L, Fanghanel G, Yamamoto J, et al</AU>
<TI>Use of sibutramine in overweight adult Hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial</TI>
<SO>Clin Ther</SO>
<YR>2004</YR>
<VL>26</VL>
<PG>1427-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sjostrom-1998" NAME="Sjostrom 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF, et al</AU>
<TI>Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>167-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2001" NAME="Smith 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith IG, Goulder MA</AU>
<TI>Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity</TI>
<SO>Journal of Family Practice</SO>
<YR>2001</YR>
<VL>50</VL>
<PG>505-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swinburn-2005" NAME="Swinburn 2005" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swinburn BA, Carey D, Hills AP, et al</AU>
<TI>Effect of orlistat on cardiovascular disease risk in obese adults</TI>
<SO>Diab Obes Metab</SO>
<YR>2005</YR>
<VL>7</VL>
<PG>254-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-XENDOS" NAME="XENDOS" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L</AU>
<TI>Xenical in the prevention of diabetes in obese subjects (XENDOS) study</TI>
<SO>Diabetes Care</SO>
<YR>2004</YR>
<VL>1</VL>
<PG>155-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Derosa-2002" NAME="Derosa 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Derosa G, Mugellini A, Ciccarelli L, Rinaldi A, Fogari R</AU>
<TI>Effects of orlistat, simvastatin, and orlistat plus simvastatin in obese patients with hypercholesterolemia: a randomized, open-label trial</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>2002</YR>
<VL>63</VL>
<PG>621-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gaciong-2005" NAME="Gaciong 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gaciong Z, Placha G</AU>
<TI>Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-labl, observational study</TI>
<SO>Journal of Hum Hypertens</SO>
<YR>2005</YR>
<VL>19</VL>
<PG>737-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gilbert-1983" NAME="Gilbert 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gilbert S, Garrow JS</AU>
<TI>A prospective controlled trial of outpatients treatment for obesity</TI>
<SO>Human Nutrition. Clinical Nutrition</SO>
<YR>1983</YR>
<VL>37</VL>
<PG>21-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanefeld-2002" NAME="Hanefeld 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hanefeld M, Sachse G</AU>
<TI>The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial.</TI>
<SO>Diabetes, Obesity and Metabolism</SO>
<YR>2002</YR>
<VL>4</VL>
<PG>415-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heymsfield-2000" NAME="Heymsfield 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A et al</AU>
<TI>Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<PG>1321-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hill-1999" NAME="Hill 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Smith DK et al</AU>
<TI>Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1999</YR>
<VL>69</VL>
<PG>1108-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hsieh-2005" NAME="Hsieh 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hsieh CJ, Wang PW, Liu RT, et al</AU>
<TI>Orlistat for obesity: benefits beyond weight loss</TI>
<SO>Diabetes Res Clin Pract</SO>
<YR>2005</YR>
<VL>67</VL>
<PG>78-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-James-1997" NAME="James 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>James WPT, Avenell A, Broom J, Whitehead J</AU>
<TI>A one-year trial to assess the value of orlistat in the management of obesity</TI>
<SO>International Journal of Obesity and Related Metabolic Disorders</SO>
<YR>1997</YR>
<VL>21</VL>
<NO>Suppl 3</NO>
<PG>S24-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lucas-2003" NAME="Lucas 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lucas CP, Boldrin MN, Reaven GM</AU>
<TI>Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia</TI>
<SO>Am J Cardiol</SO>
<YR>2003</YR>
<VL>91</VL>
<PG>961-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poston-2003" NAME="Poston 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poston WS, Reeves RS, Haddock CK, et al</AU>
<TI>Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification</TI>
<SO>Int J Obes Relat Metab Disord</SO>
<YR>2003</YR>
<VL>27</VL>
<PG>1486-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Redmon-1999" NAME="Redmon 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Redmon JB, Raatz SK, Kwong CA, Swanson JE, Thomas W, Bantle JE</AU>
<TI>Pharmacologic induction of weight loss to treat type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>1999</YR>
<VL>22</VL>
<PG>896-903</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Redmon-2003" NAME="Redmon 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Redmon JB, Raatz SK, Reck JP, et al</AU>
<TI>One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial.</TI>
<SO>Diabetes Care</SO>
<YR>2003</YR>
<VL>26</VL>
<PG>2505-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Redmon-2005" NAME="Redmon 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Redmon JB, Reck KP, Raatz SK, et al</AU>
<TI>Two-year outcome of a combination of weight loss therapies for type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2005</YR>
<VL>28</VL>
<PG>1311-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rossner-2001" NAME="Rossner 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rossner S</AU>
<TI>Sibutramine - antidepressive agent tested against obesity</TI>
<SO>Ladartidningen</SO>
<YR>2001</YR>
<VL>98</VL>
<PG>1802-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scholze-2002" NAME="Scholze 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scholze J</AU>
<TI>Treating obesity with sibutramine under practical conditions</TI>
<SO>Dtsch Med Wochenschr</SO>
<YR>2002</YR>
<VL>127</VL>
<PG>606-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Toubro-2001" NAME="Toubro 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Toubro S, Hansen DL, Hilsted JC, Porsborg PA, Astrup AV</AU>
<TI>The effect of sibutramine for the maintenance of weight loss: a randomised, clinical, controlled study</TI>
<SO>Ugeskrift for Laeger</SO>
<YR>2001</YR>
<VL>163</VL>
<PG>2395-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wadden-2001" NAME="Wadden 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg C</AU>
<TI>Benefits of lifestyle modification in the pharmacologic treatment of obesity</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2001</YR>
<VL>161</VL>
<PG>218-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wadden-2005" NAME="Wadden 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wadden TA, Berkowitz RI, Womble LG, et al</AU>
<TI>Randomized trial of lifestyle modification and pharmacotherapy for obesity</TI>
<SO>N Engl J Med</SO>
<YR>2005</YR>
<VL>353</VL>
<PG>2111-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weintraub-1992" NAME="Weintraub 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weintraub M</AU>
<TI>Long-term weight control: The national heart, lung, and blood institute funded multimodal intervention study</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1992</YR>
<VL>51</VL>
<PG>581-585</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wirth-2001" NAME="Wirth 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wirth A, Krause J</AU>
<TI>Long-term weight loss with sibutramine</TI>
<SO>Journal of the American Medical Association</SO>
<YR>2001</YR>
<VL>286</VL>
<PG>1331-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wirth-2005" NAME="Wirth 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wirth A</AU>
<TI>Reduction of body weight and co-morbidities by orlistat: the XXL - Primary Health Care Trial</TI>
<SO>Diab Obes Metab</SO>
<YR>2005</YR>
<VL>7</VL>
<PG>21-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zavoral-1998" NAME="Zavoral 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zavoral JH</AU>
<TI>Treatment with orlistat reduces cardiovascular risk in obese patients</TI>
<SO>J Hypertens</SO>
<YR>1998</YR>
<VL>16</VL>
<PG>2013-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-AUDITOR-2005" NAME="AUDITOR 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<TI>ClinicalTrials.gov. Atherosclerosis underlying development assessed by intima-media thickness in patients on rimonabant (AUDITOR)</TI>
<SO>http://www.clinicaltrials.gov/ct/show/NCT00228176?order=1. Accessed March 2007.</SO>
<YR>December 2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CRESCENDO-2005" NAME="CRESCENDO 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>ClinicalTrials.gov</AU>
<TI>CRESCENDO: comprehensive rimonabant evaluation study of cardiovascular endpoints and outcomes</TI>
<SO>http://www.clinicaltrials.gov/ct/show/NCT00263042?order=3 (accessed March 2007)</SO>
<YR>December 2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SCOUT-2005" NAME="SCOUT 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>James WP</AU>
<TI>The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients</TI>
<SO>Eur Heart J</SO>
<YR>2005</YR>
<VL>7(suppl L)</VL>
<PG>L44-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-STRADIVARIUS-2005" NAME="STRADIVARIUS 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<TI>ClinicalTrials.gov. STRADIVARIUS (Strategy to reduce atherosclerosis development involving administration of rimonabant - the intravascular ultrasound study)</TI>
<SO>http://www.clinicaltrials.gov/ct/show/NCT00124332?order=1. Accessed March 2007</SO>
<YR>December 2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Abenhaim-1996" NAME="Abenhaim 1996" TYPE="JOURNAL_ARTICLE">
<AU>Abenhaim L, Moride Y, Brenot F, et al</AU>
<TI>Appetite-suppressant drugs and the risk of primary pulmonary hypertension</TI>
<SO>N Engl J Med</SO>
<YR>1996</YR>
<VL>335</VL>
<PG>609-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allison-1999" NAME="Allison 1999" TYPE="JOURNAL_ARTICLE">
<AU>Allison DB, Zannolli R, Faith MS, Heo M, Pietrobelli A, VanItallie TB, et al</AU>
<TI>Weight loss increases and fat loss decreases all-cause mortality rate: results from two independent cohort studies</TI>
<SO>International Journal of Obesity and Related Metabolic Disorders</SO>
<YR>1999</YR>
<VL>23</VL>
<PG>603-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andres-1993" NAME="Andres 1993" TYPE="JOURNAL_ARTICLE">
<AU>Andres R, Muller DC, Sorkin JD</AU>
<TI>Long-term effects of change in body weight on all-cause mortality</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1993</YR>
<VL>119</VL>
<PG>737-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arterburn-2004" NAME="Arterburn 2004" TYPE="JOURNAL_ARTICLE">
<AU>Arterburn DE, Crane PK, Veenstra DL</AU>
<TI>The efficacy and safety of sibutramine for weight loss: a systematic review</TI>
<SO>Arch Intern Med</SO>
<YR>2004</YR>
<VL>164</VL>
<PG>994-1003</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Birmingham-1999" NAME="Birmingham 1999" TYPE="JOURNAL_ARTICLE">
<AU>Birmingham CL, Muller JL, Palepu A, Spinelli JJ, Anis AH</AU>
<TI>The cost of obesity in Canada</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1999</YR>
<VL>160</VL>
<PG>483-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blackburn-1995" NAME="Blackburn 1995" TYPE="JOURNAL_ARTICLE">
<AU>Blackburn G</AU>
<TI>Effect of degree of weight loss on health benefits</TI>
<SO>Obesity Research</SO>
<YR>1995</YR>
<VL>3</VL>
<NO>Supp 2</NO>
<PG>2112S-5S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bray-1998" NAME="Bray 1998" TYPE="JOURNAL_ARTICLE">
<AU>Bray GA</AU>
<TI>Obesity: a time bomb to be defused</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>160-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bray-2000" NAME="Bray 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bray GA, Tartaglia LA.</AU>
<TI>Medicinal strategies in the treatment of obesity</TI>
<SO>Nature</SO>
<YR>2000</YR>
<VL>404</VL>
<PG>672-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Buchanan-2002" NAME="Buchanan 2002" TYPE="JOURNAL_ARTICLE">
<AU>Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J et al</AU>
<TI>Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women</TI>
<SO>Diabetes</SO>
<YR>2002</YR>
<VL>51</VL>
<PG>2796-803</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Calle-1999" NAME="Calle 1999" TYPE="JOURNAL_ARTICLE">
<AU>Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr</AU>
<TI>Body-mass index and mortality in a prospective cohort of U.S. adults</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<PG>1097-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chiasson-2002" NAME="Chiasson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M</AU>
<TI>Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>359</VL>
<PG>2072-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1960" NAME="Cohen 1960" TYPE="JOURNAL_ARTICLE">
<AU>Cohen J</AU>
<TI>A coefficient of agreement for nominal scales</TI>
<SO>Educational and Psychological Measurement</SO>
<YR>1960</YR>
<VL>20</VL>
<PG>37-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Colditz-1995" NAME="Colditz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Colditz GA, Willett WC, Rotnitzky A, Manson JE</AU>
<TI>Weight gain as a risk factor for clinical diabetes mellitus in women</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1995</YR>
<VL>122</VL>
<PG>481-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Connolly-1997" NAME="Connolly 1997" TYPE="JOURNAL_ARTICLE">
<AU>Connolly HM, Crary JL, McGoon MD, et al</AU>
<TI>Valvular heart disease associated with fenfluramine-phentermine</TI>
<SO>N Engl J Med</SO>
<YR>1997</YR>
<VL>337</VL>
<PG>581-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curioni-2006" NAME="Curioni 2006" TYPE="COCHRANE_REVIEW">
<AU>Curioni C, Andre C</AU>
<TI>Rimonabant for overweight or obesity</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Art. No.:CD006162"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-DPP-2002" NAME="DPP 2002" TYPE="JOURNAL_ARTICLE">
<AU>Diabetes Prevention Program Research Group</AU>
<TI>Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>346</VL>
<PG>393-403</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DREAM-2006" NAME="DREAM 2006" TYPE="JOURNAL_ARTICLE">
<AU>The DREAM Trial Investigators</AU>
<TI>Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>368</VL>
<PG>1096-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Smith GD, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>British Medical Journal</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Field-2001" NAME="Field 2001" TYPE="JOURNAL_ARTICLE">
<AU>Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH et al</AU>
<TI>Impact of overweight on the risk of developing common chronic diseases during a 10-year period</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2001</YR>
<VL>161</VL>
<PG>1581-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Flegal-2002" NAME="Flegal 2002" TYPE="JOURNAL_ARTICLE">
<AU>Flegal KM, Carroll MD, Ogden CL, Johnson CL</AU>
<TI>Prevalence and trends in obesity among US adults, 1999-2000</TI>
<SO>Journal of the American Medical Association</SO>
<YR>2002</YR>
<VL>288</VL>
<PG>1723-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-French-1999" NAME="French 1999" TYPE="JOURNAL_ARTICLE">
<AU>French SA, Folsom AR, Jeffery RW, Williamson DF</AU>
<TI>Prospective study of intentionality of weight loss and mortality in older women: the Iowa Women's Health Study</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>504-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldstein-1992" NAME="Goldstein 1992" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein DJ</AU>
<TI>Beneficial effects of modest weight loss</TI>
<SO>International Journal of Obesity and Related Metabolic Disorders</SO>
<YR>1992</YR>
<VL>16</VL>
<PG>397-415</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenway-2000" NAME="Greenway 2000" TYPE="JOURNAL_ARTICLE">
<AU>Greenway FL</AU>
<TI>Obesity surgery</TI>
<SO>Endocrinology and Metabolism Clinics of North America</SO>
<YR>1996</YR>
<VL>25</VL>
<PG>1005-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haddock-2002" NAME="Haddock 2002" TYPE="JOURNAL_ARTICLE">
<AU>Haddock CK, Poston WSC, Dill PL, Foreyt JP, Ericsson M</AU>
<TI>Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials</TI>
<SO>International Journal of Obesity and Related Metabolic Disorders</SO>
<YR>2002</YR>
<VL>26</VL>
<PG>262-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haslam-2005" NAME="Haslam 2005" TYPE="JOURNAL_ARTICLE">
<AU>Haslam DW, James WPT</AU>
<TI>Obesity</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>366</VL>
<PG>1197-209</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Health-Canada-2002" NAME="Health Canada 2002" TYPE="OTHER">
<AU>Health Canada</AU>
<TI>Health Canada investigates safety of MERIDIA® (Sibutramine)</TI>
<SO>http://www.hc-sc.gc.ca/english/protection/warnings/2002/2002_21e.htm</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hollis-1999" NAME="Hollis 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hollis S, Campbell F</AU>
<TI>What is meant by intention to treat analysis? Survey of published randomised controlled trials</TI>
<SO>British Medical Journal</SO>
<YR>1999</YR>
<VL>319</VL>
<PG>670-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-INTERHEART-2005" NAME="INTERHEART 2005" TYPE="JOURNAL_ARTICLE">
<AU>Yusuf S, Hawken S, Ounpuu S, et al</AU>
<TI>Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case control study</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>366</VL>
<PG>1640-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-IOTF-2007" NAME="IOTF 2007" TYPE="OTHER">
<AU>International Obesity Task Force</AU>
<TI>Global obesity map</TI>
<SO>Available at http://www.iotf.org/database/documents/GlobalAdultmapswithtop5ineachregion_000.ppt. Accessed January 2007</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jick-1998" NAME="Jick 1998" TYPE="JOURNAL_ARTICLE">
<AU>Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE</AU>
<TI>A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>339</VL>
<PG>719-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Juni-2001" NAME="Juni 2001" TYPE="BOOK_SECTION">
<AU>Juni P, Smith GD, Altman DG</AU>
<TI>Assessing the quality of randomised controlled trials</TI>
<SO>Systematic Reviews in Health Care</SO>
<YR>2001</YR>
<PG>87-108</PG>
<EN>Second</EN>
<ED>Egger M, Smith GD, Altman DG</ED>
<PB>BMJ Publishing Group</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kenchaiah-2002" NAME="Kenchaiah 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kenchaiah S, Evans JC, Levy D, Wilson PWF, Benjamin, EJ, Larson MG, et al</AU>
<TI>Obesity and risk of heart failure</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>347</VL>
<PG>305-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Khan-1998" NAME="Khan 1998" TYPE="JOURNAL_ARTICLE">
<AU>Khan MA, Herzog CA, St Peter JV, Hartley GG, Madlon-Kay R, Dick CD, et al</AU>
<TI>The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>339</VL>
<PG>713-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kissebah-1994" NAME="Kissebah 1994" TYPE="JOURNAL_ARTICLE">
<AU>Kissbah AH, Krakower GR</AU>
<TI>Regional adiposity and morbidity</TI>
<SO>Physiological Reviews</SO>
<YR>1994</YR>
<VL>74</VL>
<PG>761-811</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kopelman-2000" NAME="Kopelman 2000" TYPE="JOURNAL_ARTICLE">
<AU>Kopelman PG</AU>
<TI>Obesity as a medical problem</TI>
<SO>Nature</SO>
<YR>2000</YR>
<VL>404</VL>
<PG>635-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lau-2007" NAME="Lau 2007" TYPE="JOURNAL_ARTICLE">
<AU>Lau DCW</AU>
<TI>Synopsis of the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children</TI>
<SO>CMAJ</SO>
<YR>2007</YR>
<VL>176</VL>
<PG>1103-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lau-D-2007" NAME="Lau D 2007" TYPE="JOURNAL_ARTICLE">
<AU>Lau DCW, Douketis JD, Morrison KM, et al</AU>
<TI>2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]</TI>
<SO>CMAJ</SO>
<YR>2007</YR>
<VL>176</VL>
<PG>S1-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lau-DC-2007" NAME="Lau DC 2007" TYPE="JOURNAL_ARTICLE">
<AU>Lau DCW, Douketis JD, Morrison KM, et al.</AU>
<TI>2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children</TI>
<SO>CMAJ</SO>
<YR>2007</YR>
<VL>176</VL>
<PG>S1-130. Available at www.cmaj.ca/cgi/content/full/176/8/S1/DC1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leibel-1995" NAME="Leibel 1995" TYPE="JOURNAL_ARTICLE">
<AU>Leibel RL, Rosenbaum M, Hirsch J</AU>
<TI>Changes in energy expenditure resulting from altered body weight</TI>
<SO>N Engl J Med</SO>
<YR>1995</YR>
<VL>332</VL>
<PG>621-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lexchin-2003" NAME="Lexchin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lexchin J, Bero LA, Djulbegovic B, Clark O</AU>
<TI>Pharmaceutical industry sponsorship and research outcome and quality: systematic review</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>326</VL>
<PG>1167-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Li-2005" NAME="Li 2005" TYPE="JOURNAL_ARTICLE">
<AU>Li Z, Maglione M, Tu W, et al</AU>
<TI>Meta-analysis: pharmacologic treatment of obesity</TI>
<SO>Ann Intern Med</SO>
<YR>2005</YR>
<VL>142</VL>
<PG>532-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Look-AHEAD" NAME="Look AHEAD" TYPE="JOURNAL_ARTICLE">
<AU>The Look AHEAD Research Group</AU>
<TI>Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes</TI>
<SO>Control Clin Trials</SO>
<YR>2003</YR>
<VL>24</VL>
<PG>610-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Luque-1999" NAME="Luque 1999" TYPE="JOURNAL_ARTICLE">
<AU>Luque CA, Rey JA</AU>
<TI>Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>1999</YR>
<VL>33</VL>
<PG>968-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Manson-1995" NAME="Manson 1995" TYPE="JOURNAL_ARTICLE">
<AU>Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, et al</AU>
<TI>Body weight and mortality among women</TI>
<SO>New England Journal of Medicine</SO>
<YR>1995</YR>
<VL>333</VL>
<PG>677-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McNeely-1998" NAME="McNeely 1998" TYPE="JOURNAL_ARTICLE">
<AU>McNeely W, Benfield P</AU>
<TI>Orlistat</TI>
<SO>Drugs</SO>
<YR>1998</YR>
<VL>52</VL>
<PG>241-49.</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1999" NAME="Moher 1999" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup D</AU>
<TI>Improving the quality of reporting of meta-analysis of randomized controlled trials: the QUOROM statement</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<PG>1896-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NIH-1993" NAME="NIH 1993" TYPE="JOURNAL_ARTICLE">
<AU>NIH Technology Assessment Conference Panel</AU>
<TI>Methods for voluntary weight loss and control</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1993</YR>
<VL>119</VL>
<PG>764-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Norris-2005" NAME="Norris 2005" TYPE="COCHRANE_REVIEW">
<AU>Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J</AU>
<TI>Pharmacotherapy for weight loss in adults with type 2 diabetes</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>1</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NTF-1994" NAME="NTF 1994" TYPE="JOURNAL_ARTICLE">
<AU>The National Task Force on Prevention and Treatment of Obesity</AU>
<TI>Towards prevention of obesity: research directions</TI>
<SO>Obes Res</SO>
<YR>1994</YR>
<VL>2</VL>
<PG>571-584</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Meara-2001" NAME="O'Meara 2001" TYPE="OTHER">
<AU>O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G</AU>
<TI>A rapid and systematic review of the clinical effectiveness and cost effectiveness of orlistat in the management of obesity</TI>
<SO>Health Technology Assessment</SO>
<YR>2001</YR>
<VL>5</VL>
<NO>18</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="http://www.ncchta.org/projectdata/index.asp"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Meara-2002" NAME="O'Meara 2002" TYPE="OTHER">
<AU>O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G</AU>
<TI>The clinical effectiveness and cost effectiveness of sibutramine in the management of obesity: a technology assessment</TI>
<SO>Health Technology Assessment</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>6</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="http://www.ncchta.org/projectdata/index.asp"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ogden-2002" NAME="Ogden 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ogden CL, Flegal KM, Carroll MD, Johnson CL</AU>
<TI>Prevalence and trends in overweight among US children and adolescents, 1999-2000</TI>
<SO>Journal of the American Medical Association</SO>
<YR>2002</YR>
<VL>288</VL>
<PG>1728-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Padwal-2003" NAME="Padwal 2003" TYPE="COCHRANE_REVIEW">
<AU>Padwal R, Li SK, Lau DCW</AU>
<TI>Long-term pharmacotherapy for obesity and overweight</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Padwal-2005" NAME="Padwal 2005" TYPE="JOURNAL_ARTICLE">
<AU>Padwal R, Majumdar SR, Johnson JA, Varney J, McAlister FA</AU>
<TI>A systematic review of drug therapy to delay or prevent type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2005</YR>
<VL>28</VL>
<PG>736-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Padwal-2007" NAME="Padwal 2007" TYPE="JOURNAL_ARTICLE">
<AU>Padwal RS, Majumdar SR</AU>
<TI>Drug treatments for obesity: orlistat, sibutramine and rimonabant</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>369</VL>
<PG>71-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Padwal-R-2007" NAME="Padwal R 2007" TYPE="JOURNAL_ARTICLE">
<AU>Padwal R, Kezouh A, Levine M, Etminan M</AU>
<TI>Long-term persistence with orlistat and sibutramine in a population-based cohort</TI>
<SO>Int J Obes (Lond)</SO>
<YR>2007</YR>
<PG>In press</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Padwal-RS-2007" NAME="Padwal RS 2007" TYPE="JOURNAL_ARTICLE">
<AU>Padwal RS</AU>
<TI>Antiobesity drug therapy: A call for more rigorous endpoint evaluation</TI>
<SO>Future Drugs</SO>
<YR>2007</YR>
<VL>4</VL>
<PG>221-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rexrode-1998" NAME="Rexrode 1998" TYPE="JOURNAL_ARTICLE">
<AU>Rexrode KM, Hennekens CH, Willett WC, Colditz GA, Stampfer MJ, Rich-Edwards JW, et al</AU>
<TI>A prospective study of body mass index, weight change, and risk of stroke in women</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1997</YR>
<VL>277</VL>
<PG>1539-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rimm-1995" NAME="Rimm 1995" TYPE="JOURNAL_ARTICLE">
<AU>Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA, Willett WC. Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA et al</AU>
<TI>Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1995</YR>
<VL>141</VL>
<PG>1117-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seidell-1996" NAME="Seidell 1996" TYPE="JOURNAL_ARTICLE">
<AU>Seidell JC</AU>
<TI>The impact of obesity on health status: some implications for health care costs</TI>
<SO>International Journal of Obesity and Related Metabolic Disorders</SO>
<YR>1996</YR>
<VL>19(Suppl 6)</VL>
<PG>S13-S16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SOS-2004" NAME="SOS 2004" TYPE="JOURNAL_ARTICLE">
<AU>Sjostrom L, Lindroos AK, Peltonen M, et al</AU>
<TI>Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery</TI>
<SO>N Engl J Med</SO>
<YR>2004</YR>
<VL>351</VL>
<PG>2683-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2001" NAME="Sterne 2001" TYPE="BOOK_SECTION">
<AU>Sterne JAC, Egger M, Smith GD</AU>
<TI>Investigating and dealing with publication and other biases</TI>
<SO>Systematic Reviews in Health Care</SO>
<YR>2001</YR>
<EN>Second</EN>
<ED>Egger M, Smith GD, Altman DG</ED>
<PB>BMJ Publishing Group</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stevens-1998" NAME="Stevens 1998" TYPE="JOURNAL_ARTICLE">
<AU>Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL</AU>
<TI>The effect of age on the association between body-mass index and mortality</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>338</VL>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tuomilehto-2001" NAME="Tuomilehto 2001" TYPE="JOURNAL_ARTICLE">
<AU>Toumilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P et al</AU>
<TI>Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>344</VL>
<PG>1343-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-US-Guidelines-1998" NAME="US Guidelines 1998" TYPE="JOURNAL_ARTICLE">
<AU>Expert Panel on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults</AU>
<TI>Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1998</YR>
<VL>158</VL>
<PG>1855-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-UTD-2001" NAME="UTD 2001" TYPE="OTHER">
<AU>Bray GA</AU>
<TI>Health hazards associated with obesity</TI>
<SO>UpToDate Clinical Reference Library [CD-ROM]</SO>
<YR>2001</YR>
<VL>Version 9.1</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verhagen-1998" NAME="Verhagen 1998" TYPE="JOURNAL_ARTICLE">
<AU>Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, et al</AU>
<TI>The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1998</YR>
<VL>51</VL>
<PG>1235-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Visscher-2002" NAME="Visscher 2002" TYPE="JOURNAL_ARTICLE">
<AU>Visscher TL, Seidell JC, Molarius A, van der Kuip D, Hofman A, Witteman JC</AU>
<TI>A comparison of body mass index, waist-hip ratio and waist circumference as predictors of all-cause mortality among the elderly: the Rotterdam study</TI>
<SO>International Journal of Obesity and Related Metabolic Disorders</SO>
<YR>2001</YR>
<VL>25</VL>
<PG>1730-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wadden-1993" NAME="Wadden 1993" TYPE="JOURNAL_ARTICLE">
<AU>Wadden TA</AU>
<TI>Treatment of obesity by moderate and severe caloric restriction. Results of clinical research trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1993</YR>
<VL>119</VL>
<PG>688-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weissman-1998" NAME="Weissman 1998" TYPE="JOURNAL_ARTICLE">
<AU>Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT</AU>
<TI>An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>339</VL>
<PG>725-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1998" NAME="WHO 1998" TYPE="OTHER">
<AU>World Health Organisation (WHO)</AU>
<TI>Obesity: Preventing and managing the Global Epidemic - Report of a WHO Consultation on Obesity, 3-5 June 1997</TI>
<SO>WHO/NUT/NCD/98.1</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Williamson-1993" NAME="Williamson 1993" TYPE="JOURNAL_ARTICLE">
<AU>Williamson DF, Pamuk ER</AU>
<TI>The association between weight loss and increased longevity. A review of the evidence</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1993</YR>
<VL>119</VL>
<PG>731-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Williamson-1995" NAME="Williamson 1995" TYPE="JOURNAL_ARTICLE">
<AU>Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C</AU>
<TI>Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1995</YR>
<VL>141</VL>
<PG>1128-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wing-1987" NAME="Wing 1987" TYPE="JOURNAL_ARTICLE">
<AU>Wing RR, Marcus MD, Epstein LH, Salata R</AU>
<TI>Type 2 diabetic subjects lose less weight than their overweight spouses.</TI>
<SO>Diabetes Care</SO>
<YR>2000</YR>
<VL>23</VL>
<PG>1499-1504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wooltorton-2002" NAME="Wooltorton 2002" TYPE="JOURNAL_ARTICLE">
<AU>Wooltorton 2002</AU>
<TI>Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2002</YR>
<VL>166</VL>
<PG>1307-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Apfelbaum-1999">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight maintenance trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>205 participants underwent 4 week VLCD. Those who lost 6 or more kg (n=160) were randomized for 1 y treatment. Mean age 38y. Mean BMI 35.5 kg/m2. Mean weight 104 kg.<BR/>France.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Sibutramine 10 mg daily (n=352). Attrition rate 34%.<BR/>Placebo (n=78). Attrition rate 42%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, % wieght maintenance, waist circumference, 5 and 10% responders, triglycerides, HDL chol, Total/HDL chol ratio, LDL chol, blood pressure, pulse rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-intervention: diet counseling.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bakris-2002">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>554 patients with HTN. 1 year follow-up. Mean age 53 y. Mean BMI 35.6 kg/m2. Mean weight 101 kg. US.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orlistat 120 mg tid (n=278). Attrition rate 42%.<BR/>Placebo (n=278). Attrition rate 61%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, 5% responders, BMI, waist circ, lipid profile, blood pressure, insulin</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-interventions: 600 kcal/d deficit, exercise, educational package</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Berne-2004">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>220 patients with DM2 on oral agents. 1 year follow-up. Mean age 59 y. Mean BMI 32.7 kg/m2. Mean weight 96 kg. Sweden.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orlistat 120 mg tid (n=111). Attrition rate 14%.<BR/>Placebo (n=109). Attrition rate 14%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, 5% and 10% responders, waist circ, A1c, lipid profile, blood pressure, heart rate, insulin, apolipoprotein B</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-interventions: 600 kcal/d deficit, exercise, educational package</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Broom-2002">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>531 patients with HTN, IGT or dyslipidemia. 1 year follow-up. Mean age 46 y. Mean BMI 37.1 kg/m2. Mean weight 101 kg. UK.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orlistat 120 mg tid (n=265). Attrition rate 30%.<BR/>Placebo (n=266). Attrition rate 40%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, 5% and 10% responders, BMI, waist circ, lipid profile, blood pressure, glucose, OGTT score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-interventions: 600-900 kcal/d deficit diet, food diary</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Davidson-1999">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial. Second year weight maintenance.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>892 patients with 1 year follow-up and a second weight maintenance year. Mean age 46 y. Mean BMI 37.1 kg/m2. Mean weight 101 kg. UK.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orlistat 120 mg tid (n=668). Attrition rate 31%.<BR/>Placebo (n=224). Attrition rate 41%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, 5% and 10% responders, waist circ, lipid profile, blood pressure, glucose, insulin</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-interventions: 500-800 kcal/d deficit diet, food diary, exercise counseling.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Derosa-2003">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>50 patients with dyslipidemia. 1 year follow-up. Mean age 52 y. Mean BMI 31.9 kg/m2. Mean weight 95 kg. Italy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orlistat 120 mg tid (n=27). Attrition rate 7%.<BR/>Placebo (n=23). Attrition rate 0%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, waist circ, BMI, lipid profile, blood pressure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-interventions: 1500 kcal/d diet, exercise. Data for fluvastatin and orlistat/fluvastatin arm not presented in this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Finer-2000">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>228 patients followed for 1 year. Mean age 41 y. Mean BMI 36.8 kg/m2. Mean weight 98 kg. UK.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orlistat 120 mg tid (n=114). Attrition rate 36%.<BR/>Placebo (n=114). Attrition rate 42%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, 5% and 10% responders, waist circ, lipid profile, blood pressure, glucose, insulin</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-interventions: 600-900 kcal/d deficit diet</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hauner-2004">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>362 patients from primary care. 54 week follow-up. Mean age 43 y. Mean BMI 35.3 kg/m2. Mean weight 100 kg. Germany.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Sibutramine 15 mg daily (n=180). Attrition rate 40%.<BR/>Placebo (n=182). Attrition rate 48%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, 5% and 10% responders, waist circ, waist-hip ratio, lipid profile, blood pressure, heart rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-interventions: 500-1000 kcal/d deficit diet. Food diary. Exercise.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hauptman-2000">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial. Second year weight maintenance.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>635 patients with 1-year follow-up and second weight maintenance year. Mean age 42 y. Mean BMI 36.0 kg/m2. Mean weight 101 kg. US.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orlistat 60 mg tid (n=213). Attrition rate 28%.<BR/>Orlistat 120 mg tid (n=210). Attrition rate 28%.<BR/>Placebo (n=212). Attrition rate 42%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, 5% and 10% responders, lipid profile, blood pressure, glucose, insulin</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-interventions: 1200-1500 kcal/d diet. Food diary. Exercise. Educational video.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hollander-1998">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>322 patients with DM2 followed for 1 year. Mean age 55 y. Mean BMI 34.3 kg/m2. Mean weight 100 kg. US.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orlistat 120 mg tid (n=63). Attrition rate 15%.<BR/>Placebo (n=159). Attrition rate 28%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, 5% and 10% responders, waist circ, lipid profile, apolipoproteins, A1c, glucose, insulin</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-interventions: 500 kcal/d deficit diet.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-James-2000">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight maintenance trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>605 patients received sibutramine and diet for 6 mo. 5% responders (n=467) then randomized to continue sibutramine or take placebo for 18 mo. Mean age 41 y. Mean BMI 36.7 kg/m2. Mean weight 102 kg. Eight European centers.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Sibutramine 10-20 mg daily (n=352). Attrition rate 42%<BR/>Placebo (n=115). Attrition rate 50%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, weight maintenance, 5 and 10% responders, waist circumference, waist/hip ratio, lipid profile, uric acid, glucose, insulin, C-peptide, A1c, blood pressure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-interventions: 600 kcal/d deficit diet and exercise counseling.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kaukua-2003">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>236 patients with DM2. 52 week follow-up. Mean age 53 y. Mean BMI 35.7 kg/m2. Mean weight 99 kg. Finland.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Sibutramine 15 mg daily (n=114). Attrition rate 11%.<BR/>Placebo (n=122). Attrition rate 11%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HRQL (primary), weight loss, A1c, blood pressure, heart rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-interventions: 700 kcal/d deficit diet.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kelley-2002">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>550 patients with DM2. 1 year follow-up. Mean age 58 y. Mean BMI 35.7 kg/m2. Mean weight 102 kg. US.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orlistat 120 mg tid (n=274). Attrition rate 50%.<BR/>Placebo (n=276). Attrition rate 54%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, 5% and 10% responders, waist circ, lipid panel, A1c, glucose, blood pressure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-interventions: 600-800 kcal/d deficit diet, exercise counselling, food records.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Krempf--2003">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>696 patients followed for 18 months. Mean age 41 y. Mean BMI 36.1 kg/m2. Mean weight 97 kg. France.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orlistat 120 mg tid (n=346). Attrition rate 35%.<BR/>Placebo (n=350). Attrition rate 43%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, waist circ, lipid panel, A1c, glucose, blood pressure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-intervention: 20% energy reduced diet increased by 10% if weight stable; food diary</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lindgarde-2000">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>376 patients with DM2, HTN or dyslipidemia. 1 year follow-up. Mean age 53 y. Mean BMI 33.2 kg/m2. Mean weight 96 kg. Sweden.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orlistat 120 mg tid (n=190). Attrition rate 16%.<BR/>Placebo (n=186). Attrition rate 12%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, 5% and 10% responders, waist circ, waist-hip ratio, lipid panel, A1c, glucose, blood pressure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-interventions: 600-900 kcal/d deficit diet, exercise, educational package.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mathus_x002d_Vliegen-2005">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight maintenance trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>221 patients on VLCD for 3 mo. Those who lost 10% or more weight (n=189) randomized to sibutramine or placebo for 18 mo. Mean age 43 y. Mean BMI 36.6 kg/m2. Mean weight 105 kg. Dutch.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Sibutramine 10-15 mg daily (n=94). Attrition rate 35%.<BR/>Placebo (n=95). Attrition rate 39%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, weight maintenance, waist circ, hip circ, BMI, waist/hip ratio, lipid profile, glucose, uric acid, blood pressure, pulse rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-intervention: 600 kcal/d deficit diet</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-McMahon-2000">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>224 patients with controlled HTN. 36% African American. 52 week follow-up. Mean age 53 y. Mean BMI 34.3 kg/m2. Mean weight 97 kg. US.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Sibutramine 20 mg daily (n=170). Attrition rate 22%.<BR/>Placebo (n=169). Attrition rate 19%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, 5% and 10% responders, BMI, waist circ, lipid profile, glucose, blood pressure, heart rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-intervention: diet counseling</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-McMahon-2002">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>220 patients with controlled HTN. 15% African American. 52 week follow-up. Mean age 51 y. Mean BMI 33.9 kg/m2. Mean weight 98 kg. US.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Sibutramine 20 mg daily (n=146). Attrition rate 42%.<BR/>Placebo (n=74). Attrition rate 51%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, 5% and 10% responders, BMI, waist circ, waist-hip ratio, lipid profile, blood pressure, heart rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-intervention: diet counseling</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-McNulty-2003">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>194 patients with DM2. 52 week follow-up. Mean age 49 y. Mean BMI 36.6 kg/m2. Mean weight 103 kg. UK, Canada, France, Belgium.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Sibutramine 15 mg daily (n=68). Attrition rate 28%.<BR/>Sibutramine 20 mg daily (n=62). Attrition rate 21%.<BR/>Placebo (n=64). Attrition rate 28%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, 5% and 10% responders, BMI, waist circ, waist-hip ratio, lipid profile, A1c, glucose, insulin, blood pressure, heart rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-intervention: diet counseling</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Miles-2002">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>516 patients with DM2 on oral hypoglycemics. 52 week follow-up. Mean age 53 y. Mean BMI 35.4 kg/m2. Mean weight 102 kg. US, Canada.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orlistat 120 mg tid (n=255). Attrition rate 35%.<BR/>Placebo (n=261). Attrition rate 44%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, 5% and 10% responders, BMI, lipid profile, A1c, glucose, blood pressure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-interventions: 600-800 kcal/d deficit diet and exercise.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-RIO_x002d_Diabetes">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1047 patients with DM2 on oral agents. 1 year follow-up. Mean age 56 y. Mean BMI 34.2 kg/m2. Mean weight 98 kg. 11 countries.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rimonabant 20 mg daily (n=339). Attrition rate 32%.<BR/>Rimonabant 5 mg daily (n=358). Attrition rate 35%.<BR/>Placebo (n=348). Attrition rate 34%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, 5% and 10% responders, waist circ, lipid profile, glucose, A1c, insulin, blood pressure, insulin resistance</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-interventions: 600 kcal/d deficit diet and exercise counseling</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-RIO_x002d_Europe">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1507 patients. 41% hypertensive and 61% dyslipidemic. 1 year follow-up. Mean age 45 y. Mean BMI 36.0 kg/m2. Mean weight 101 kg. Europe and US.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rimonabant 20 mg daily (n=599). Attrition rate 39%.<BR/>Rimonabant 5 mg daily (n=603). Attrition rate 37%.<BR/>Placebo (n=305). Attrition rate 42%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, 5% and 10% responders, waist circ, lipid profile, glucose, insulin, blood pressure, insulin resistance</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-interventions:600 kcal/d deficit diet and exercise counseling</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-RIO_x002d_Lipids">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1036 patients with untreated dyslipidemia. 1 year follow-up. Mean age 48 y. Mean BMI 34.0 kg/m2. Mean weight 96 kg. Europe and NA.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rimonabant 20 mg daily (n=346). Attrition rate 36%.<BR/>Rimonabant 5 mg daily (n=345). Attrition rate 40%.<BR/>Placebo (n=342). Attrition rate 37%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, 5% and 10% responders, waist circ, lipid profile, apolipoprotein B:A-1 ratio, metabolic syndrome, adiponectin, leptin, c-reactive protein, glucose, insulin, blood pressure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-interventions:600 kcal/d deficit diet</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-RIO_x002d_North-America">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial. Second year weight maintenance</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>3045 patients. 30% hypertensive and 63% dyslipidemic. 2 year follow-up. Mean age 45 y. Mean BMI 37.6 kg/m2. Mean weight 104 kg. Europe and US.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rimonabant 20 mg daily (n=1222). Attrition rate 45%.<BR/>Rimonabant 5 mg daily (n=1216). Attrition rate 49%.<BR/>Placebo (n=607). Attrition rate 49%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, 5% and 10% responders, waist circ, lipid profile, glucose, insulin, blood pressure, insulin resistance</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-interventions:600 kcal/d deficit diet and exercise counseling</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rossner-2000">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial. Second year weight maintenance.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>729 patients followed for 1 year with a second weight maintenance year. Mean age 44 y. Mean BMI 35.1 kg/m2. Mean weight 98 kg. Europe.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orlistat 60 mg tid (n=242). Attrition rate 25%.<BR/>Orlistat 120 mg tid (n=244). Attrition rate 26%.<BR/>Placebo (n=243). Attrition rate 35%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, 5% and 10% responders, BMI, lipid profile, lipoprotein a, glucose, insulin, blood pressure, satisfaction</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-interventions:600 kcal/d deficit diet and food intake diary.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sanchez_x002d_Reyes-2004">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>86 patients with DM2 on sulfonylurea treatment. 52 week follow-up. Mean age 47 y. Mean BMI 30 kg/m2. Mean weight 74 kg. Mexico</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Sibutramine 10 mg daily (n=44). Attrition rate 45%.<BR/>Placebo (n=42). Attrition rate 45%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, 5% and 10% responders, waist circ, lipid profile, A1c, uric acid, glucose, blood pressure, heart rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-interventions: diet and exercise counseling</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sjostrom-1998">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial. Second year weight maintenance.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>688 patients followed for 1 year with a second weight maintenance year. Mean age 45 y. Mean BMI 36.1 kg/m2. Mean weight 100 kg. Europe.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orlistat 120 mg tid (n=345). Attrition rate 17%.<BR/>Placebo (n=343). Attrition rate 20%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, 5% and 10% responders, lipids, glucose, insulin, blood pressure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-interventions: 600-900 kcal/d deficit diet</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Smith-2001">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>485 patients from primary care. 52 week follow-up. Mean age 42 y. Mean BMI 32.7 kg/m2. Mean weight 87 kg. UK.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Sibutramine 10 mg daily (n=161). Attrition rate 42%.<BR/>Sibutramine 15 mg daily (n=161). Attrition rate 49%.<BR/>Placebo (n=163). Attrition rate 51%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, 5% and 10% responders, BMI, waist circ, waist-hip ratio, total cholesterol, triglycerides, glucose, uric acid, blood pressure, heart rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-intervention: diet counseling</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Swinburn-2005">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>339 patients with one or more cardiovascular risk factor(s). 1 year follow-up. Mean age 52 y. Mean BMI 37.8 kg/m2. Mean weight 108 kg. Australia and New Zealand.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orlistat 120 mg tid (n=170). Attrition rate 22%.<BR/>Placebo (n=169). Attrition rate 19%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>weight loss, 10-year risk of cardiovascular disease based on Framingham model (primary), waist circ, lipid panel, A1c, glucose, blood pressure, HRQL,</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-intervention: diet and exercise counseling.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-XENDOS">
<CHAR_METHODS>
<P>Randomized, double-blind, placebo-controlled.<BR/>Weight loss trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>3305 patients (21% with impaired glucose tolerance) 4 years follow-up. Mean age 43 y. Mean BMI 37.3 kg/m2. Mean weight 111 kg. Sweden.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Orlistat 120 mg tid (n=1650). Attrition rate 48%.<BR/>Placebo (n=1655). Attrition rate 66%.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Diabetes incidence (primary), weight loss, waist circ, 5% and 10% responders, A1c, glucose, lipid profile, blood pressure, insulin, fibrinogen, PAI-1</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-intervention: 800 kcal/d deficit diet and exercise counseling.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Derosa-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open-label randomized trial (n=87) of orlistat alone, simvastatin alone, and orlistat plus simvastatin for the treatment of hypercholesterolemia. No placebo arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gaciong-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Short-term (12 weeks), open-label cohort study of 2225 obese Polish patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gilbert-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pseudorandomized one-year trial using diethylpropion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hanefeld-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>A trial of orlistat vs. placebo in patients with Type 2 diabetes. Follow-up period after randomization too short (44 weeks). Results similar to trials included in the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Heymsfield-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pooled results from three orlistat trials already included in the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hill-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Orlistat weight maintenance trial lasting one year. Did not use intention-to-treat analysis. Results are not presented for 36% of patients randomized.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hsieh-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>One-year placebo-controlled RCT of orlistat. Unable to determine if the study was blinded. Attempts to contact the author to clarify were unsuccessful.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-James-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Preliminary publication of Finer 2000</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lucas-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Subgroup analysis of 5 previous sibutramine trials. Unable to determine which trials. Trials may already have been included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Poston-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open-label 1-year trial of orlistat</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Redmon-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients were randomized to phentermine plus fenfluramine vs. dual placebo for two years. Did not contain a phentermine only arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Redmon-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open-label 1-year trial involving sibutramine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Redmon-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open-label 1-year trial involving sibutramine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rossner-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplicate publication of James et al. Lancet 2000;356:2119-25. (Swedish)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Scholze-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized cohort study of 12 weeks duration in 6360 obese Germans.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Toubro-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplicate publication of James et al. Lancet 2000;356:2119-25. (Danish)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wadden-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>A 16-week comparison of different dietary and lifestyle modification regimens in sibutramine treated patients. Not a comparison of sibutramine vs. placebo or another drug.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wadden-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>A three-arm one-year open-label study of behavioural modification +/- pharmacotherapy with sibutramine in 224 adults. Excluded because open label. Results of sibutramine arm similar to this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weintraub-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>A mulitmodal intervention study lasting four years that included a comparison of combination therapy with phentermine/ fenfluramine and placebo. Only 24 weeks of this period was double-blind.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wirth-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Follow-up period after randomization too short (44 weeks). Results showed slightly lower efficacy compared to sibutramine studies included in this review. Also included an intermittent sibutramine arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wirth-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>XXL trial. Study of 15 549 patients on orlistat. No control arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zavoral-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pooled data from five randomized controlled trials of orlistat. It is not known how many of these studies were subsequently published (and included in the present review). Attempts to contact the author to clarify and obtain unpublished data were unsuccessful.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-AUDITOR-2005">
<CHAR_STUDY_NAME>
<P>AUDITOR</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>600 overweight patients 55 years or older with the metabolic syndrome</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rimonabant 20 mg daily versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Change in carotid intima media thickness; major cardiovascular events are secondary outcomes.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>August 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Sanofi-Aventis</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>24-26 months follow-up</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-CRESCENDO-2005">
<CHAR_STUDY_NAME>
<P>CRESCENDO</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>17 000 patients 55 years or older with central adiposity and cardiovascular risk factors</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rimonabant 20 mg daily versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>MI, stroke, cardiovascular death</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>December 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Sanofi-Aventis</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-SCOUT-2005">
<CHAR_STUDY_NAME>
<P>SCOUT</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>9000 patients with central obesity and cardiovascular disease or risk factors</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Sibutramine 10-15 mg daily versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>MI, stroke, cardiovascular mortality, cardiac arrest</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>December 2002</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Abbott</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>5 year follow-up</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-STRADIVARIUS-2005">
<CHAR_STUDY_NAME>
<P>STRADIVARIUS</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>800 patients 18 years or older with central adiposity and cardiovascular risk factors</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rimonabant 20 mg daily versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Intravascular ultrasound</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>January 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Sanofi-Aventis</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Over 2 year follow-up</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Apfelbaum-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bakris-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Berne-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Broom-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Davidson-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Derosa-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Finer-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hauner-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hauptman-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hollander-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-James-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kaukua-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kelley-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Krempf--2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lindgarde-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Mathus_x002d_Vliegen-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-McMahon-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-McMahon-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-McNulty-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Miles-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-RIO_x002d_Diabetes">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-RIO_x002d_Europe">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-RIO_x002d_Lipids">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-RIO_x002d_North-America">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rossner-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sanchez_x002d_Reyes-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Sjostrom-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Smith-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Swinburn-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-XENDOS">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-11-01 16:49:07 +0100" MODIFIED_BY="Gudrun Paletta"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-11-01 16:18:16 +0100" MODIFIED_BY="Gudrun Paletta">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Orlistat: Anthropometric Outcomes</NAME>
<CONT_OUTCOME CHI2="18.971019718096276" CI_END="-2.500241179762165" CI_START="-3.353355883182008" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.9267985314720866" ESTIMABLE="YES" I2="36.74562475651578" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.08923031442898766" P_Q="1.0" P_Z="3.15546766811972E-41" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.21050611678452874" TOTALS="YES" TOTAL_1="3317" TOTAL_2="2879" UNITS="" WEIGHT="99.99999999999999" Z="13.448179215982744">
<NAME>Orlistat: Change in Weight (%)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.42030089595917" CI_START="-4.579699104040832" EFFECT_SIZE="-3.000000000000001" ESTIMABLE="YES" MEAN_1="-8.8" MEAN_2="-5.8" ORDER="1" SD_1="10.25" SD_2="10.45" SE="0.8059837407734508" STUDY_ID="STD-Davidson-1999" TOTAL_1="657" TOTAL_2="223" WEIGHT="5.506830398433767"/>
<CONT_DATA CI_END="-0.5150071706090318" CI_START="-3.284992829390969" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" MEAN_1="-6.2" MEAN_2="-4.3" ORDER="1" SD_1="6.38" SD_2="6.3" SE="0.7066419792994235" STUDY_ID="STD-Hollander-1998" TOTAL_1="163" TOTAL_2="159" WEIGHT="6.672563318637534"/>
<CONT_DATA CI_END="-1.7551700102888124" CI_START="-5.644829989711188" EFFECT_SIZE="-3.7" ESTIMABLE="YES" MEAN_1="-7.9" MEAN_2="-4.2" ORDER="1" SD_1="11.45" SD_2="8.74" SE="0.9922784321812842" STUDY_ID="STD-Hauptman-2000" TOTAL_1="210" TOTAL_2="212" WEIGHT="3.963202109074902"/>
<CONT_DATA CI_END="-1.622174305365064" CI_START="-4.777825694634936" EFFECT_SIZE="-3.2" ESTIMABLE="YES" MEAN_1="-5.0" MEAN_2="-1.8" ORDER="27590" SD_1="5.97" SD_2="5.97" SE="0.8050279020842341" STUDY_ID="STD-Berne-2004" TOTAL_1="111" TOTAL_2="109" WEIGHT="5.516706970136519"/>
<CONT_DATA CI_END="-2.290108071599895" CI_START="-4.709891928400105" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="-5.8" MEAN_2="-2.3" ORDER="27591" SD_1="7.8" SD_2="6.2" SE="0.6173031432942533" STUDY_ID="STD-Broom-2002" TOTAL_1="259" TOTAL_2="263" WEIGHT="8.006690887865874"/>
<CONT_DATA CI_END="-0.46187077030827917" CI_START="-5.738129229691721" EFFECT_SIZE="-3.0999999999999996" ESTIMABLE="YES" MEAN_1="-8.5" MEAN_2="-5.4" ORDER="27593" SD_1="10.5" SD_2="9.35" SE="1.346009034094987" STUDY_ID="STD-Finer-2000" TOTAL_1="110" TOTAL_2="108" WEIGHT="2.342203372432829"/>
<CONT_DATA CI_END="-1.7619866749306183" CI_START="-3.3180133250693817" EFFECT_SIZE="-2.54" ESTIMABLE="YES" MEAN_1="-3.76" MEAN_2="-1.22" ORDER="27596" SD_1="4.24" SD_2="4.92" SE="0.3969528681170937" STUDY_ID="STD-Kelley-2002" TOTAL_1="266" TOTAL_2="269" WEIGHT="12.86824078595617"/>
<CONT_DATA CI_END="-1.2695492833345723" CI_START="-4.330450716665428" EFFECT_SIZE="-2.8000000000000003" ESTIMABLE="YES" MEAN_1="-5.4" MEAN_2="-2.6" ORDER="27597" SD_1="11.16" SD_2="9.35" SE="0.780856550802682" STUDY_ID="STD-Krempf--2003" TOTAL_1="346" TOTAL_2="350" WEIGHT="5.774522941658705"/>
<CONT_DATA CI_END="-0.19825488912961275" CI_START="-2.4017451108703884" EFFECT_SIZE="-1.3000000000000007" ESTIMABLE="YES" MEAN_1="-5.9" MEAN_2="-4.6" ORDER="27598" SD_1="5.5" SD_2="5.4" SE="0.5621251816670167" STUDY_ID="STD-Lindgarde-2000" TOTAL_1="190" TOTAL_2="186" WEIGHT="8.99638150202399"/>
<CONT_DATA CI_END="-2.19350492735587" CI_START="-3.6064950726441287" EFFECT_SIZE="-2.8999999999999995" ESTIMABLE="YES" MEAN_1="-4.6" MEAN_2="-1.7" ORDER="27599" SD_1="4.74" SD_2="3.19" SE="0.3604632933139956" STUDY_ID="STD-Miles-2002" TOTAL_1="250" TOTAL_2="254" WEIGHT="13.912917926132451"/>
<CONT_DATA CI_END="-1.925470016816118" CI_START="-4.274529983183881" EFFECT_SIZE="-3.0999999999999996" ESTIMABLE="YES" MEAN_1="-9.7" MEAN_2="-6.6" ORDER="27600" SD_1="6.3" SD_2="6.8" SE="0.5992610029819039" STUDY_ID="STD-Rossner-2000" TOTAL_1="242" TOTAL_2="237" WEIGHT="8.315216344342144"/>
<CONT_DATA CI_END="-3.0591678848900745" CI_START="-5.140832115109925" EFFECT_SIZE="-4.1" ESTIMABLE="YES" MEAN_1="-10.2" MEAN_2="-6.1" ORDER="27601" SD_1="7.4" SD_2="6.45" SE="0.5310465515284342" STUDY_ID="STD-Sjostrom-1998" TOTAL_1="343" TOTAL_2="340" WEIGHT="9.61696080998809"/>
<CONT_DATA CI_END="-2.3467226592775443" CI_START="-4.653277340722457" EFFECT_SIZE="-3.5000000000000004" ESTIMABLE="YES" MEAN_1="-4.4" MEAN_2="-0.9" ORDER="27602" SD_1="6.6" SD_2="3.9" SE="0.5884176188028762" STUDY_ID="STD-Swinburn-2005" TOTAL_1="170" TOTAL_2="169" WEIGHT="8.507562633317018"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="11.043883493632329" CI_END="-2.5301282894102877" CI_START="-3.2093089389671126" CI_STUDY="95" CI_TOTAL="95" DF="13.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.8697186141887" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.6071412870156006" P_Q="1.0" P_Z="1.2956441953910258E-61" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4948" TOTAL_2="4509" UNITS="" WEIGHT="100.0" Z="16.562736683514593">
<NAME>Orlistat: Change in Weight (kg)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.6123095547885506" CI_START="-3.7876904452114495" EFFECT_SIZE="-2.7" ESTIMABLE="YES" MEAN_1="-5.4" MEAN_2="-2.7" ORDER="27603" SD_1="6.4" SD_2="6.4" SE="0.5549543021152495" STUDY_ID="STD-Bakris-2002" TOTAL_1="267" TOTAL_2="265" WEIGHT="9.747651406598202"/>
<CONT_DATA CI_END="-2.207762325520334" CI_START="-4.792237674479666" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="-5.8" MEAN_2="-2.3" ORDER="27604" SD_1="8.5" SD_2="6.4" SE="0.659317051064546" STUDY_ID="STD-Broom-2002" TOTAL_1="259" TOTAL_2="263" WEIGHT="6.905988004148411"/>
<CONT_DATA CI_END="-1.4506345534373657" CI_START="-4.449365446562634" EFFECT_SIZE="-2.95" ESTIMABLE="YES" MEAN_1="-8.76" MEAN_2="-5.81" ORDER="27605" SD_1="9.48" SD_2="10.0" SE="0.7649964276840991" STUDY_ID="STD-Davidson-1999" TOTAL_1="657" TOTAL_2="223" WEIGHT="5.129743151656611"/>
<CONT_DATA CI_END="1.3931249933568606" CI_START="-3.3931249933568606" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-8.6" MEAN_2="-7.6" ORDER="27606" SD_1="5.0" SD_2="3.36" SE="1.2210045757133932" STUDY_ID="STD-Derosa-2003" TOTAL_1="25" TOTAL_2="23" WEIGHT="2.0136308288486076"/>
<CONT_DATA CI_END="-0.3737117143235744" CI_START="-3.5862882856764253" EFFECT_SIZE="-1.98" ESTIMABLE="YES" MEAN_1="-3.29" MEAN_2="-1.31" ORDER="27607" SD_1="6.05" SD_2="6.05" SE="0.8195498990525452" STUDY_ID="STD-Finer-2000" TOTAL_1="110" TOTAL_2="108" WEIGHT="4.469548274442272"/>
<CONT_DATA CI_END="-2.2342267220638323" CI_START="-5.365773277936169" EFFECT_SIZE="-3.8000000000000007" ESTIMABLE="YES" MEAN_1="-7.94" MEAN_2="-4.14" ORDER="27608" SD_1="8.26" SD_2="8.15" SE="0.7988785968960592" STUDY_ID="STD-Hauptman-2000" TOTAL_1="210" TOTAL_2="212" WEIGHT="4.703843485702017"/>
<CONT_DATA CI_END="-0.3819032954053978" CI_START="-3.3780967045946038" EFFECT_SIZE="-1.8800000000000008" ESTIMABLE="YES" MEAN_1="-6.19" MEAN_2="-4.31" ORDER="27609" SD_1="6.51" SD_2="7.18" SE="0.7643490984586444" STUDY_ID="STD-Hollander-1998" TOTAL_1="163" TOTAL_2="159" WEIGHT="5.138435616379944"/>
<CONT_DATA CI_END="-1.8514224062785745" CI_START="-3.3885775937214255" EFFECT_SIZE="-2.62" ESTIMABLE="YES" MEAN_1="-3.89" MEAN_2="-1.27" ORDER="27610" SD_1="4.48" SD_2="4.59" SE="0.39213863100744073" STUDY_ID="STD-Kelley-2002" TOTAL_1="266" TOTAL_2="269" WEIGHT="19.52248860109986"/>
<CONT_DATA CI_END="-1.514443152812997" CI_START="-4.285556847187003" EFFECT_SIZE="-2.9" ESTIMABLE="YES" MEAN_1="-5.3" MEAN_2="-2.4" ORDER="27611" SD_1="9.3" SD_2="9.35" SE="0.7069297487689052" STUDY_ID="STD-Krempf--2003" TOTAL_1="346" TOTAL_2="350" WEIGHT="6.007059295272015"/>
<CONT_DATA CI_END="-2.0688626479577925" CI_START="-3.731137352042208" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="-4.7" MEAN_2="-1.8" ORDER="27612" SD_1="4.74" SD_2="4.78" SE="0.424057461564658" STUDY_ID="STD-Miles-2002" TOTAL_1="250" TOTAL_2="254" WEIGHT="16.694177084635413"/>
<CONT_DATA CI_END="-1.8262033072765396" CI_START="-4.17379669272346" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="-9.4" MEAN_2="-6.4" ORDER="27613" SD_1="6.4" SD_2="6.7" SE="0.5988868683211624" STUDY_ID="STD-Rossner-2000" TOTAL_1="242" TOTAL_2="237" WEIGHT="8.369988352041743"/>
<CONT_DATA CI_END="-1.7086109188066354" CI_START="-6.691389081193367" EFFECT_SIZE="-4.200000000000001" ESTIMABLE="YES" MEAN_1="-10.3" MEAN_2="-6.1" ORDER="27614" SD_1="16.61" SD_2="16.61" SE="1.2711402356600043" STUDY_ID="STD-Sjostrom-1998" TOTAL_1="343" TOTAL_2="340" WEIGHT="1.8579221103120802"/>
<CONT_DATA CI_END="-2.48063207301868" CI_START="-5.119367926981321" EFFECT_SIZE="-3.8000000000000003" ESTIMABLE="YES" MEAN_1="-4.7" MEAN_2="-0.9" ORDER="27615" SD_1="7.7" SD_2="4.2" SE="0.6731592709806536" STUDY_ID="STD-Swinburn-2005" TOTAL_1="170" TOTAL_2="169" WEIGHT="6.624891527577103"/>
<CONT_DATA CI_END="-0.7758416810855784" CI_START="-4.824158318914421" EFFECT_SIZE="-2.8" ESTIMABLE="YES" MEAN_1="-5.8" MEAN_2="-3.0" ORDER="27616" SD_1="29.56" SD_2="29.56" SE="1.032752813256123" STUDY_ID="STD-XENDOS" TOTAL_1="1640" TOTAL_2="1637" WEIGHT="2.814632261285714"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="27.651508894146485" CI_END="0.2439089134528304" CI_START="0.18250088594449743" CI_STUDY="95" CI_TOTAL="95" DF="13.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.2132048996986639" ESTIMABLE="YES" EVENTS_1="2652" EVENTS_2="1468" I2="52.986290730948305" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.6127723284577099" LOG_CI_START="-0.738735022934232" LOG_EFFECT_SIZE="-0.6712028189342009" METHOD="MH" NO="3" P_CHI2="0.010118001089061579" P_Q="0.0" P_Z="3.504446290982873E-42" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0016698960769982883" TOTALS="YES" TOTAL_1="4931" TOTAL_2="4458" WEIGHT="100.00000000000001" Z="13.609749138421721">
<NAME>Orlistat: 5% Responders (absolute % difference)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.31583300593410607" CI_START="0.16028882291191188" EFFECT_SIZE="0.23806091442300897" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="58" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27617" O_E="0.0" SE="0.03968036766213738" STUDY_ID="STD-Bakris-2002" TOTAL_1="267" TOTAL_2="265" VAR="0.001574531577802398" WEIGHT="7.56407849920683"/>
<DICH_DATA CI_END="0.45913037524642875" CI_START="0.2396050574339581" EFFECT_SIZE="0.3493677163401934" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27618" O_E="0.0" SE="0.05600238564179197" STUDY_ID="STD-Berne-2004" TOTAL_1="111" TOTAL_2="109" VAR="0.0031362671975719873" WEIGHT="5.106173898785025"/>
<DICH_DATA CI_END="0.39233124236628264" CI_START="0.2329458543937039" EFFECT_SIZE="0.3126385483799933" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="64" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27619" O_E="0.0" SE="0.04066028489038328" STUDY_ID="STD-Broom-2002" TOTAL_1="259" TOTAL_2="263" VAR="0.0016532587673671307" WEIGHT="7.3848817209106645"/>
<DICH_DATA CI_END="0.29564443097191206" CI_START="0.1465885754235121" EFFECT_SIZE="0.2211165031977121" ESTIMABLE="YES" EVENTS_1="434" EVENTS_2="98" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27620" O_E="0.0" SE="0.0380251516671055" STUDY_ID="STD-Davidson-1999" TOTAL_1="657" TOTAL_2="223" VAR="0.0014459121593063762" WEIGHT="7.87632087878924"/>
<DICH_DATA CI_END="0.2597072415179454" CI_START="0.02345774164703779" EFFECT_SIZE="0.1415824915824916" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27621" O_E="0.0" SE="0.06026883701292817" STUDY_ID="STD-Finer-2000" TOTAL_1="110" TOTAL_2="108" VAR="0.0036323327148909007" WEIGHT="4.628450870217144"/>
<DICH_DATA CI_END="0.2899461656795354" CI_START="0.10637009667446277" EFFECT_SIZE="0.1981581311769991" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="65" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27622" O_E="0.0" SE="0.046831490387858464" STUDY_ID="STD-Hauptman-2000" TOTAL_1="210" TOTAL_2="212" VAR="0.0021931884919480795" WEIGHT="6.352722812020484"/>
<DICH_DATA CI_END="0.3591063870011253" CI_START="0.15707989999196806" EFFECT_SIZE="0.25809314349654666" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="37" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27623" O_E="0.0" SE="0.05153831616364289" STUDY_ID="STD-Hollander-1998" TOTAL_1="163" TOTAL_2="159" VAR="0.002656198032983614" WEIGHT="5.672808968553062"/>
<DICH_DATA CI_END="0.2662007443420442" CI_START="0.12771154567668294" EFFECT_SIZE="0.19695614500936356" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="35" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27624" O_E="0.0" SE="0.03532952639888956" STUDY_ID="STD-Kelley-2002" TOTAL_1="266" TOTAL_2="269" VAR="0.0012481754355698343" WEIGHT="8.410042509311873"/>
<DICH_DATA CI_END="0.2991847635776475" CI_START="0.11163247811723682" EFFECT_SIZE="0.20540862084744216" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="74" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27625" O_E="0.0" SE="0.04784584995943782" STUDY_ID="STD-Krempf--2003" TOTAL_1="223" TOTAL_2="196" VAR="0.0022892253583410354" WEIGHT="6.198624080295876"/>
<DICH_DATA CI_END="0.2335502616113587" CI_START="0.03345596362916195" EFFECT_SIZE="0.13350311262026032" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="76" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27626" O_E="0.0" SE="0.0510454017422042" STUDY_ID="STD-Lindgarde-2000" TOTAL_1="190" TOTAL_2="186" VAR="0.002605633039023023" WEIGHT="5.739899039384201"/>
<DICH_DATA CI_END="0.3061434032389549" CI_START="0.15502195109175382" EFFECT_SIZE="0.23058267716535435" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="41" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27627" O_E="0.0" SE="0.03855209925774856" STUDY_ID="STD-Miles-2002" TOTAL_1="250" TOTAL_2="254" VAR="0.0014862643571792972" WEIGHT="7.775620402612612"/>
<DICH_DATA CI_END="0.27659260523614104" CI_START="0.1014455438031587" EFFECT_SIZE="0.1890190745196499" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="107" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27628" O_E="0.0" SE="0.04468119384195833" STUDY_ID="STD-Rossner-2000" TOTAL_1="242" TOTAL_2="237" VAR="0.0019964090831426553" WEIGHT="6.693688712198325"/>
<DICH_DATA CI_END="0.2720020358729658" CI_START="0.12756922120129255" EFFECT_SIZE="0.19978562853712917" ESTIMABLE="YES" EVENTS_1="237" EVENTS_2="167" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27629" O_E="0.0" SE="0.03684578283349614" STUDY_ID="STD-Sjostrom-1998" TOTAL_1="343" TOTAL_2="340" VAR="0.001357611712613159" WEIGHT="8.106042055488663"/>
<DICH_DATA CI_END="0.18846069400413593" CI_START="0.12114938987923193" EFFECT_SIZE="0.15480504194168393" ESTIMABLE="YES" EVENTS_1="866" EVENTS_2="611" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27630" O_E="0.0" SE="0.017171566583836992" STUDY_ID="STD-XENDOS" TOTAL_1="1640" TOTAL_2="1637" VAR="2.948626989431472E-4" WEIGHT="12.490645552226008"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="28.212089414946895" CI_END="0.14471480439828258" CI_START="0.09236994206261975" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.11854237323045116" ESTIMABLE="YES" EVENTS_1="1271" EVENTS_2="586" I2="57.46504335959482" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.839487038061323" LOG_CI_START="-1.0344693287804352" LOG_EFFECT_SIZE="-0.9261263823899651" METHOD="MH" NO="4" P_CHI2="0.005150034547121041" P_Q="0.0" P_Z="6.854382583670668E-19" Q="0.0" RANDOM="YES" SCALE="0.5" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.00120612866018902" TOTALS="YES" TOTAL_1="4664" TOTAL_2="4193" WEIGHT="100.0" Z="8.877233478376947">
<NAME>Orlistat: 10% Responders (absolute % difference)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.1782381066983528" CI_START="0.036986292012284455" EFFECT_SIZE="0.10761219935531863" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27631" O_E="0.0" SE="0.03603428833392976" STUDY_ID="STD-Berne-2004" TOTAL_1="111" TOTAL_2="109" VAR="0.0012984699357327868" WEIGHT="7.119570875489708"/>
<DICH_DATA CI_END="0.14466136097854135" CI_START="0.021024150714574884" EFFECT_SIZE="0.08284275584655812" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="30" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27632" O_E="0.0" SE="0.03154068422664932" STUDY_ID="STD-Broom-2002" TOTAL_1="259" TOTAL_2="263" VAR="9.948147614852049E-4" WEIGHT="8.101828989658001"/>
<DICH_DATA CI_END="0.20657371104577246" CI_START="0.07048398428085825" EFFECT_SIZE="0.13852884766331536" ESTIMABLE="YES" EVENTS_1="256" EVENTS_2="56" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27633" O_E="0.0" SE="0.03471740497232924" STUDY_ID="STD-Davidson-1999" TOTAL_1="657" TOTAL_2="223" VAR="0.0012052982080127108" WEIGHT="7.394653950926113"/>
<DICH_DATA CI_END="0.2247339792807731" CI_START="0.0055690510222572015" EFFECT_SIZE="0.11515151515151514" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="18" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27634" O_E="0.0" SE="0.05591044784171058" STUDY_ID="STD-Finer-2000" TOTAL_1="110" TOTAL_2="108" VAR="0.003125978177860639" WEIGHT="4.116165155877188"/>
<DICH_DATA CI_END="0.24702050109146598" CI_START="0.09799297599748277" EFFECT_SIZE="0.17250673854447438" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="24" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27635" O_E="0.0" SE="0.03801792437756339" STUDY_ID="STD-Hauptman-2000" TOTAL_1="210" TOTAL_2="212" VAR="0.0014453625739781289" WEIGHT="6.725146584887111"/>
<DICH_DATA CI_END="0.16325967753799298" CI_START="0.01646791439008513" EFFECT_SIZE="0.08986379596403905" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="14" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27636" O_E="0.0" SE="0.037447566461879536" STUDY_ID="STD-Hollander-1998" TOTAL_1="163" TOTAL_2="159" VAR="0.001402320233916885" WEIGHT="6.836119066242795"/>
<DICH_DATA CI_END="0.10708674482323505" CI_START="0.021571331594575256" EFFECT_SIZE="0.06432903820890515" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27637" O_E="0.0" SE="0.021815557301867395" STUDY_ID="STD-Kelley-2002" TOTAL_1="266" TOTAL_2="269" VAR="4.759185403910598E-4" WEIGHT="10.601169344218038"/>
<DICH_DATA CI_END="0.2491303943821805" CI_START="0.08678065165058246" EFFECT_SIZE="0.16795552301638147" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="33" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27638" O_E="0.0" SE="0.04141651173495842" STUDY_ID="STD-Krempf--2003" TOTAL_1="223" TOTAL_2="196" VAR="0.0017153274442919483" WEIGHT="6.1036916457402395"/>
<DICH_DATA CI_END="0.1195971819377615" CI_START="-0.03097239416187017" EFFECT_SIZE="0.04431239388794567" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27639" O_E="0.0" SE="0.03841131196473641" STUDY_ID="STD-Lindgarde-2000" TOTAL_1="190" TOTAL_2="186" VAR="0.0014754288868523025" WEIGHT="6.649742511769607"/>
<DICH_DATA CI_END="0.1498440641062444" CI_START="0.051415778413440666" EFFECT_SIZE="0.10062992125984253" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27640" O_E="0.0" SE="0.025109717951246422" STUDY_ID="STD-Miles-2002" TOTAL_1="250" TOTAL_2="254" VAR="6.304979355911468E-4" WEIGHT="9.708923555439819"/>
<DICH_DATA CI_END="0.26924591125700903" CI_START="0.1113378318123497" EFFECT_SIZE="0.19029187153467936" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="45" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27641" O_E="0.0" SE="0.04028341354489626" STUDY_ID="STD-Rossner-2000" TOTAL_1="242" TOTAL_2="237" VAR="0.0016227534068291314" WEIGHT="6.3034325206469966"/>
<DICH_DATA CI_END="0.2770570936533207" CI_START="0.14546048480663465" EFFECT_SIZE="0.21125878922997768" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="61" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27642" O_E="0.0" SE="0.03357118035961459" STUDY_ID="STD-Sjostrom-1998" TOTAL_1="343" TOTAL_2="340" VAR="0.0011270241507377724" WEIGHT="7.642734387052035"/>
<DICH_DATA CI_END="0.13402177264259585" CI_START="0.07882296118042963" EFFECT_SIZE="0.10642236691151274" ESTIMABLE="YES" EVENTS_1="430" EVENTS_2="255" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27643" O_E="0.0" SE="0.01408158820712202" STUDY_ID="STD-XENDOS" TOTAL_1="1640" TOTAL_2="1637" VAR="1.9829112643495795E-4" WEIGHT="12.696821412052346"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="20.40301511899555" CI_END="-1.255932376973695" CI_START="-2.8586090207280015" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.0572706988508482" ESTIMABLE="YES" I2="60.790108945457455" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="0.00891425342302865" P_Q="1.0" P_Z="4.858887186226881E-7" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.8927987675051574" TOTALS="YES" TOTAL_1="2457" TOTAL_2="2174" UNITS="" WEIGHT="99.99999999999999" Z="5.0318028804010595">
<NAME>Orlistat: Change in Waist Circumference (cm)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.2916803214930046" CI_START="-1.2916803214930046" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-5.4" MEAN_2="-5.4" ORDER="27644" SD_1="7.7" SD_2="7.5" SE="0.6590326820704943" STUDY_ID="STD-Bakris-2002" TOTAL_1="267" TOTAL_2="265" WEIGHT="12.59576408177446"/>
<CONT_DATA CI_END="-0.7076101094196252" CI_START="-3.292389890580375" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="-5.0" MEAN_2="-3.0" ORDER="27645" SD_1="4.89" SD_2="4.89" SE="0.6593947137674883" STUDY_ID="STD-Berne-2004" TOTAL_1="111" TOTAL_2="109" WEIGHT="12.591235522697328"/>
<CONT_DATA CI_END="-1.9007235864468275" CI_START="-4.879276413553173" EFFECT_SIZE="-3.39" ESTIMABLE="YES" MEAN_1="-5.99" MEAN_2="-2.6" ORDER="27646" SD_1="8.68" SD_2="8.68" SE="0.7598488672753146" STUDY_ID="STD-Broom-2002" TOTAL_1="259" TOTAL_2="263" WEIGHT="11.370206734559787"/>
<CONT_DATA CI_END="1.511198986281736" CI_START="-2.7111989862817363" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="-3.0" MEAN_2="-2.4" ORDER="27647" SD_1="5.0" SD_2="1.92" SE="1.0771621330466297" STUDY_ID="STD-Derosa-2003" TOTAL_1="25" TOTAL_2="23" WEIGHT="8.14198688785878"/>
<CONT_DATA CI_END="-1.4150506569831078" CI_START="-4.184949343016892" EFFECT_SIZE="-2.8" ESTIMABLE="YES" MEAN_1="-4.8" MEAN_2="-2.0" ORDER="27648" SD_1="6.36" SD_2="6.3" SE="0.7066197919661767" STUDY_ID="STD-Hollander-1998" TOTAL_1="162" TOTAL_2="159" WEIGHT="12.007759923883592"/>
<CONT_DATA CI_END="-1.1489132831497837" CI_START="-4.311086716850215" EFFECT_SIZE="-2.7299999999999995" ESTIMABLE="YES" MEAN_1="-5.27" MEAN_2="-2.54" ORDER="27649" SD_1="11.42" SD_2="6.57" SE="0.8066917195018001" STUDY_ID="STD-Kelley-2002" TOTAL_1="266" TOTAL_2="269" WEIGHT="10.829660859398073"/>
<CONT_DATA CI_END="0.8853450004790089" CI_START="-3.2853450004790092" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" MEAN_1="-6.5" MEAN_2="-5.3" ORDER="27650" SD_1="14.97" SD_2="13.02" SE="1.0639710815749392" STUDY_ID="STD-Krempf--2003" TOTAL_1="346" TOTAL_2="350" WEIGHT="8.255557049182258"/>
<CONT_DATA CI_END="-1.9719077868449657" CI_START="-4.4280922131550335" EFFECT_SIZE="-3.1999999999999997" ESTIMABLE="YES" MEAN_1="-5.1" MEAN_2="-1.9" ORDER="27651" SD_1="7.0" SD_2="4.2" SE="0.6265891734960788" STUDY_ID="STD-Swinburn-2005" TOTAL_1="170" TOTAL_2="169" WEIGHT="13.004481336230244"/>
<CONT_DATA CI_END="-0.4827466523176738" CI_START="-3.5172533476823262" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="-6.4" MEAN_2="-4.4" ORDER="27652" SD_1="14.28" SD_2="14.28" SE="0.7741230755515035" STUDY_ID="STD-XENDOS" TOTAL_1="851" TOTAL_2="567" WEIGHT="11.203347604415471"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.42244482481475365" CI_END="-0.7052370114391069" CI_START="-1.3956190393907897" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0504280254149483" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="0.8095940860595273" P_Q="1.0" P_Z="2.45779436762418E-9" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="638" TOTAL_2="638" UNITS="" WEIGHT="100.0" Z="5.964237233327607">
<NAME>Orlistat: Change in Body Mass Index (kg/m2)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.6175463611796985" CI_START="-1.3824536388203013" EFFECT_SIZE="-0.9999999999999999" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-0.9" ORDER="27653" SD_1="2.3" SD_2="2.2" SE="0.19513299317591895" STUDY_ID="STD-Bakris-2002" TOTAL_1="267" TOTAL_2="265" WEIGHT="81.4631817555135"/>
<CONT_DATA CI_END="2.132653438917421" CI_START="-3.932653438917421" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="-3.0" MEAN_2="-2.1" ORDER="27654" SD_1="5.9" SD_2="4.8" SE="1.547300594724497" STUDY_ID="STD-Derosa-2003" TOTAL_1="25" TOTAL_2="23" WEIGHT="1.2956073296277804"/>
<CONT_DATA CI_END="-0.46866589168779804" CI_START="-2.1313341083122017" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-1.0" ORDER="27655" SD_1="5.58" SD_2="5.61" SE="0.42415784926134315" STUDY_ID="STD-Krempf--2003" TOTAL_1="346" TOTAL_2="350" WEIGHT="17.24121091485872"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="17.898149057472633" CI_END="-2.36354488706127" CI_START="-3.1273983730861774" CI_STUDY="95" CI_TOTAL="95" DF="14.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.7454716300737236" ESTIMABLE="YES" I2="21.779621149401045" I2_Q="8.799033241548956" ID="CMP-001.07" NO="7" P_CHI2="0.21145918566354338" P_Q="0.2950404689598183" P_Z="4.428213854945882E-45" Q="1.096479604924074" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.11867265621658481" TOTALS="YES" TOTAL_1="5138" TOTAL_2="4695" UNITS="" WEIGHT="100.00000000000001" Z="14.08915613784476">
<NAME>Orlistat: Sensitivity Analysis According to Baseline CV Risk (Absolute Weight Loss)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.504786703495876" CI_END="-2.412388863618804" CI_START="-3.588422016859515" DF="6.0" EFFECT_SIZE="-3.0004054402391596" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" NO="1" P_CHI2="0.7433327834169419" P_Z="1.510399815458305E-23" STUDIES="7" TAU2="0.0" TOTAL_1="3548" TOTAL_2="3107" WEIGHT="34.70412972467825" Z="10.000885750000855">
<NAME>Change in Weight in Lower Risk Population (kg)</NAME>
<CONT_DATA CI_END="-1.4506345534373657" CI_START="-4.449365446562634" EFFECT_SIZE="-2.95" ESTIMABLE="YES" MEAN_1="-8.76" MEAN_2="-5.81" ORDER="27656" SD_1="9.48" SD_2="10.0" SE="0.7649964276840991" STUDY_ID="STD-Davidson-1999" TOTAL_1="657" TOTAL_2="223" WEIGHT="5.394582133259297"/>
<CONT_DATA CI_END="-0.3737117143235744" CI_START="-3.5862882856764253" EFFECT_SIZE="-1.98" ESTIMABLE="YES" MEAN_1="-3.29" MEAN_2="-1.31" ORDER="27657" SD_1="6.05" SD_2="6.05" SE="0.8195498990525452" STUDY_ID="STD-Finer-2000" TOTAL_1="110" TOTAL_2="108" WEIGHT="4.804552131507583"/>
<CONT_DATA CI_END="-2.2342267220638323" CI_START="-5.365773277936169" EFFECT_SIZE="-3.8000000000000007" ESTIMABLE="YES" MEAN_1="-7.94" MEAN_2="-4.14" ORDER="27658" SD_1="8.26" SD_2="8.15" SE="0.7988785968960592" STUDY_ID="STD-Hauptman-2000" TOTAL_1="210" TOTAL_2="212" WEIGHT="5.016919322354713"/>
<CONT_DATA CI_END="-1.514443152812997" CI_START="-4.285556847187003" EFFECT_SIZE="-2.9" ESTIMABLE="YES" MEAN_1="-5.3" MEAN_2="-2.4" ORDER="27659" SD_1="9.3" SD_2="9.35" SE="0.7069297487689052" STUDY_ID="STD-Krempf--2003" TOTAL_1="346" TOTAL_2="350" WEIGHT="6.140147397625215"/>
<CONT_DATA CI_END="-1.8262033072765396" CI_START="-4.17379669272346" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="-9.4" MEAN_2="-6.4" ORDER="27660" SD_1="6.4" SD_2="6.7" SE="0.5988868683211624" STUDY_ID="STD-Rossner-2000" TOTAL_1="242" TOTAL_2="237" WEIGHT="7.954956745840449"/>
<CONT_DATA CI_END="-1.7086109188066354" CI_START="-6.691389081193367" EFFECT_SIZE="-4.200000000000001" ESTIMABLE="YES" MEAN_1="-10.3" MEAN_2="-6.1" ORDER="27661" SD_1="16.61" SD_2="16.61" SE="1.2711402356600043" STUDY_ID="STD-Sjostrom-1998" TOTAL_1="343" TOTAL_2="340" WEIGHT="2.189258906693929"/>
<CONT_DATA CI_END="-0.7758416810855784" CI_START="-4.824158318914421" EFFECT_SIZE="-2.8" ESTIMABLE="YES" MEAN_1="-5.8" MEAN_2="-3.0" ORDER="27662" SD_1="29.56" SD_2="29.56" SE="1.032752813256123" STUDY_ID="STD-XENDOS" TOTAL_1="1640" TOTAL_2="1637" WEIGHT="3.2037130873970643"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="13.296882749052685" CI_END="-2.0218688700329297" CI_START="-3.1578794982396703" DF="7.0" EFFECT_SIZE="-2.5898741841363" ESTIMABLE="YES" I2="47.35608238330368" ID="CMP-001.07.02" NO="2" P_CHI2="0.06519698124627316" P_Z="4.011756070325754E-19" STUDIES="8" TAU2="0.29963288290049805" TOTAL_1="1590" TOTAL_2="1588" WEIGHT="65.29587027532176" Z="8.93664196330639">
<NAME>Change in Weight in Higher Risk Population (kg)</NAME>
<CONT_DATA CI_END="-1.6123095547885506" CI_START="-3.7876904452114495" EFFECT_SIZE="-2.7" ESTIMABLE="YES" MEAN_1="-5.4" MEAN_2="-2.7" ORDER="27663" SD_1="6.4" SD_2="6.4" SE="0.5549543021152495" STUDY_ID="STD-Bakris-2002" TOTAL_1="267" TOTAL_2="265" WEIGHT="8.900109049338964"/>
<CONT_DATA CI_END="-2.207762325520334" CI_START="-4.792237674479666" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="-5.8" MEAN_2="-2.3" ORDER="27664" SD_1="8.5" SD_2="6.4" SE="0.659317051064546" STUDY_ID="STD-Broom-2002" TOTAL_1="259" TOTAL_2="263" WEIGHT="6.861942370978627"/>
<CONT_DATA CI_END="1.3931249933568606" CI_START="-3.3931249933568606" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-8.6" MEAN_2="-7.6" ORDER="27665" SD_1="5.0" SD_2="3.36" SE="1.2210045757133932" STUDY_ID="STD-Derosa-2003" TOTAL_1="25" TOTAL_2="23" WEIGHT="2.3592082358681354"/>
<CONT_DATA CI_END="-0.3819032954053978" CI_START="-3.3780967045946038" EFFECT_SIZE="-1.8800000000000008" ESTIMABLE="YES" MEAN_1="-6.19" MEAN_2="-4.31" ORDER="27666" SD_1="6.51" SD_2="7.18" SE="0.7643490984586444" STUDY_ID="STD-Hollander-1998" TOTAL_1="163" TOTAL_2="159" WEIGHT="5.402180036151309"/>
<CONT_DATA CI_END="-1.8514224062785745" CI_START="-3.3885775937214255" EFFECT_SIZE="-2.62" ESTIMABLE="YES" MEAN_1="-3.89" MEAN_2="-1.27" ORDER="27667" SD_1="4.48" SD_2="4.59" SE="0.39213863100744073" STUDY_ID="STD-Kelley-2002" TOTAL_1="266" TOTAL_2="269" WEIGHT="13.937488989280348"/>
<CONT_DATA CI_END="-0.17499718738525805" CI_START="-2.425002812614742" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" MEAN_1="-5.6" MEAN_2="-4.3" ORDER="27668" SD_1="5.2" SD_2="5.9" SE="0.573991574074126" STUDY_ID="STD-Lindgarde-2000" TOTAL_1="190" TOTAL_2="186" WEIGHT="8.47327364137165"/>
<CONT_DATA CI_END="-2.0688626479577925" CI_START="-3.731137352042208" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="-4.7" MEAN_2="-1.8" ORDER="27669" SD_1="4.74" SD_2="4.78" SE="0.424057461564658" STUDY_ID="STD-Miles-2002" TOTAL_1="250" TOTAL_2="254" WEIGHT="12.721063571745864"/>
<CONT_DATA CI_END="-2.48063207301868" CI_START="-5.119367926981321" EFFECT_SIZE="-3.8000000000000003" ESTIMABLE="YES" MEAN_1="-4.7" MEAN_2="-0.9" ORDER="27670" SD_1="7.7" SD_2="4.2" SE="0.6731592709806536" STUDY_ID="STD-Swinburn-2005" TOTAL_1="170" TOTAL_2="169" WEIGHT="6.640604380586862"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="18.971019718096276" CI_END="-2.500241179762165" CI_START="-3.353355883182009" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.926798531472087" ESTIMABLE="YES" I2="36.74562475651578" I2_Q="75.8671300415916" ID="CMP-001.08" NO="8" P_CHI2="0.08923031442898766" P_Q="0.04178920955187759" P_Z="3.15546766811963E-41" Q="4.143725970941052" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.21050611678452874" TOTALS="YES" TOTAL_1="3317" TOTAL_2="2879" UNITS="" WEIGHT="100.0" Z="13.448179215982746">
<NAME>Orlistat: Sensitivity Analysis According to Baseline CV Risk (% Weight Loss)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.9628171672028505" CI_END="-2.8279224895986443" CI_START="-4.005677345634296" DF="5.0" EFFECT_SIZE="-3.41679991761647" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.01" NO="1" P_CHI2="0.7057186485079676" P_Z="5.7549618241806965E-30" STUDIES="6" TAU2="0.0" TOTAL_1="1908" TOTAL_2="1470" WEIGHT="35.51893597593043" Z="11.372153970053319">
<NAME>Change in Weight in Lower Risk Population (%)</NAME>
<CONT_DATA CI_END="-1.7551700102888124" CI_START="-5.644829989711188" EFFECT_SIZE="-3.7" ESTIMABLE="YES" MEAN_1="-7.9" MEAN_2="-4.2" ORDER="1" SD_1="11.45" SD_2="8.74" SE="0.9922784321812842" STUDY_ID="STD-Hauptman-2000" TOTAL_1="210" TOTAL_2="212" WEIGHT="3.963202109074902"/>
<CONT_DATA CI_END="-1.42030089595917" CI_START="-4.579699104040832" EFFECT_SIZE="-3.000000000000001" ESTIMABLE="YES" MEAN_1="-8.8" MEAN_2="-5.8" ORDER="1" SD_1="10.25" SD_2="10.45" SE="0.8059837407734508" STUDY_ID="STD-Davidson-1999" TOTAL_1="657" TOTAL_2="223" WEIGHT="5.506830398433767"/>
<CONT_DATA CI_END="-0.46187077030827917" CI_START="-5.738129229691721" EFFECT_SIZE="-3.0999999999999996" ESTIMABLE="YES" MEAN_1="-8.5" MEAN_2="-5.4" ORDER="27672" SD_1="10.5" SD_2="9.35" SE="1.346009034094987" STUDY_ID="STD-Finer-2000" TOTAL_1="110" TOTAL_2="108" WEIGHT="2.342203372432829"/>
<CONT_DATA CI_END="-1.2695492833345723" CI_START="-4.330450716665428" EFFECT_SIZE="-2.8000000000000003" ESTIMABLE="YES" MEAN_1="-5.4" MEAN_2="-2.6" ORDER="27674" SD_1="11.16" SD_2="9.35" SE="0.780856550802682" STUDY_ID="STD-Krempf--2003" TOTAL_1="346" TOTAL_2="350" WEIGHT="5.774522941658705"/>
<CONT_DATA CI_END="-1.925470016816118" CI_START="-4.274529983183881" EFFECT_SIZE="-3.0999999999999996" ESTIMABLE="YES" MEAN_1="-9.7" MEAN_2="-6.6" ORDER="27675" SD_1="6.3" SD_2="6.8" SE="0.5992610029819039" STUDY_ID="STD-Rossner-2000" TOTAL_1="242" TOTAL_2="237" WEIGHT="8.315216344342144"/>
<CONT_DATA CI_END="-3.0591678848900745" CI_START="-5.140832115109925" EFFECT_SIZE="-4.1" ESTIMABLE="YES" MEAN_1="-10.2" MEAN_2="-6.1" ORDER="27676" SD_1="7.4" SD_2="6.45" SE="0.5310465515284342" STUDY_ID="STD-Sjostrom-1998" TOTAL_1="343" TOTAL_2="340" WEIGHT="9.61696080998809"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="11.864476579952374" CI_END="-2.11429998555386" CI_START="-3.2474451642060442" DF="6.0" EFFECT_SIZE="-2.680872574879952" ESTIMABLE="YES" I2="49.428868947001746" ID="CMP-001.08.02" NO="2" P_CHI2="0.065061443391225" P_Z="1.79235067296368E-20" STUDIES="7" TAU2="0.2756849858713729" TOTAL_1="1409" TOTAL_2="1409" WEIGHT="64.48106402406957" Z="9.274034418353544">
<NAME>Change in Weight in Higher Risk Population (%)</NAME>
<CONT_DATA CI_END="-0.5150071706090318" CI_START="-3.284992829390969" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" MEAN_1="-6.2" MEAN_2="-4.3" ORDER="1" SD_1="6.38" SD_2="6.3" SE="0.7066419792994235" STUDY_ID="STD-Hollander-1998" TOTAL_1="163" TOTAL_2="159" WEIGHT="6.672563318637534"/>
<CONT_DATA CI_END="-1.622174305365064" CI_START="-4.777825694634936" EFFECT_SIZE="-3.2" ESTIMABLE="YES" MEAN_1="-5.0" MEAN_2="-1.8" ORDER="27677" SD_1="5.97" SD_2="5.97" SE="0.8050279020842341" STUDY_ID="STD-Berne-2004" TOTAL_1="111" TOTAL_2="109" WEIGHT="5.516706970136519"/>
<CONT_DATA CI_END="-2.290108071599895" CI_START="-4.709891928400105" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="-5.8" MEAN_2="-2.3" ORDER="27678" SD_1="7.8" SD_2="6.2" SE="0.6173031432942533" STUDY_ID="STD-Broom-2002" TOTAL_1="259" TOTAL_2="263" WEIGHT="8.006690887865874"/>
<CONT_DATA CI_END="-1.7619866749306183" CI_START="-3.3180133250693817" EFFECT_SIZE="-2.54" ESTIMABLE="YES" MEAN_1="-3.76" MEAN_2="-1.22" ORDER="27680" SD_1="4.24" SD_2="4.92" SE="0.3969528681170937" STUDY_ID="STD-Kelley-2002" TOTAL_1="266" TOTAL_2="269" WEIGHT="12.86824078595617"/>
<CONT_DATA CI_END="-0.19825488912961275" CI_START="-2.4017451108703884" EFFECT_SIZE="-1.3000000000000007" ESTIMABLE="YES" MEAN_1="-5.9" MEAN_2="-4.6" ORDER="27681" SD_1="5.5" SD_2="5.4" SE="0.5621251816670167" STUDY_ID="STD-Lindgarde-2000" TOTAL_1="190" TOTAL_2="186" WEIGHT="8.99638150202399"/>
<CONT_DATA CI_END="-2.19350492735587" CI_START="-3.6064950726441287" EFFECT_SIZE="-2.8999999999999995" ESTIMABLE="YES" MEAN_1="-4.6" MEAN_2="-1.7" ORDER="27682" SD_1="4.74" SD_2="3.19" SE="0.3604632933139956" STUDY_ID="STD-Miles-2002" TOTAL_1="250" TOTAL_2="254" WEIGHT="13.912917926132451"/>
<CONT_DATA CI_END="-2.3467226592775443" CI_START="-4.653277340722457" EFFECT_SIZE="-3.5000000000000004" ESTIMABLE="YES" MEAN_1="-4.4" MEAN_2="-0.9" ORDER="27683" SD_1="6.6" SD_2="3.9" SE="0.5884176188028762" STUDY_ID="STD-Swinburn-2005" TOTAL_1="170" TOTAL_2="169" WEIGHT="8.507562633317018"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Orlistat: Change in Blood Pressure</NAME>
<CONT_OUTCOME CHI2="13.543556421026612" CI_END="-0.8575014098484534" CI_START="-2.1853768980967776" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.5214391539726155" ESTIMABLE="YES" I2="11.396980032735069" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="0.33079981890610755" P_Q="1.0" P_Z="7.077856353312257E-6" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.1675002079845055" TOTALS="YES" TOTAL_1="3841" TOTAL_2="3124" UNITS="" WEIGHT="100.0" Z="4.49133367223925">
<NAME>Orlistat: Change in Systolic Blood Pressure (mm Hg)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.26626202794331544" CI_START="-4.866262027943317" EFFECT_SIZE="-2.3000000000000007" ESTIMABLE="YES" MEAN_1="-13.3" MEAN_2="-11.0" ORDER="27684" SD_1="15.2" SD_2="15.0" SE="1.309341420651432" STUDY_ID="STD-Bakris-2002" TOTAL_1="267" TOTAL_2="265" WEIGHT="6.097723455500235"/>
<CONT_DATA CI_END="1.3166073238263416" CI_START="-1.5166073238263418" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="-3.2" MEAN_2="-3.1" ORDER="27685" SD_1="5.36" SD_2="5.36" SE="0.7227721197942204" STUDY_ID="STD-Berne-2004" TOTAL_1="111" TOTAL_2="109" WEIGHT="16.633075178870765"/>
<CONT_DATA CI_END="-0.8981700652853339" CI_START="-6.501829934714666" EFFECT_SIZE="-3.7" ESTIMABLE="YES" MEAN_1="-6.0" MEAN_2="-2.3" ORDER="27686" SD_1="16.33" SD_2="16.33" SE="1.4295313367057472" STUDY_ID="STD-Broom-2002" TOTAL_1="259" TOTAL_2="263" WEIGHT="5.189888136950345"/>
<CONT_DATA CI_END="0.7097239698773994" CI_START="-4.3097239698774" EFFECT_SIZE="-1.8" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="1.0" ORDER="27687" SD_1="14.27" SD_2="17.22" SE="1.2804949425978138" STUDY_ID="STD-Davidson-1999" TOTAL_1="657" TOTAL_2="223" WEIGHT="6.34980116044477"/>
<CONT_DATA CI_END="8.37299109368845" CI_START="-12.37299109368845" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="-6.0" MEAN_2="-4.0" ORDER="27688" SD_1="15.0" SD_2="20.91" SE="5.292439644559431" STUDY_ID="STD-Derosa-2003" TOTAL_1="25" TOTAL_2="23" WEIGHT="0.4072464868826756"/>
<CONT_DATA CI_END="1.7716550643332494" CI_START="-3.7716550643332494" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="3.0" ORDER="27689" SD_1="14.49" SD_2="14.56" SE="1.4141357117761912" STUDY_ID="STD-Hauptman-2000" TOTAL_1="210" TOTAL_2="212" WEIGHT="5.294726211897122"/>
<CONT_DATA CI_END="2.4715786770417143" CI_START="-3.071578677041714" EFFECT_SIZE="-0.29999999999999993" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="-0.9" ORDER="27690" SD_1="16.31" SD_2="16.61" SE="1.4140967379521119" STUDY_ID="STD-Kelley-2002" TOTAL_1="266" TOTAL_2="276" WEIGHT="5.2949955133464135"/>
<CONT_DATA CI_END="3.4668656679512693" CI_START="-2.6668656679512694" EFFECT_SIZE="0.4" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="-0.9" ORDER="27691" SD_1="16.01" SD_2="14.3" SE="1.5647561343689549" STUDY_ID="STD-Lindgarde-2000" TOTAL_1="190" TOTAL_2="186" WEIGHT="4.3865906565067565"/>
<CONT_DATA CI_END="0.6598478957301293" CI_START="-4.05984789573013" EFFECT_SIZE="-1.7000000000000002" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="-0.4" ORDER="27692" SD_1="12.65" SD_2="14.34" SE="1.2040261526968394" STUDY_ID="STD-Miles-2002" TOTAL_1="250" TOTAL_2="254" WEIGHT="7.095784089788616"/>
<CONT_DATA CI_END="2.1591240376763228" CI_START="-3.7591240376763233" EFFECT_SIZE="-0.8000000000000003" ESTIMABLE="YES" MEAN_1="-2.7" MEAN_2="-1.9" ORDER="27693" SD_1="15.48" SD_2="17.48" SE="1.5097849047316765" STUDY_ID="STD-Rossner-2000" TOTAL_1="242" TOTAL_2="237" WEIGHT="4.689573224196512"/>
<CONT_DATA CI_END="-1.1745954879640768" CI_START="-4.825404512035924" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="1.0" ORDER="27694" SD_1="12.2" SD_2="12.14" SE="0.9313459463717094" STUDY_ID="STD-Sjostrom-1998" TOTAL_1="343" TOTAL_2="340" WEIGHT="11.08811823942675"/>
<CONT_DATA CI_END="-0.5852239892489224" CI_START="-6.494776010751078" EFFECT_SIZE="-3.54" ESTIMABLE="YES" MEAN_1="-4.05" MEAN_2="-0.51" ORDER="27695" SD_1="13.0" SD_2="14.7" SE="1.5075664828833457" STUDY_ID="STD-Swinburn-2005" TOTAL_1="170" TOTAL_2="169" WEIGHT="4.7024369801871"/>
<CONT_DATA CI_END="-0.36312249158257126" CI_START="-2.6368775084174296" EFFECT_SIZE="-1.5000000000000004" ESTIMABLE="YES" MEAN_1="-4.9" MEAN_2="-3.4" ORDER="27696" SD_1="10.7" SD_2="10.7" SE="0.5800502036695439" STUDY_ID="STD-XENDOS" TOTAL_1="851" TOTAL_2="567" WEIGHT="22.770040666001947"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="19.901642468781418" CI_END="-0.735312770996736" CI_START="-2.032491606928623" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.3839021889626795" ESTIMABLE="YES" I2="44.728180012001125" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="0.04670798598291526" P_Q="1.0" P_Z="2.889608649424014E-5" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.4812201046890192" TOTALS="YES" TOTAL_1="4382" TOTAL_2="3940" UNITS="" WEIGHT="100.00000000000003" Z="4.181996149427496">
<NAME>Orlistat: Change in Diastolic Blood Pressure (mm Hg)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.7808464857669193" CI_START="-3.6191535142330826" EFFECT_SIZE="-2.200000000000001" ESTIMABLE="YES" MEAN_1="-11.4" MEAN_2="-9.2" ORDER="27697" SD_1="8.3" SD_2="8.4" SE="0.7240712204036317" STUDY_ID="STD-Bakris-2002" TOTAL_1="267" TOTAL_2="265" WEIGHT="10.890850337307803"/>
<CONT_DATA CI_END="6.577750770908475" CI_START="-7.577750770908475" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-2.4" MEAN_2="-1.9" ORDER="27698" SD_1="26.78" SD_2="26.78" SE="3.611163688076347" STUDY_ID="STD-Berne-2004" TOTAL_1="111" TOTAL_2="109" WEIGHT="0.8098628755502538"/>
<CONT_DATA CI_END="-0.40972276529760365" CI_START="-4.390277234702396" EFFECT_SIZE="-2.4" ESTIMABLE="YES" MEAN_1="-5.5" MEAN_2="-3.1" ORDER="27699" SD_1="11.6" SD_2="11.6" SE="1.0154662281559503" STUDY_ID="STD-Broom-2002" TOTAL_1="259" TOTAL_2="263" WEIGHT="7.240677948194799"/>
<CONT_DATA CI_END="-0.5583761903888138" CI_START="-4.041623809611186" EFFECT_SIZE="-2.3" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="1.3" ORDER="27700" SD_1="10.25" SD_2="11.85" SE="0.8885999045640085" STUDY_ID="STD-Davidson-1999" TOTAL_1="657" TOTAL_2="223" WEIGHT="8.61700039148637"/>
<CONT_DATA CI_END="6.340440452703437" CI_START="-10.340440452703437" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="-4.0" MEAN_2="-2.0" ORDER="27701" SD_1="17.3" SD_2="12.71" SE="4.2554049556480456" STUDY_ID="STD-Derosa-2003" TOTAL_1="27" TOTAL_2="23" WEIGHT="0.5890760337809204"/>
<CONT_DATA CI_END="-0.2197648126409102" CI_START="-5.780235187359089" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="2.0" ORDER="27702" SD_1="14.49" SD_2="14.65" SE="1.418513406006044" STUDY_ID="STD-Hauptman-2000" TOTAL_1="210" TOTAL_2="212" WEIGHT="4.3918905914205135"/>
<CONT_DATA CI_END="0.38658343459990396" CI_START="-2.9865834345999036" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-1.0" ORDER="27703" SD_1="11.42" SD_2="8.31" SE="0.8605175645590728" STUDY_ID="STD-Kelley-2002" TOTAL_1="266" TOTAL_2="276" WEIGHT="8.963449977749207"/>
<CONT_DATA CI_END="2.093196360399797" CI_START="-1.2931963603997967" EFFECT_SIZE="0.4" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-1.3" ORDER="27704" SD_1="8.03" SD_2="8.7" SE="0.8638915682918225" STUDY_ID="STD-Lindgarde-2000" TOTAL_1="190" TOTAL_2="186" WEIGHT="8.920965586383062"/>
<CONT_DATA CI_END="2.2168041896361657" CI_START="-1.4168041896361658" EFFECT_SIZE="0.4" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-1.3" ORDER="27705" SD_1="9.82" SD_2="10.45" SE="0.9269579461494626" STUDY_ID="STD-Rossner-2000" TOTAL_1="242" TOTAL_2="237" WEIGHT="8.169322999899297"/>
<CONT_DATA CI_END="-1.145051419314334" CI_START="-3.4549485806856666" EFFECT_SIZE="-2.3000000000000003" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="0.2" ORDER="27706" SD_1="7.7" SD_2="7.7" SE="0.5892703079218563" STUDY_ID="STD-Sjostrom-1998" TOTAL_1="343" TOTAL_2="340" WEIGHT="13.218196393616287"/>
<CONT_DATA CI_END="0.17834846842439167" CI_START="-3.358348468424391" EFFECT_SIZE="-1.5899999999999999" ESTIMABLE="YES" MEAN_1="-2.96" MEAN_2="-1.37" ORDER="27707" SD_1="8.01" SD_2="8.59" SE="0.902235185122226" STUDY_ID="STD-Swinburn-2005" TOTAL_1="170" TOTAL_2="169" WEIGHT="8.454549271235445"/>
<CONT_DATA CI_END="-0.1679394405289225" CI_START="-1.2320605594710778" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="-2.6" MEAN_2="-1.9" ORDER="27708" SD_1="7.77" SD_2="7.77" SE="0.27146445734100394" STUDY_ID="STD-XENDOS" TOTAL_1="1640" TOTAL_2="1637" WEIGHT="19.73415759337606"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Orlistat: Change in Lipid Parameters</NAME>
<CONT_OUTCOME CHI2="5.836484164447231" CI_END="-0.27711537472273884" CI_START="-0.3682888666874058" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3227021207050723" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="0.9240992363947579" P_Q="1.0" P_Z="9.066440871259765E-44" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2605" TOTAL_2="2601" UNITS="" WEIGHT="100.00000000000001" Z="13.874307557765794">
<NAME>Orlistat: Change in Total Cholesterol Levels</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.17248803184707218" CI_START="-0.46751196815292784" EFFECT_SIZE="-0.32" ESTIMABLE="YES" MEAN_1="-0.36" MEAN_2="-0.04" ORDER="27709" SD_1="0.94" SD_2="0.79" SE="0.07526259120906476" STUDY_ID="STD-Bakris-2002" TOTAL_1="267" TOTAL_2="265" WEIGHT="9.550424396695009"/>
<CONT_DATA CI_END="-0.06066092487121705" CI_START="-0.6193390751287828" EFFECT_SIZE="-0.33999999999999997" ESTIMABLE="YES" MEAN_1="-0.24" MEAN_2="0.1" ORDER="27710" SD_1="1.0" SD_2="1.11" SE="0.14252255517559195" STUDY_ID="STD-Berne-2004" TOTAL_1="111" TOTAL_2="109" WEIGHT="2.663261458774865"/>
<CONT_DATA CI_END="-0.13930798858138238" CI_START="-0.4206920114186177" EFFECT_SIZE="-0.28" ESTIMABLE="YES" MEAN_1="-0.12" MEAN_2="0.16" ORDER="27711" SD_1="0.82" SD_2="0.82" SE="0.0717829575075758" STUDY_ID="STD-Broom-2002" TOTAL_1="259" TOTAL_2="263" WEIGHT="10.49876727369516"/>
<CONT_DATA CI_END="1.4144677963257801" CI_START="-1.7744677963257804" EFFECT_SIZE="-0.18000000000000005" ESTIMABLE="YES" MEAN_1="-1.01" MEAN_2="-0.83" ORDER="27712" SD_1="2.8" SD_2="2.83" SE="0.8135189263184113" STUDY_ID="STD-Derosa-2003" TOTAL_1="25" TOTAL_2="23" WEIGHT="0.0817420794728235"/>
<CONT_DATA CI_END="-0.15864095044495202" CI_START="-0.541359049555048" EFFECT_SIZE="-0.35" ESTIMABLE="YES" MEAN_1="-0.05" MEAN_2="0.3" ORDER="27713" SD_1="0.76" SD_2="0.68" SE="0.09763396218729717" STUDY_ID="STD-Finer-2000" TOTAL_1="110" TOTAL_2="108" WEIGHT="5.6751739225666515"/>
<CONT_DATA CI_END="-0.13759450395001815" CI_START="-0.5424054960499818" EFFECT_SIZE="-0.33999999999999997" ESTIMABLE="YES" MEAN_1="-0.04" MEAN_2="0.3" ORDER="27714" SD_1="1.16" SD_2="0.95" SE="0.1032700078402106" STUDY_ID="STD-Hauptman-2000" TOTAL_1="210" TOTAL_2="212" WEIGHT="5.072622970884211"/>
<CONT_DATA CI_END="-0.3161571909964771" CI_START="-0.623842809003523" EFFECT_SIZE="-0.47000000000000003" ESTIMABLE="YES" MEAN_1="-0.08" MEAN_2="0.39" ORDER="27715" SD_1="0.64" SD_2="0.76" SE="0.07849267140468669" STUDY_ID="STD-Hollander-1998" TOTAL_1="162" TOTAL_2="159" WEIGHT="8.780571505152329"/>
<CONT_DATA CI_END="-0.18635916282447457" CI_START="-0.5736408371755255" EFFECT_SIZE="-0.38" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="0.08" ORDER="27716" SD_1="1.14" SD_2="1.16" SE="0.09879816093710887" STUDY_ID="STD-Kelley-2002" TOTAL_1="266" TOTAL_2="276" WEIGHT="5.542213895842918"/>
<CONT_DATA CI_END="-0.1383833121615426" CI_START="-0.4416166878384575" EFFECT_SIZE="-0.29000000000000004" ESTIMABLE="YES" MEAN_1="-0.03" MEAN_2="0.26" ORDER="27717" SD_1="0.76" SD_2="0.74" SE="0.0773568744295255" STUDY_ID="STD-Lindgarde-2000" TOTAL_1="190" TOTAL_2="186" WEIGHT="9.040306941066016"/>
<CONT_DATA CI_END="-0.15523811924785838" CI_START="-0.5047618807521417" EFFECT_SIZE="-0.33" ESTIMABLE="YES" MEAN_1="-0.27" MEAN_2="0.06" ORDER="27718" SD_1="0.95" SD_2="1.05" SE="0.08916586331720432" STUDY_ID="STD-Miles-2002" TOTAL_1="250" TOTAL_2="254" WEIGHT="6.804304904638117"/>
<CONT_DATA CI_END="-0.11674159602654746" CI_START="-0.48325840397345254" EFFECT_SIZE="-0.3" ESTIMABLE="YES" MEAN_1="-0.35" MEAN_2="-0.05" ORDER="27719" SD_1="0.95" SD_2="1.09" SE="0.09350090380178995" STUDY_ID="STD-Rossner-2000" TOTAL_1="242" TOTAL_2="237" WEIGHT="6.187986908821525"/>
<CONT_DATA CI_END="-0.21025491547998526" CI_START="-0.40974508452001474" EFFECT_SIZE="-0.31" ESTIMABLE="YES" MEAN_1="-0.08" MEAN_2="0.23" ORDER="27720" SD_1="0.67" SD_2="0.66" SE="0.05089128438419851" STUDY_ID="STD-Sjostrom-1998" TOTAL_1="343" TOTAL_2="340" WEIGHT="20.88787119344116"/>
<CONT_DATA CI_END="-0.08982530644654318" CI_START="-0.3901746935534568" EFFECT_SIZE="-0.24" ESTIMABLE="YES" MEAN_1="-0.08" MEAN_2="0.16" ORDER="27721" SD_1="0.73" SD_2="0.68" SE="0.07662114954050973" STUDY_ID="STD-Swinburn-2005" TOTAL_1="170" TOTAL_2="169" WEIGHT="9.214752548949228"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.52199630521385" CI_END="-0.21844779130682837" CI_START="-0.30075488884513396" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2596013400759812" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" NO="2" P_CHI2="0.7431247127945554" P_Q="1.0" P_Z="4.1090971452989373E-35" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2605" TOTAL_2="2601" UNITS="" WEIGHT="100.00000000000001" Z="12.363679247721223">
<NAME>Orlistat: Change in LDL cholesterol levels</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.07584974087380437" CI_START="-0.32415025912619566" EFFECT_SIZE="-0.2" ESTIMABLE="YES" MEAN_1="-0.31" MEAN_2="-0.11" ORDER="27722" SD_1="0.76" SD_2="0.7" SE="0.06334313288686784" STUDY_ID="STD-Bakris-2002" TOTAL_1="267" TOTAL_2="265" WEIGHT="10.988016986609214"/>
<CONT_DATA CI_END="0.16239069854773994" CI_START="-0.34239069854773996" EFFECT_SIZE="-0.09" ESTIMABLE="YES" MEAN_1="-0.08" MEAN_2="0.01" ORDER="27723" SD_1="0.96" SD_2="0.95" SE="0.1287731308016706" STUDY_ID="STD-Berne-2004" TOTAL_1="111" TOTAL_2="109" WEIGHT="2.6586911598957066"/>
<CONT_DATA CI_END="-0.17930798858138236" CI_START="-0.46069201141861765" EFFECT_SIZE="-0.32" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="0.02" ORDER="27724" SD_1="0.82" SD_2="0.82" SE="0.0717829575075758" STUDY_ID="STD-Broom-2002" TOTAL_1="259" TOTAL_2="263" WEIGHT="8.556097120088944"/>
<CONT_DATA CI_END="1.120586320997599" CI_START="-1.8005863209975992" EFFECT_SIZE="-0.33999999999999997" ESTIMABLE="YES" MEAN_1="-0.96" MEAN_2="-0.62" ORDER="27725" SD_1="2.6" SD_2="2.56" SE="0.7452107959730473" STUDY_ID="STD-Derosa-2003" TOTAL_1="25" TOTAL_2="23" WEIGHT="0.07938896222763381"/>
<CONT_DATA CI_END="-0.16555897011401763" CI_START="-0.47444102988598236" EFFECT_SIZE="-0.32" ESTIMABLE="YES" MEAN_1="-0.11" MEAN_2="0.21" ORDER="27726" SD_1="0.63" SD_2="0.53" SE="0.07879789174913085" STUDY_ID="STD-Finer-2000" TOTAL_1="110" TOTAL_2="108" WEIGHT="7.10050446321405"/>
<CONT_DATA CI_END="-0.18347764823272023" CI_START="-0.5565223517672797" EFFECT_SIZE="-0.37" ESTIMABLE="YES" MEAN_1="-0.12" MEAN_2="0.25" ORDER="27727" SD_1="1.04" SD_2="0.91" SE="0.09516621388890013" STUDY_ID="STD-Hauptman-2000" TOTAL_1="210" TOTAL_2="212" WEIGHT="4.86802519828317"/>
<CONT_DATA CI_END="-0.19615719099647708" CI_START="-0.5038428090035229" EFFECT_SIZE="-0.35" ESTIMABLE="YES" MEAN_1="-0.13" MEAN_2="0.22" ORDER="27728" SD_1="0.64" SD_2="0.76" SE="0.07849267140468669" STUDY_ID="STD-Hollander-1998" TOTAL_1="162" TOTAL_2="159" WEIGHT="7.155832738211268"/>
<CONT_DATA CI_END="-0.16107969337455785" CI_START="-0.4389203066254421" EFFECT_SIZE="-0.3" ESTIMABLE="YES" MEAN_1="-0.38" MEAN_2="-0.08" ORDER="27729" SD_1="0.82" SD_2="0.83" SE="0.07087900988039973" STUDY_ID="STD-Kelley-2002" TOTAL_1="266" TOTAL_2="276" WEIGHT="8.775727240254609"/>
<CONT_DATA CI_END="-0.08100380718366151" CI_START="-0.49899619281633856" EFFECT_SIZE="-0.29000000000000004" ESTIMABLE="YES" MEAN_1="-0.22" MEAN_2="0.07" ORDER="27730" SD_1="1.13" SD_2="0.93" SE="0.1066326700209156" STUDY_ID="STD-Lindgarde-2000" TOTAL_1="190" TOTAL_2="186" WEIGHT="3.877375244133796"/>
<CONT_DATA CI_END="-0.025238119247858376" CI_START="-0.3747618807521417" EFFECT_SIZE="-0.2" ESTIMABLE="YES" MEAN_1="-0.25" MEAN_2="-0.05" ORDER="27731" SD_1="0.95" SD_2="1.05" SE="0.08916586331720432" STUDY_ID="STD-Miles-2002" TOTAL_1="250" TOTAL_2="254" WEIGHT="5.545250416651125"/>
<CONT_DATA CI_END="-0.11093435009833136" CI_START="-0.4290656499016687" EFFECT_SIZE="-0.27" ESTIMABLE="YES" MEAN_1="-0.33" MEAN_2="-0.06" ORDER="27732" SD_1="0.82" SD_2="0.95" SE="0.0811574351142971" STUDY_ID="STD-Rossner-2000" TOTAL_1="242" TOTAL_2="237" WEIGHT="6.693631108789037"/>
<CONT_DATA CI_END="-0.13675362211263697" CI_START="-0.30324637788736303" EFFECT_SIZE="-0.22" ESTIMABLE="YES" MEAN_1="-0.09" MEAN_2="0.13" ORDER="27733" SD_1="0.56" SD_2="0.55" SE="0.04247342223836756" STUDY_ID="STD-Sjostrom-1998" TOTAL_1="343" TOTAL_2="340" WEIGHT="24.439025842338705"/>
<CONT_DATA CI_END="-0.09477881438947447" CI_START="-0.3652211856105255" EFFECT_SIZE="-0.22999999999999998" ESTIMABLE="YES" MEAN_1="-0.12" MEAN_2="0.11" ORDER="27734" SD_1="0.65" SD_2="0.62" SE="0.06899166855979649" STUDY_ID="STD-Swinburn-2005" TOTAL_1="170" TOTAL_2="169" WEIGHT="9.262433519302737"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="12.470544977034312" CI_END="-0.015442258472691506" CI_START="-0.044474104745746056" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.02995818160921878" ESTIMABLE="YES" I2="19.81104259343961" I2_Q="0.0" ID="CMP-003.03" NO="3" P_CHI2="0.25479789246094053" P_Q="1.0" P_Z="5.232238699513111E-5" Q="0.0" RANDOM="YES" SCALE="0.5" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="1.1430721402503153E-4" TOTALS="YES" TOTAL_1="2079" TOTAL_2="2073" UNITS="" WEIGHT="100.0" Z="4.045003300453285">
<NAME>Orlistat: Change in HDL cholesterol Levels</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.026478932868881824" CI_START="-0.13352106713111817" EFFECT_SIZE="-0.08" ESTIMABLE="YES" MEAN_1="-0.01" MEAN_2="0.07" ORDER="27735" SD_1="0.17" SD_2="0.23" SE="0.027307168679264273" STUDY_ID="STD-Berne-2004" TOTAL_1="111" TOTAL_2="109" WEIGHT="6.378233370920802"/>
<CONT_DATA CI_END="0.26324242957081884" CI_START="-0.26324242957081884" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.03" MEAN_2="0.03" ORDER="27736" SD_1="0.5" SD_2="0.43" SE="0.1343098300005722" STUDY_ID="STD-Derosa-2003" TOTAL_1="25" TOTAL_2="23" WEIGHT="0.30215811316545454"/>
<CONT_DATA CI_END="0.048446455447199596" CI_START="-0.06844645544719961" EFFECT_SIZE="-0.010000000000000009" ESTIMABLE="YES" MEAN_1="0.15" MEAN_2="0.16" ORDER="27737" SD_1="0.23" SD_2="0.21" SE="0.02982016807870848" STUDY_ID="STD-Finer-2000" TOTAL_1="110" TOTAL_2="108" WEIGHT="5.4658068303429355"/>
<CONT_DATA CI_END="0.0145395980920809" CI_START="-0.1145395980920809" EFFECT_SIZE="-0.05" ESTIMABLE="YES" MEAN_1="0.06" MEAN_2="0.11" ORDER="27738" SD_1="0.38" SD_2="0.29" SE="0.0329289714510884" STUDY_ID="STD-Hauptman-2000" TOTAL_1="210" TOTAL_2="212" WEIGHT="4.576253063524957"/>
<CONT_DATA CI_END="0.008443817933722828" CI_START="-0.048443817933722835" EFFECT_SIZE="-0.020000000000000004" ESTIMABLE="YES" MEAN_1="0.06" MEAN_2="0.08" ORDER="27739" SD_1="0.13" SD_2="0.13" SE="0.014512418676100192" STUDY_ID="STD-Hollander-1998" TOTAL_1="162" TOTAL_2="159" WEIGHT="16.881849395776356"/>
<CONT_DATA CI_END="-0.0022161194682317788" CI_START="-0.05778388053176822" EFFECT_SIZE="-0.030000000000000002" ESTIMABLE="YES" MEAN_1="0.02" MEAN_2="0.05" ORDER="27740" SD_1="0.16" SD_2="0.17" SE="0.014175709732895057" STUDY_ID="STD-Kelley-2002" TOTAL_1="266" TOTAL_2="276" WEIGHT="17.39911169726136"/>
<CONT_DATA CI_END="-0.008554336933995293" CI_START="-0.09144566306600471" EFFECT_SIZE="-0.05" ESTIMABLE="YES" MEAN_1="0.03" MEAN_2="0.08" ORDER="27741" SD_1="0.21" SD_2="0.2" SE="0.021146135027440713" STUDY_ID="STD-Lindgarde-2000" TOTAL_1="190" TOTAL_2="186" WEIGHT="9.769435934984086"/>
<CONT_DATA CI_END="0.04587615004752732" CI_START="-0.06587615004752734" EFFECT_SIZE="-0.010000000000000009" ESTIMABLE="YES" MEAN_1="0.09" MEAN_2="0.1" ORDER="27742" SD_1="0.32" SD_2="0.32" SE="0.028508763675389584" STUDY_ID="STD-Miles-2002" TOTAL_1="250" TOTAL_2="254" WEIGHT="5.916798568519192"/>
<CONT_DATA CI_END="-0.010592192884252075" CI_START="-0.1294078071157479" EFFECT_SIZE="-0.06999999999999999" ESTIMABLE="YES" MEAN_1="0.08" MEAN_2="0.15" ORDER="27743" SD_1="0.3" SD_2="0.36" SE="0.0303106626368388" STUDY_ID="STD-Rossner-2000" TOTAL_1="242" TOTAL_2="237" WEIGHT="5.309755644357762"/>
<CONT_DATA CI_END="0.02775560429863338" CI_START="-0.02775560429863338" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.1" ORDER="27744" SD_1="0.19" SD_2="0.18" SE="0.014161282818238521" STUDY_ID="STD-Sjostrom-1998" TOTAL_1="343" TOTAL_2="340" WEIGHT="17.42170354625386"/>
<CONT_DATA CI_END="-5.955734652528313E-4" CI_START="-0.07940442653474716" EFFECT_SIZE="-0.04" ESTIMABLE="YES" MEAN_1="0.04" MEAN_2="0.08" ORDER="27745" SD_1="0.18" SD_2="0.19" SE="0.020104668680426915" STUDY_ID="STD-Swinburn-2005" TOTAL_1="170" TOTAL_2="169" WEIGHT="10.57889383489322"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="18.25346915010782" CI_END="0.0704401506338127" CI_START="-0.12060211949822405" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.025080984432205678" ESTIMABLE="YES" I2="45.21589338571878" I2_Q="0.0" ID="CMP-003.04" NO="4" P_CHI2="0.05083559651573921" P_Q="1.0" P_Z="0.6068131764688561" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.009972572374842014" TOTALS="YES" TOTAL_1="2228" TOTAL_2="2228" UNITS="" WEIGHT="100.0" Z="0.5146277433780285">
<NAME>Orlistat: Change in Triglyceride Levels</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4135368478527791" CI_START="-0.573536847852779" EFFECT_SIZE="-0.07999999999999999" ESTIMABLE="YES" MEAN_1="-0.12" MEAN_2="-0.04" ORDER="27746" SD_1="1.06" SD_2="2.41" SE="0.25180914126266335" STUDY_ID="STD-Berne-2004" TOTAL_1="111" TOTAL_2="109" WEIGHT="3.236850174270796"/>
<CONT_DATA CI_END="0.9700285446194635" CI_START="-0.4300285446194635" EFFECT_SIZE="0.27" ESTIMABLE="YES" MEAN_1="0.44" MEAN_2="0.17" ORDER="27747" SD_1="4.08" SD_2="4.08" SE="0.3571639836962308" STUDY_ID="STD-Broom-2002" TOTAL_1="259" TOTAL_2="263" WEIGHT="1.7269426030017188"/>
<CONT_DATA CI_END="0.6068134269236185" CI_START="-0.9868134269236186" EFFECT_SIZE="-0.19000000000000003" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.21" ORDER="27748" SD_1="1.56" SD_2="1.25" SE="0.40654493307467954" STUDY_ID="STD-Derosa-2003" TOTAL_1="25" TOTAL_2="23" WEIGHT="1.355318549944531"/>
<CONT_DATA CI_END="0.3328976303301528" CI_START="-0.012897630330152787" EFFECT_SIZE="0.16" ESTIMABLE="YES" MEAN_1="0.06" MEAN_2="-0.1" ORDER="27749" SD_1="0.66" SD_2="1.1" SE="0.08821469766482815" STUDY_ID="STD-Hauptman-2000" TOTAL_1="210" TOTAL_2="212" WEIGHT="13.378167775713827"/>
<CONT_DATA CI_END="-0.011604766453601506" CI_START="-0.4283952335463985" EFFECT_SIZE="-0.22" ESTIMABLE="YES" MEAN_1="-0.01" MEAN_2="0.21" ORDER="27750" SD_1="0.89" SD_2="1.01" SE="0.10632605251432858" STUDY_ID="STD-Hollander-1998" TOTAL_1="162" TOTAL_2="159" WEIGHT="11.162873606135925"/>
<CONT_DATA CI_END="0.2741222659179492" CI_START="-0.5341222659179492" EFFECT_SIZE="-0.13" ESTIMABLE="YES" MEAN_1="0.18" MEAN_2="0.31" ORDER="27751" SD_1="2.61" SD_2="2.16" SE="0.2061886183142211" STUDY_ID="STD-Kelley-2002" TOTAL_1="266" TOTAL_2="276" WEIGHT="4.5253966787522355"/>
<CONT_DATA CI_END="0.35100846673128105" CI_START="-0.07100846673128108" EFFECT_SIZE="0.13999999999999999" ESTIMABLE="YES" MEAN_1="0.18" MEAN_2="0.04" ORDER="27752" SD_1="1.14" SD_2="0.94" SE="0.10765935925133774" STUDY_ID="STD-Lindgarde-2000" TOTAL_1="190" TOTAL_2="186" WEIGHT="11.015174165980945"/>
<CONT_DATA CI_END="0.03260985546554568" CI_START="-0.5926098554655457" EFFECT_SIZE="-0.28" ESTIMABLE="YES" MEAN_1="-0.25" MEAN_2="0.03" ORDER="27753" SD_1="1.74" SD_2="1.84" SE="0.1594977550257925" STUDY_ID="STD-Miles-2002" TOTAL_1="250" TOTAL_2="254" WEIGHT="6.707350609098308"/>
<CONT_DATA CI_END="0.14957110135237917" CI_START="-0.16957110135237913" EFFECT_SIZE="-0.009999999999999995" ESTIMABLE="YES" MEAN_1="-0.09" MEAN_2="-0.08" ORDER="27754" SD_1="0.94" SD_2="0.84" SE="0.08141532324627168" STUDY_ID="STD-Rossner-2000" TOTAL_1="242" TOTAL_2="237" WEIGHT="14.307633435097559"/>
<CONT_DATA CI_END="-0.003256718080584864" CI_START="-0.25674328191941514" EFFECT_SIZE="-0.13" ESTIMABLE="YES" MEAN_1="-0.07" MEAN_2="0.06" ORDER="27755" SD_1="0.85" SD_2="0.84" SE="0.06466612801008079" STUDY_ID="STD-Sjostrom-1998" TOTAL_1="343" TOTAL_2="340" WEIGHT="16.78088918302773"/>
<CONT_DATA CI_END="0.20938074227997572" CI_START="-0.06938074227997572" EFFECT_SIZE="0.06999999999999999" ESTIMABLE="YES" MEAN_1="0.01" MEAN_2="-0.06" ORDER="27756" SD_1="0.73" SD_2="0.57" SE="0.07111393034739068" STUDY_ID="STD-Swinburn-2005" TOTAL_1="170" TOTAL_2="169" WEIGHT="15.803403218976428"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Orlistat: Subgroup Analysis in Diabetes</NAME>
<CONT_OUTCOME CHI2="3.1280870613340213" CI_END="-2.1649992725238127" CI_START="-3.0554392687897916" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.610219270656802" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" NO="1" P_CHI2="0.5366238926227426" P_Q="1.0" P_Z="1.4673971124861346E-30" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="843" TOTAL_2="835" UNITS="" WEIGHT="99.99999999999999" Z="11.490804060224592">
<NAME>Change in Weight (%)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.6684342483618291" CI_START="-3.1315657516381714" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" MEAN_1="-6.2" MEAN_2="-4.3" ORDER="1" SD_1="5.89" SD_2="5.36" SE="0.6283614195733211" STUDY_ID="STD-Hollander-1998" TOTAL_1="162" TOTAL_2="159" WEIGHT="13.068752119365731"/>
<CONT_DATA CI_END="-1.622174305365064" CI_START="-4.777825694634936" EFFECT_SIZE="-3.2" ESTIMABLE="YES" MEAN_1="-5.0" MEAN_2="-1.8" ORDER="27757" SD_1="5.97" SD_2="5.97" SE="0.8050279020842341" STUDY_ID="STD-Berne-2004" TOTAL_1="111" TOTAL_2="109" WEIGHT="7.96216693149231"/>
<CONT_DATA CI_END="-1.7619866749306183" CI_START="-3.3180133250693817" EFFECT_SIZE="-2.54" ESTIMABLE="YES" MEAN_1="-3.76" MEAN_2="-1.22" ORDER="27759" SD_1="4.24" SD_2="4.92" SE="0.3969528681170937" STUDY_ID="STD-Kelley-2002" TOTAL_1="266" TOTAL_2="269" WEIGHT="32.74728175879133"/>
<CONT_DATA CI_END="-0.15490443921520058" CI_START="-3.6450955607848003" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" MEAN_1="-5.4" MEAN_2="-3.5" ORDER="27760" SD_1="4.6" SD_2="4.2" SE="0.8903712387318802" STUDY_ID="STD-Lindgarde-2000" TOTAL_1="54" TOTAL_2="44" WEIGHT="6.508949461236829"/>
<CONT_DATA CI_END="-2.19350492735587" CI_START="-3.6064950726441287" EFFECT_SIZE="-2.8999999999999995" ESTIMABLE="YES" MEAN_1="-4.6" MEAN_2="-1.7" ORDER="27761" SD_1="4.74" SD_2="3.19" SE="0.3604632933139956" STUDY_ID="STD-Miles-2002" TOTAL_1="250" TOTAL_2="254" WEIGHT="39.7128497291138"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.840412129745768" CI_END="-1.5972485152243465" CI_START="-2.9957720869320914" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.296510301078219" ESTIMABLE="YES" I2="48.63376191004196" I2_Q="0.0" ID="CMP-004.02" NO="2" P_CHI2="0.11963820158547112" P_Q="1.0" P_Z="1.2193902505538607E-10" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.2420776826380482" TOTALS="YES" TOTAL_1="869" TOTAL_2="868" UNITS="" WEIGHT="100.0" Z="6.4368989858958985">
<NAME>Change in Weight (kg)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.3819032954053978" CI_START="-3.3780967045946038" EFFECT_SIZE="-1.8800000000000008" ESTIMABLE="YES" MEAN_1="-6.19" MEAN_2="-4.31" ORDER="27762" SD_1="6.51" SD_2="7.18" SE="0.7643490984586444" STUDY_ID="STD-Hollander-1998" TOTAL_1="163" TOTAL_2="159" WEIGHT="15.404296058666377"/>
<CONT_DATA CI_END="-1.8514224062785745" CI_START="-3.3885775937214255" EFFECT_SIZE="-2.62" ESTIMABLE="YES" MEAN_1="-3.89" MEAN_2="-1.27" ORDER="27763" SD_1="4.48" SD_2="4.59" SE="0.39213863100744073" STUDY_ID="STD-Kelley-2002" TOTAL_1="266" TOTAL_2="269" WEIGHT="32.15528272054987"/>
<CONT_DATA CI_END="-0.17499718738525805" CI_START="-2.425002812614742" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" MEAN_1="-5.6" MEAN_2="-4.3" ORDER="27764" SD_1="5.2" SD_2="5.9" SE="0.573991574074126" STUDY_ID="STD-Lindgarde-2000" TOTAL_1="190" TOTAL_2="186" WEIGHT="22.270692969115274"/>
<CONT_DATA CI_END="-2.0688626479577925" CI_START="-3.731137352042208" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="-4.7" MEAN_2="-1.8" ORDER="27765" SD_1="4.74" SD_2="4.78" SE="0.424057461564658" STUDY_ID="STD-Miles-2002" TOTAL_1="250" TOTAL_2="254" WEIGHT="30.169728251668474"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.375115068818321" CI_END="-0.5664866792670942" CI_START="-1.4870073268681303" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0267470030676122" ESTIMABLE="YES" I2="57.33385701788323" I2_Q="0.0" ID="CMP-004.03" NO="3" P_CHI2="0.05237770780093154" P_Q="1.0" P_Z="1.2295552320219877E-5" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.14971748731390763" TOTALS="YES" TOTAL_1="843" TOTAL_2="835" UNITS="" WEIGHT="99.99999999999999" Z="4.372280301352126">
<NAME>Change in Fasting Glucose Levels (mmol/L)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.8286222977337933" CI_START="-2.4513777022662064" EFFECT_SIZE="-1.64" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-0.26" ORDER="27766" SD_1="3.07" SD_2="3.07" SE="0.4139758223448239" STUDY_ID="STD-Berne-2004" TOTAL_1="111" TOTAL_2="109" WEIGHT="17.174314968918438"/>
<CONT_DATA CI_END="-0.15821186516723118" CI_START="-0.9617881348327689" EFFECT_SIZE="-0.56" ESTIMABLE="YES" MEAN_1="-0.02" MEAN_2="0.54" ORDER="27767" SD_1="1.78" SD_2="1.89" SE="0.20499771322433596" STUDY_ID="STD-Hollander-1998" TOTAL_1="162" TOTAL_2="159" WEIGHT="28.760382791727174"/>
<CONT_DATA CI_END="0.28126906470659785" CI_START="-1.3812690647065975" EFFECT_SIZE="-0.5499999999999998" ESTIMABLE="YES" MEAN_1="-1.63" MEAN_2="-1.08" ORDER="27768" SD_1="4.89" SD_2="4.92" SE="0.424124663138477" STUDY_ID="STD-Kelley-2002" TOTAL_1="266" TOTAL_2="269" WEIGHT="16.7311088131324"/>
<CONT_DATA CI_END="-0.3429328450233722" CI_START="-2.3570671549766278" EFFECT_SIZE="-1.3499999999999999" ESTIMABLE="YES" MEAN_1="-1.63" MEAN_2="-0.28" ORDER="27769" SD_1="2.53" SD_2="2.53" SE="0.5138192144959014" STUDY_ID="STD-Lindgarde-2000" TOTAL_1="54" TOTAL_2="44" WEIGHT="13.328961861127498"/>
<CONT_DATA CI_END="-0.745618424123946" CI_START="-1.854381575876054" EFFECT_SIZE="-1.3" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-0.7" ORDER="27770" SD_1="3.16" SD_2="3.19" SE="0.28285294028305885" STUDY_ID="STD-Miles-2002" TOTAL_1="250" TOTAL_2="254" WEIGHT="24.00523156509448"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.149608760647292" CI_END="-0.17953399994543806" CI_START="-0.5888192688005351" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3841766343729866" ESTIMABLE="YES" I2="56.282283705898934" I2_Q="0.0" ID="CMP-004.04" NO="4" P_CHI2="0.05746692939846543" P_Q="1.0" P_Z="2.3373739366395154E-4" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.02889885496774405" TOTALS="YES" TOTAL_1="843" TOTAL_2="835" UNITS="" WEIGHT="99.99999999999999" Z="3.679450126212326">
<NAME>Orlistat: Change in HgbA1c (%)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.4439175215833092" CI_START="-1.316082478416691" EFFECT_SIZE="-0.8800000000000001" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.22" ORDER="27771" SD_1="1.65" SD_2="1.65" SE="0.22249514881725063" STUDY_ID="STD-Berne-2004" TOTAL_1="111" TOTAL_2="109" WEIGHT="13.90476556591737"/>
<CONT_DATA CI_END="0.17935608468221415" CI_START="-0.3793560846822142" EFFECT_SIZE="-0.10000000000000003" ESTIMABLE="YES" MEAN_1="-0.28" MEAN_2="-0.18" ORDER="27772" SD_1="1.15" SD_2="1.39" SE="0.14253123367864884" STUDY_ID="STD-Hollander-1998" TOTAL_1="162" TOTAL_2="159" WEIGHT="22.151713328210647"/>
<CONT_DATA CI_END="-0.12883704075372096" CI_START="-0.571162959246279" EFFECT_SIZE="-0.35" ESTIMABLE="YES" MEAN_1="-0.62" MEAN_2="-0.27" ORDER="27773" SD_1="1.3" SD_2="1.31" SE="0.11284031798073037" STUDY_ID="STD-Kelley-2002" TOTAL_1="266" TOTAL_2="269" WEIGHT="26.18610743831683"/>
<CONT_DATA CI_END="-0.008456673806106263" CI_START="-1.0115433261938938" EFFECT_SIZE="-0.51" ESTIMABLE="YES" MEAN_1="-0.65" MEAN_2="-0.14" ORDER="27774" SD_1="1.26" SD_2="1.26" SE="0.2558941542548758" STUDY_ID="STD-Lindgarde-2000" TOTAL_1="54" TOTAL_2="44" WEIGHT="11.550824447592191"/>
<CONT_DATA CI_END="-0.11911979806613796" CI_START="-0.5608802019338621" EFFECT_SIZE="-0.34" ESTIMABLE="YES" MEAN_1="-0.75" MEAN_2="-0.41" ORDER="27775" SD_1="1.26" SD_2="1.27" SE="0.11269605139489139" STUDY_ID="STD-Miles-2002" TOTAL_1="250" TOTAL_2="254" WEIGHT="26.206589219962954"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Orlistat: GI Adverse Events</NAME>
<DICH_OUTCOME CHI2="56.26866254636705" CI_END="0.28575109150514794" CI_START="0.20144795628574289" CI_STUDY="95" CI_TOTAL="95" DF="13.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.2435995238954454" ESTIMABLE="YES" EVENTS_1="3805" EVENTS_2="2407" I2="76.89655411786691" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-0.5440121020218938" LOG_CI_START="-0.6958371342241103" LOG_EFFECT_SIZE="-0.613323564847795" METHOD="MH" NO="1" P_CHI2="2.416913833513945E-7" P_Q="0.0" P_Z="9.656988377080645E-30" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.004592640284386192" TOTALS="YES" TOTAL_1="4684" TOTAL_2="4254" WEIGHT="100.00000000000001" Z="11.32689293805239">
<NAME>Orlistat: Overall GI Adverse Events (Absolute % Difference)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.36901813426896246" CI_START="0.2086936882170809" EFFECT_SIZE="0.2888559112430217" ESTIMABLE="YES" EVENTS_1="194" EVENTS_2="116" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27776" O_E="0.0" SE="0.04089984492483033" STUDY_ID="STD-Bakris-2002" TOTAL_1="267" TOTAL_2="265" VAR="0.001672797314875169" WEIGHT="7.382099085616185"/>
<DICH_DATA CI_END="0.5924410974706892" CI_START="0.3826808134310381" EFFECT_SIZE="0.48756095545086364" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="48" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27777" O_E="0.0" SE="0.05351125982268386" STUDY_ID="STD-Berne-2004" TOTAL_1="111" TOTAL_2="109" VAR="0.0028634549278107792" WEIGHT="6.203257852291317"/>
<DICH_DATA CI_END="0.2421194857898441" CI_START="0.07360199342973393" EFFECT_SIZE="0.15786073960978902" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="124" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27778" O_E="0.0" SE="0.04298994616466288" STUDY_ID="STD-Broom-2002" TOTAL_1="259" TOTAL_2="263" VAR="0.0018481354712406128" WEIGHT="7.181135150076559"/>
<DICH_DATA CI_END="0.2696581981862777" CI_START="0.12639397537065652" EFFECT_SIZE="0.19802608677846711" ESTIMABLE="YES" EVENTS_1="519" EVENTS_2="132" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27779" O_E="0.0" SE="0.036547667188190976" STUDY_ID="STD-Davidson-1999" TOTAL_1="657" TOTAL_2="223" VAR="0.0013357319768987715" WEIGHT="7.801817958453829"/>
<DICH_DATA CI_END="0.1831873243176808" CI_START="-0.045256289834922206" EFFECT_SIZE="0.06896551724137931" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27780" O_E="0.0" SE="0.05827750304458069" STUDY_ID="STD-Derosa-2003" TOTAL_1="29" TOTAL_2="23" VAR="0.003396267361111111" WEIGHT="5.789537596990634"/>
<DICH_DATA CI_END="0.3744979584267298" CI_START="0.1410864571576858" EFFECT_SIZE="0.2577922077922078" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="62" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27781" O_E="0.0" SE="0.059544844474226075" STUDY_ID="STD-Finer-2000" TOTAL_1="112" TOTAL_2="110" VAR="0.003545588503459772" WEIGHT="5.68331050628212"/>
<DICH_DATA CI_END="0.2869591455032247" CI_START="0.11474795243028817" EFFECT_SIZE="0.20085354896675645" ESTIMABLE="YES" EVENTS_1="166" EVENTS_2="125" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27782" O_E="0.0" SE="0.04393223406943099" STUDY_ID="STD-Hauptman-2000" TOTAL_1="210" TOTAL_2="212" VAR="0.001930041190331273" WEIGHT="7.090961187016418"/>
<DICH_DATA CI_END="0.29885466096482577" CI_START="0.10157748781782656" EFFECT_SIZE="0.20021607439132616" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="94" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27783" O_E="0.0" SE="0.05032673424182698" STUDY_ID="STD-Hollander-1998" TOTAL_1="163" TOTAL_2="159" VAR="0.0025327801794474804" WEIGHT="6.4911371065403305"/>
<DICH_DATA CI_END="0.25520558277271355" CI_START="0.10466248889344063" EFFECT_SIZE="0.1799340358330771" ESTIMABLE="YES" EVENTS_1="213" EVENTS_2="167" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27784" O_E="0.0" SE="0.038404556172138275" STUDY_ID="STD-Kelley-2002" TOTAL_1="266" TOTAL_2="269" VAR="0.001474909934778924" WEIGHT="7.622859226842422"/>
<DICH_DATA CI_END="0.34162299937833457" CI_START="0.1985586686646051" EFFECT_SIZE="0.27009083402146983" ESTIMABLE="YES" EVENTS_1="219" EVENTS_2="127" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27785" O_E="0.0" SE="0.03649667336803193" STUDY_ID="STD-Krempf--2003" TOTAL_1="346" TOTAL_2="350" VAR="0.0013320071669328112" WEIGHT="7.806722940484074"/>
<DICH_DATA CI_END="0.49785613020367286" CI_START="0.31719763323718747" EFFECT_SIZE="0.40752688172043017" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="73" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27786" O_E="0.0" SE="0.04608719813004131" STUDY_ID="STD-Lindgarde-2000" TOTAL_1="190" TOTAL_2="186" VAR="0.002124029831477683" WEIGHT="6.88616239515044"/>
<DICH_DATA CI_END="0.2853629093085337" CI_START="0.13600287838585448" EFFECT_SIZE="0.21068289384719407" ESTIMABLE="YES" EVENTS_1="212" EVENTS_2="162" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27787" O_E="0.0" SE="0.038102748851716675" STUDY_ID="STD-Miles-2002" TOTAL_1="255" TOTAL_2="261" VAR="0.0014518194700569964" WEIGHT="7.651979341659669"/>
<DICH_DATA CI_END="0.31943731070684933" CI_START="0.13235524063321313" EFFECT_SIZE="0.22589627567003123" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="101" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27788" O_E="0.0" SE="0.04772589485044514" STUDY_ID="STD-Swinburn-2005" TOTAL_1="170" TOTAL_2="169" VAR="0.002277761039275746" WEIGHT="6.732078519663553"/>
<DICH_DATA CI_END="0.28689807919236865" CI_START="0.23329707707738376" EFFECT_SIZE="0.2600975781348762" ESTIMABLE="YES" EVENTS_1="1501" EVENTS_2="1076" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27789" O_E="0.0" SE="0.013673976291856065" STUDY_ID="STD-XENDOS" TOTAL_1="1649" TOTAL_2="1655" VAR="1.869776276302417E-4" WEIGHT="9.676941132932456"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.336720574980663" CI_END="0.08291101605323621" CI_START="0.04601019539353578" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.064460605723386" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-1.0813877626549218" LOG_CI_START="-1.337145922393665" LOG_EFFECT_SIZE="-1.1907056178263509" METHOD="MH" NO="2" P_CHI2="0.9529806539965727" P_Q="0.0" P_Z="7.511524271551098E-12" Q="0.0" RANDOM="YES" SCALE="0.5" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="824" TOTAL_2="812" WEIGHT="100.00000000000001" Z="6.847569424245898">
<NAME>Orlistat: Fecal Incontinence (Absolute % Difference)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.1831873243176808" CI_START="-0.045256289834922206" EFFECT_SIZE="0.06896551724137931" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27790" O_E="0.0" SE="0.05827750304458069" STUDY_ID="STD-Derosa-2003" TOTAL_1="29" TOTAL_2="23" VAR="0.003396267361111111" WEIGHT="2.6092398622915773"/>
<DICH_DATA CI_END="0.09339264872271548" CI_START="0.02107276008231597" EFFECT_SIZE="0.057232704402515724" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27791" O_E="0.0" SE="0.018449290193812123" STUDY_ID="STD-Hauptman-2000" TOTAL_1="210" TOTAL_2="212" VAR="3.4037630865549215E-4" WEIGHT="26.034938261758324"/>
<DICH_DATA CI_END="0.09771431740867184" CI_START="0.02572955747363804" EFFECT_SIZE="0.061721937441154937" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27792" O_E="0.0" SE="0.018363796606172458" STUDY_ID="STD-Rossner-2000" TOTAL_1="242" TOTAL_2="237" VAR="3.37229025792871E-4" WEIGHT="26.27791650133299"/>
<DICH_DATA CI_END="0.09745131605938222" CI_START="0.04249037490271691" EFFECT_SIZE="0.06997084548104957" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27793" O_E="0.0" SE="0.014020905891687347" STUDY_ID="STD-Sjostrom-1998" TOTAL_1="343" TOTAL_2="340" VAR="1.9658580202355295E-4" WEIGHT="45.07790537461712"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.90837470947342" CI_END="0.03410274891750194" CI_START="0.014443694518296546" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.02427322171789924" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="52" I2="30.854030025773085" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-1.4672106124566184" LOG_CI_START="-1.840321705403137" LOG_EFFECT_SIZE="-1.6148725771312913" METHOD="MH" NO="3" P_CHI2="0.1445667185955295" P_Q="0.0" P_Z="1.298571614931652E-6" Q="0.0" RANDOM="YES" SCALE="0.5" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="8.792417399398261E-5" TOTALS="YES" TOTAL_1="3216" TOTAL_2="2778" WEIGHT="100.0" Z="4.839972400479335">
<NAME>Orlistat: Discontinuation Due to GI Side Effects (Absolute % Difference)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.06645722883128574" CI_START="6.193028625874827E-4" EFFECT_SIZE="0.033538265846936616" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27794" O_E="0.0" SE="0.01679569790261949" STUDY_ID="STD-Bakris-2002" TOTAL_1="267" TOTAL_2="265" VAR="2.820954680360568E-4" WEIGHT="6.797423002381836"/>
<DICH_DATA CI_END="0.059515210232374105" CI_START="-0.00475648627212924" EFFECT_SIZE="0.027379361980122432" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27795" O_E="0.0" SE="0.016396142227987423" STUDY_ID="STD-Broom-2002" TOTAL_1="259" TOTAL_2="263" VAR="2.688334799603924E-4" WEIGHT="7.0501081005251365"/>
<DICH_DATA CI_END="0.016339987071889436" CI_START="-0.012968226589741338" EFFECT_SIZE="0.0016858802410740486" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27796" O_E="0.0" SE="0.007476722504293503" STUDY_ID="STD-Davidson-1999" TOTAL_1="657" TOTAL_2="223" VAR="5.59013794062089E-5" WEIGHT="17.487713181743498"/>
<DICH_DATA CI_END="0.05246113309896848" CI_START="-0.017071522709358092" EFFECT_SIZE="0.017694805194805194" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27797" O_E="0.0" SE="0.017738248344559206" STUDY_ID="STD-Finer-2000" TOTAL_1="112" TOTAL_2="110" VAR="3.146454543332574E-4" WEIGHT="6.247813667710541"/>
<DICH_DATA CI_END="0.07818213392813442" CI_START="0.00780169356512702" EFFECT_SIZE="0.04299191374663072" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27798" O_E="0.0" SE="0.017954523888744727" STUDY_ID="STD-Hauptman-2000" TOTAL_1="210" TOTAL_2="212" VAR="3.2236492807150507E-4" WEIGHT="6.1302628156733885"/>
<DICH_DATA CI_END="0.06598503963908041" CI_START="-0.0052527017913356865" EFFECT_SIZE="0.030366168923872363" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27799" O_E="0.0" SE="0.018173227159358617" STUDY_ID="STD-Hollander-1998" TOTAL_1="163" TOTAL_2="159" VAR="3.302661853856496E-4" WEIGHT="6.014438089388877"/>
<DICH_DATA CI_END="0.06794332661175961" CI_START="0.002213568516233763" EFFECT_SIZE="0.03507844756399669" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27800" O_E="0.0" SE="0.01676810355036975" STUDY_ID="STD-Krempf--2003" TOTAL_1="346" TOTAL_2="350" VAR="2.811692966759226E-4" WEIGHT="6.81447987010723"/>
<DICH_DATA CI_END="0.046009291086102674" CI_START="-0.004130400310777268" EFFECT_SIZE="0.0209394453876627" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27801" O_E="0.0" SE="0.012790972638368722" STUDY_ID="STD-Lindgarde-2000" TOTAL_1="190" TOTAL_2="186" VAR="1.6360898103549731E-4" WEIGHT="9.99939759739944"/>
<DICH_DATA CI_END="0.09771505526309765" CI_START="0.006589655126805448" EFFECT_SIZE="0.052152355194951545" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27802" O_E="0.0" SE="0.023246702708589983" STUDY_ID="STD-Miles-2002" TOTAL_1="255" TOTAL_2="261" VAR="5.404091868215648E-4" WEIGHT="4.002938858448478"/>
<DICH_DATA CI_END="0.05528465095419537" CI_START="0.0022178772042591374" EFFECT_SIZE="0.028751264079227255" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27803" O_E="0.0" SE="0.013537691041396722" STUDY_ID="STD-Rossner-2000" TOTAL_1="242" TOTAL_2="237" VAR="1.8326907873231305E-4" WEIGHT="9.27449337615546"/>
<DICH_DATA CI_END="0.049897934382008895" CI_START="0.008005475429120529" EFFECT_SIZE="0.028951704905564712" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27804" O_E="0.0" SE="0.01068704815071367" STUDY_ID="STD-Sjostrom-1998" TOTAL_1="345" TOTAL_2="343" VAR="1.1421299817567246E-4" WEIGHT="12.44293664085236"/>
<DICH_DATA CI_END="0.04775826194327793" CI_START="-0.01260337158476766" EFFECT_SIZE="0.017577445179255136" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27805" O_E="0.0" SE="0.015398658853981617" STUDY_ID="STD-Swinburn-2005" TOTAL_1="170" TOTAL_2="169" VAR="2.3711869450130646E-4" WEIGHT="7.737994799613749"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Sibutramine: Anthropometric Outcomes</NAME>
<CONT_OUTCOME CHI2="9.38605551139258" CI_END="-3.6711828496600747" CI_START="-5.01107134841025" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.3411270990351625" ESTIMABLE="YES" I2="25.421280627377932" I2_Q="74.44703663772654" ID="CMP-006.01" NO="1" P_CHI2="0.22611403718705014" P_Q="0.04790150148387251" P_Z="5.894863773024103E-37" Q="3.91344043280869" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.22911711080635883" TOTALS="YES" TOTAL_1="931" TOTAL_2="794" UNITS="" WEIGHT="100.0" Z="12.700240019010987">
<NAME>Sibutramine: Change in Weight (%)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.472615078583891" CI_END="-3.9631393664814056" CI_START="-5.1133966194443214" DF="6.0" EFFECT_SIZE="-4.538267992962863" ESTIMABLE="YES" I2="0.0" ID="CMP-006.01.01" NO="1" P_CHI2="0.48477292072376865" P_Z="5.900735732331753E-54" STUDIES="7" TAU2="0.0" TOTAL_1="837" TOTAL_2="699" WEIGHT="91.09025077721779" Z="15.465830440079582">
<NAME>Weight Loss Studies</NAME>
<CONT_DATA CI_END="-1.8782598139980853" CI_START="-4.921740186001916" EFFECT_SIZE="-3.4000000000000004" ESTIMABLE="YES" MEAN_1="-8.3" MEAN_2="-4.9" ORDER="27806" SD_1="8.3" SD_2="6.0" SE="0.7764123208412029" STUDY_ID="STD-Hauner-2004" TOTAL_1="174" TOTAL_2="174" WEIGHT="14.04406037019321"/>
<CONT_DATA CI_END="-2.020084717419613" CI_START="-7.779915282580388" EFFECT_SIZE="-4.9" ESTIMABLE="YES" MEAN_1="-7.3" MEAN_2="-2.4" ORDER="27807" SD_1="11.18" SD_2="11.18" SE="1.469371531975481" STUDY_ID="STD-Kaukua-2003" TOTAL_1="111" TOTAL_2="121" WEIGHT="4.89233222681947"/>
<CONT_DATA CI_END="-2.647060776572224" CI_START="-5.352939223427776" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="-4.7" MEAN_2="-0.7" ORDER="27808" SD_1="5.6" SD_2="4.2" SE="0.6902877981940422" STUDY_ID="STD-McMahon-2000" TOTAL_1="142" TOTAL_2="69" WEIGHT="16.558223395532757"/>
<CONT_DATA CI_END="-3.403645159257964" CI_START="-5.596354840742036" EFFECT_SIZE="-4.5" ESTIMABLE="YES" MEAN_1="-4.8" MEAN_2="-0.3" ORDER="27809" SD_1="4.7" SD_2="3.4" SE="0.5593749933110725" STUDY_ID="STD-McMahon-2002" TOTAL_1="145" TOTAL_2="72" WEIGHT="21.55598343962914"/>
<CONT_DATA CI_END="-3.72461802592745" CI_START="-6.495381974072549" EFFECT_SIZE="-5.109999999999999" ESTIMABLE="YES" MEAN_1="-5.31" MEAN_2="-0.2" ORDER="27810" SD_1="4.12" SD_2="4.0" SE="0.7068405261526568" STUDY_ID="STD-McNulty-2003" TOTAL_1="68" TOTAL_2="64" WEIGHT="16.032754973069526"/>
<CONT_DATA CI_END="1.241785402865009" CI_START="-8.64178540286501" EFFECT_SIZE="-3.7" ESTIMABLE="YES" MEAN_1="-5.5" MEAN_2="-1.8" ORDER="27811" SD_1="12.9" SD_2="10.4" SE="2.5213654137755497" STUDY_ID="STD-Sanchez_x002d_Reyes-2004" TOTAL_1="44" TOTAL_2="42" WEIGHT="1.7739157888534134"/>
<CONT_DATA CI_END="-4.127136680104082" CI_START="-6.872863319895918" EFFECT_SIZE="-5.5" ESTIMABLE="YES" MEAN_1="-7.3" MEAN_2="-1.8" ORDER="27812" SD_1="7.26" SD_2="4.79" SE="0.7004533403291535" STUDY_ID="STD-Smith-2001" TOTAL_1="153" TOTAL_2="157" WEIGHT="16.232980583120277"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.36104958542121013" CI_START="-4.438950414578791" DF="0.0" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-006.01.02" NO="2" P_CHI2="1.0" P_Z="0.02105331756431317" STUDIES="1" TAU2="0.0" TOTAL_1="94" TOTAL_2="95" WEIGHT="8.909749222782212" Z="2.307026953310129">
<NAME>Weight Maintenance Studies</NAME>
<CONT_DATA CI_END="-0.36104958542121013" CI_START="-4.438950414578791" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" MEAN_1="-10.3" MEAN_2="-7.9" ORDER="27813" SD_1="7.0" SD_2="7.3" SE="1.0402999395202008" STUDY_ID="STD-Mathus_x002d_Vliegen-2005" TOTAL_1="94" TOTAL_2="95" WEIGHT="8.909749222782212"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="11.184467135830209" CI_END="-3.5922125361967874" CI_START="-4.725353019295587" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.158782777746187" ESTIMABLE="YES" I2="19.531258032241148" I2_Q="0.0" ID="CMP-006.02" NO="2" P_CHI2="0.26327640120345297" P_Q="0.7774133767816352" P_Z="6.273646091202712E-47" Q="0.07991445854374923" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.15907776844060154" TOTALS="YES" TOTAL_1="1362" TOTAL_2="986" UNITS="" WEIGHT="100.00000000000001" Z="14.386679472640944">
<NAME>Sibutramine: Change in Weight (kg)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.994576716684146" CI_END="-3.6413241853423663" CI_START="-4.76646928864886" DF="6.0" EFFECT_SIZE="-4.203896736995613" ESTIMABLE="YES" I2="0.0" ID="CMP-006.02.01" NO="1" P_CHI2="0.4237979993127533" P_Z="1.4270191855458176E-48" STUDIES="7" TAU2="0.0" TOTAL_1="837" TOTAL_2="699" WEIGHT="74.8315769837913" Z="14.64608640258622">
<NAME>Weight Loss Studies</NAME>
<CONT_DATA CI_END="-1.4834188859422164" CI_START="-4.516581114057784" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="-8.1" MEAN_2="-5.1" ORDER="27814" SD_1="7.7" SD_2="6.7" SE="0.7737800929100646" STUDY_ID="STD-Hauner-2004" TOTAL_1="174" TOTAL_2="174" WEIGHT="11.026788817153818"/>
<CONT_DATA CI_END="-1.8570723793135264" CI_START="-7.142927620686473" EFFECT_SIZE="-4.5" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-2.6" ORDER="27815" SD_1="10.26" SD_2="10.26" SE="1.348457237752096" STUDY_ID="STD-Kaukua-2003" TOTAL_1="111" TOTAL_2="121" WEIGHT="4.225845176379918"/>
<CONT_DATA CI_END="-2.6721730938904926" CI_START="-5.127826906109508" EFFECT_SIZE="-3.9000000000000004" ESTIMABLE="YES" MEAN_1="-4.4" MEAN_2="-0.5" ORDER="27816" SD_1="5.1" SD_2="3.8" SE="0.6264538102712343" STUDY_ID="STD-McMahon-2000" TOTAL_1="142" TOTAL_2="69" WEIGHT="15.151247161362877"/>
<CONT_DATA CI_END="-2.9918744738751535" CI_START="-5.208125526124846" EFFECT_SIZE="-4.1" ESTIMABLE="YES" MEAN_1="-4.5" MEAN_2="-0.4" ORDER="27817" SD_1="4.5" SD_2="3.6" SE="0.5653805553906087" STUDY_ID="STD-McMahon-2002" TOTAL_1="145" TOTAL_2="72" WEIGHT="17.454926574683274"/>
<CONT_DATA CI_END="-3.7688040779976144" CI_START="-6.831195922002385" EFFECT_SIZE="-5.3" ESTIMABLE="YES" MEAN_1="-5.5" MEAN_2="-0.2" ORDER="27818" SD_1="4.95" SD_2="4.0" SE="0.7812367645937698" STUDY_ID="STD-McNulty-2003" TOTAL_1="68" TOTAL_2="64" WEIGHT="10.860611357667075"/>
<CONT_DATA CI_END="1.7903034388514834" CI_START="-7.190303438851483" EFFECT_SIZE="-2.6999999999999997" ESTIMABLE="YES" MEAN_1="-4.1" MEAN_2="-1.4" ORDER="27819" SD_1="10.45" SD_2="10.78" SE="2.2910132401770764" STUDY_ID="STD-Sanchez_x002d_Reyes-2004" TOTAL_1="44" TOTAL_2="42" WEIGHT="1.5452158548873403"/>
<CONT_DATA CI_END="-3.5380405735409797" CI_START="-6.061959426459022" EFFECT_SIZE="-4.800000000000001" ESTIMABLE="YES" MEAN_1="-6.4" MEAN_2="-1.6" ORDER="27820" SD_1="6.63" SD_2="4.47" SE="0.6438686814723106" STUDY_ID="STD-Smith-2001" TOTAL_1="153" TOTAL_2="157" WEIGHT="14.566942041656988"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.109975960602314" CI_END="-2.283659112339361" CI_START="-5.7279620036170655" DF="2.0" EFFECT_SIZE="-4.005810557978213" ESTIMABLE="YES" I2="60.860872626018" ID="CMP-006.02.02" NO="2" P_CHI2="0.07769325698382312" P_Z="5.140402640849736E-6" STUDIES="3" TAU2="1.4055639301602638" TOTAL_1="525" TOTAL_2="287" WEIGHT="25.168423016208717" Z="4.558974440029625">
<NAME>Weight Maintenance Studies</NAME>
<CONT_DATA CI_END="-3.6341357537755714" CI_START="-7.765864246224429" EFFECT_SIZE="-5.7" ESTIMABLE="YES" MEAN_1="-5.2" MEAN_2="0.5" ORDER="27821" SD_1="7.5" SD_2="5.7" SE="1.05403173860321" STUDY_ID="STD-Apfelbaum-1999" TOTAL_1="81" TOTAL_2="78" WEIGHT="6.57940876351331"/>
<CONT_DATA CI_END="-2.6240996709316615" CI_START="-5.3759003290683385" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="-8.9" MEAN_2="-4.9" ORDER="27822" SD_1="8.1" SD_2="5.9" SE="0.7020028632777258" STUDY_ID="STD-James-2000" TOTAL_1="350" TOTAL_2="114" WEIGHT="12.818577240105792"/>
<CONT_DATA CI_END="0.02525910305607537" CI_START="-4.425259103056074" EFFECT_SIZE="-2.1999999999999993" ESTIMABLE="YES" MEAN_1="-10.7" MEAN_2="-8.5" ORDER="27823" SD_1="7.5" SD_2="8.1" SE="1.1353571395232944" STUDY_ID="STD-Mathus_x002d_Vliegen-2005" TOTAL_1="94" TOTAL_2="95" WEIGHT="5.770437012589614"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="6.523974465351267" CI_END="0.3653392173501533" CI_START="0.2729188102201334" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.31912901378514336" ESTIMABLE="YES" EVENTS_1="443" EVENTS_2="174" I2="8.031522320237265" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="-0.43730370593045964" LOG_CI_START="-0.5639665306793842" LOG_EFFECT_SIZE="-0.4960337098961865" METHOD="MH" NO="3" P_CHI2="0.3671176988187228" P_Q="0.0" P_Z="9.64335791572656E-42" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="3.155605684484088E-4" TOTALS="YES" TOTAL_1="808" TOTAL_2="656" WEIGHT="100.0" Z="13.535568449957612">
<NAME>Sibutramine: 5% Responders (absolute % difference)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.528722207886948" CI_END="0.37504632681465466" CI_START="0.2666175667154562" DF="5.0" EFFECT_SIZE="0.32083194676505544" ESTIMABLE="YES" EVENTS_1="372" EVENTS_2="131" I2="23.415335485406203" ID="CMP-006.03.01" LOG_CI_END="-0.42591508363945685" LOG_CI_START="-0.5741112394823586" LOG_EFFECT_SIZE="-0.49372239346458835" NO="1" P_CHI2="0.2581138424751557" P_Z="4.181391814834029E-31" STUDIES="6" TAU2="0.0010689316421248593" TOTAL_1="726" TOTAL_2="578" WEIGHT="88.66352941214807" Z="11.598750371655848">
<NAME>Weight Loss Studies</NAME>
<DICH_DATA CI_END="0.3152188693936863" CI_START="0.11006848692815267" EFFECT_SIZE="0.2126436781609195" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="72" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27824" O_E="0.0" SE="0.05233524291357741" STUDY_ID="STD-Hauner-2004" TOTAL_1="174" TOTAL_2="174" VAR="0.002738977650823155" WEIGHT="18.198433992761903"/>
<DICH_DATA CI_END="0.41895245959326616" CI_START="0.20995139833692372" EFFECT_SIZE="0.31445192896509494" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27825" O_E="0.0" SE="0.053317576982259904" STUDY_ID="STD-McMahon-2000" TOTAL_1="142" TOTAL_2="69" VAR="0.002842764015259211" WEIGHT="17.600411448694867"/>
<DICH_DATA CI_END="0.447014270810283" CI_START="0.24149147631615386" EFFECT_SIZE="0.34425287356321843" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27826" O_E="0.0" SE="0.052430247727832426" STUDY_ID="STD-McMahon-2002" TOTAL_1="145" TOTAL_2="72" VAR="0.0027489308768018773" WEIGHT="18.139326917664803"/>
<DICH_DATA CI_END="0.4743328644041378" CI_START="0.18743184147821512" EFFECT_SIZE="0.33088235294117646" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27827" O_E="0.0" SE="0.0731903813511272" STUDY_ID="STD-McNulty-2003" TOTAL_1="68" TOTAL_2="64" VAR="0.005356831922323427" WEIGHT="9.799711894445844"/>
<DICH_DATA CI_END="0.6081124087308805" CI_START="0.2403724397539682" EFFECT_SIZE="0.4242424242424243" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27828" O_E="0.0" SE="0.09381294041053768" STUDY_ID="STD-Sanchez_x002d_Reyes-2004" TOTAL_1="44" TOTAL_2="42" VAR="0.008800867788471094" WEIGHT="6.0975428079342135"/>
<DICH_DATA CI_END="0.4654499876720774" CI_START="0.264161602186796" EFFECT_SIZE="0.3648057949294367" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="32" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27829" O_E="0.0" SE="0.051350021498613875" STUDY_ID="STD-Smith-2001" TOTAL_1="153" TOTAL_2="157" VAR="0.002636824707908107" WEIGHT="18.828102350646432"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.44732772495173634" CI_START="0.18181548955733176" DF="0.0" EFFECT_SIZE="0.31457160725453404" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="43" I2="0.0" ID="CMP-006.03.02" LOG_CI_END="-0.34937418382957" LOG_CI_START="-0.7403691203290267" LOG_EFFECT_SIZE="-0.5022804786903073" NO="2" P_CHI2="1.0" P_Z="3.4135862952193936E-6" STUDIES="1" TAU2="0.0" TOTAL_1="82" TOTAL_2="78" WEIGHT="11.336470587851931" Z="4.644223042014724">
<NAME>Weight Maintenance Studies</NAME>
<DICH_DATA CI_END="0.44732772495173634" CI_START="0.18181548955733176" EFFECT_SIZE="0.31457160725453404" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="43" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27830" O_E="0.0" SE="0.0677339577381858" STUDY_ID="STD-Apfelbaum-1999" TOTAL_1="82" TOTAL_2="78" VAR="0.004587889030878341" WEIGHT="11.336470587851931"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.664551771985902" CI_END="0.25049319035119055" CI_START="0.11469444700015254" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.18259381867567154" ESTIMABLE="YES" EVENTS_1="226" EVENTS_2="69" I2="73.52694171778774" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="-0.6012040759168935" LOG_CI_START="-0.9404576082153081" LOG_EFFECT_SIZE="-0.7385139286663719" METHOD="MH" NO="4" P_CHI2="9.169769884872503E-4" P_Q="0.0" P_Z="1.3590346369903017E-7" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0059087516740155225" TOTALS="YES" TOTAL_1="808" TOTAL_2="656" WEIGHT="100.00000000000001" Z="5.270701327166852">
<NAME>Sibutramine: 10% Responders (absolute % difference)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="17.33302981568276" CI_END="0.2334285861761926" CI_START="0.10089641444150495" DF="5.0" EFFECT_SIZE="0.16716250030884877" ESTIMABLE="YES" EVENTS_1="182" EVENTS_2="51" I2="71.15334103056784" ID="CMP-006.04.01" LOG_CI_END="-0.6318459603798723" LOG_CI_START="-0.9961242670231245" LOG_EFFECT_SIZE="-0.7768611415831188" NO="1" P_CHI2="0.003909649656796299" P_Z="7.645896623657797E-7" STUDIES="6" TAU2="0.004728739951013273" TOTAL_1="726" TOTAL_2="578" WEIGHT="89.30065804687365" Z="4.944195449039911">
<NAME>Weight Loss Studies</NAME>
<DICH_DATA CI_END="0.31180195439682856" CI_START="0.12497965479857379" EFFECT_SIZE="0.21839080459770116" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="33" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27831" O_E="0.0" SE="0.04765962565431947" STUDY_ID="STD-Hauner-2004" TOTAL_1="174" TOTAL_2="174" VAR="0.002271439917509867" WEIGHT="14.671409980640002"/>
<DICH_DATA CI_END="0.16415350750310737" CI_START="0.016495604560579094" EFFECT_SIZE="0.09032455603184322" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27832" O_E="0.0" SE="0.037668524551276186" STUDY_ID="STD-McMahon-2000" TOTAL_1="142" TOTAL_2="69" VAR="0.0014189177418700968" WEIGHT="16.378324095690395"/>
<DICH_DATA CI_END="0.17002096667623742" CI_START="0.03649244328544843" EFFECT_SIZE="0.10325670498084293" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27833" O_E="0.0" SE="0.034064024758629484" STUDY_ID="STD-McMahon-2002" TOTAL_1="145" TOTAL_2="72" VAR="0.0011603577827565227" WEIGHT="16.977378168120094"/>
<DICH_DATA CI_END="0.23443112168893313" CI_START="0.059686525369890414" EFFECT_SIZE="0.14705882352941177" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27834" O_E="0.0" SE="0.04457852228342096" STUDY_ID="STD-McNulty-2003" TOTAL_1="68" TOTAL_2="64" VAR="0.0019872446489734596" WEIGHT="15.199468141852183"/>
<DICH_DATA CI_END="0.34562147957996736" CI_START="0.059140425181937406" EFFECT_SIZE="0.20238095238095238" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27835" O_E="0.0" SE="0.07308324455391935" STUDY_ID="STD-Sanchez_x002d_Reyes-2004" TOTAL_1="44" TOTAL_2="42" VAR="0.0053411606345279816" WEIGHT="10.668078227446292"/>
<DICH_DATA CI_END="0.35481904912330714" CI_START="0.18479212443316434" EFFECT_SIZE="0.26980558677823574" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27836" O_E="0.0" SE="0.04337501250821278" STUDY_ID="STD-Smith-2001" TOTAL_1="153" TOTAL_2="157" VAR="0.001881391710087615" WEIGHT="15.405999433124691"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.44861519060576477" CI_START="0.1630170795630908" DF="0.0" EFFECT_SIZE="0.3058161350844278" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="18" I2="0.0" ID="CMP-006.04.02" LOG_CI_END="-0.3481260248133164" LOG_CI_START="-0.7877668914769305" LOG_EFFECT_SIZE="-0.5145396046226145" NO="2" P_CHI2="1.0" P_Z="2.6996464045138965E-5" STUDIES="1" TAU2="0.0" TOTAL_1="82" TOTAL_2="78" WEIGHT="10.699341953126359" Z="4.197426996057087">
<NAME>Weight Maintenance Studies</NAME>
<DICH_DATA CI_END="0.44861519060576477" CI_START="0.1630170795630908" EFFECT_SIZE="0.3058161350844278" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="18" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27837" O_E="0.0" SE="0.07285799976311692" STUDY_ID="STD-Apfelbaum-1999" TOTAL_1="82" TOTAL_2="78" VAR="0.005308288129482346" WEIGHT="10.699341953126359"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.806601362441073" CI_END="-3.275066750560278" CI_START="-4.7036518108984975" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.9893592807293876" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.05" NO="5" P_CHI2="0.4492906572685804" P_Q="0.8493324287917539" P_Z="6.906779800609174E-28" Q="0.036088735238272385" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1104" TOTAL_2="733" UNITS="" WEIGHT="100.00000000000001" Z="10.94649626220935">
<NAME>Sibutramine: Change in Waist Circumference (cm)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.069109268323153" CI_END="-3.027751068022594" CI_START="-4.915697214820051" DF="5.0" EFFECT_SIZE="-3.9717241414213227" ESTIMABLE="YES" I2="17.61558774206317" ID="CMP-006.05.01" NO="1" P_CHI2="0.29955232485698446" P_Z="1.6315559683463865E-16" STUDIES="6" TAU2="0.2457310112616731" TOTAL_1="682" TOTAL_2="555" WEIGHT="74.37928381332686" Z="8.246460087771975">
<NAME>Weight Loss Studies</NAME>
<CONT_DATA CI_END="-0.8675101545395996" CI_START="-4.1324898454604" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="-8.5" MEAN_2="-6.0" ORDER="27838" SD_1="8.41" SD_2="7.07" SE="0.8329182874467449" STUDY_ID="STD-Hauner-2004" TOTAL_1="174" TOTAL_2="174" WEIGHT="19.14481790086204"/>
<CONT_DATA CI_END="-3.107514366296553" CI_START="-7.292485633703447" EFFECT_SIZE="-5.2" ESTIMABLE="YES" MEAN_1="-4.7" MEAN_2="0.5" ORDER="27839" SD_1="6.7" SD_2="5.6" SE="1.0676143287370108" STUDY_ID="STD-McMahon-2000" TOTAL_1="98" TOTAL_2="46" WEIGHT="11.652718281041814"/>
<CONT_DATA CI_END="-2.462178083551059" CI_START="-5.537821916448941" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="-5.3" MEAN_2="-1.3" ORDER="27840" SD_1="5.9" SD_2="5.2" SE="0.7846174361259103" STUDY_ID="STD-McMahon-2002" TOTAL_1="145" TOTAL_2="72" WEIGHT="21.57446946626258"/>
<CONT_DATA CI_END="-3.0916211972993857" CI_START="-6.708378802700615" EFFECT_SIZE="-4.9" ESTIMABLE="YES" MEAN_1="-4.7" MEAN_2="0.2" ORDER="27841" SD_1="5.78" SD_2="4.8" SE="0.9226592003551474" STUDY_ID="STD-McNulty-2003" TOTAL_1="68" TOTAL_2="64" WEIGHT="15.601753121775616"/>
<CONT_DATA CI_END="0.632513654704852" CI_START="-6.232513654704851" EFFECT_SIZE="-2.8" ESTIMABLE="YES" MEAN_1="-4.1" MEAN_2="-1.3" ORDER="27842" SD_1="8.4" SD_2="7.84" SE="1.7513146577080403" STUDY_ID="STD-Sanchez_x002d_Reyes-2004" TOTAL_1="44" TOTAL_2="42" WEIGHT="4.330396566839602"/>
<CONT_DATA CI_END="-0.04146237062685021" CI_START="-9.95853762937315" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="-7.4" MEAN_2="-2.4" ORDER="27843" SD_1="22.27" SD_2="22.27" SE="2.529912625173453" STUDY_ID="STD-Smith-2001" TOTAL_1="153" TOTAL_2="157" WEIGHT="2.075128476545213"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.7014033588796476" CI_END="-2.6961481413668738" CI_START="-5.51849555251052" DF="1.0" EFFECT_SIZE="-4.107321846938697" ESTIMABLE="YES" I2="0.0" ID="CMP-006.05.02" NO="2" P_CHI2="0.4023129815953207" P_Z="1.1660624731499242E-8" STUDIES="2" TAU2="0.0" TOTAL_1="422" TOTAL_2="178" WEIGHT="25.620716186673146" Z="5.704615144917509">
<NAME>Weight Maintenance Studies</NAME>
<CONT_DATA CI_END="-2.4789393159955146" CI_START="-7.521060684004485" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="-6.0" MEAN_2="-1.0" ORDER="27844" SD_1="8.0" SD_2="7.0" SE="1.286279086702761" STUDY_ID="STD-Apfelbaum-1999" TOTAL_1="72" TOTAL_2="64" WEIGHT="8.02759802849835"/>
<CONT_DATA CI_END="-1.9970390136407563" CI_START="-5.402960986359244" EFFECT_SIZE="-3.7" ESTIMABLE="YES" MEAN_1="-8.5" MEAN_2="-4.8" ORDER="27845" SD_1="8.8" SD_2="7.8" SE="0.8688736118581681" STUDY_ID="STD-James-2000" TOTAL_1="350" TOTAL_2="114" WEIGHT="17.593118158174796"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.0405845761789223" CI_END="-1.3002858538650952" CI_START="-1.7856508486739875" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.5429683512695413" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.06" NO="6" P_CHI2="0.5510568698296783" P_Q="1.0" P_Z="1.2123162368646916E-35" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="552" TOTAL_2="404" UNITS="" WEIGHT="100.0" Z="12.461394744646487">
<NAME>Sibutramine: Change in Body Mass Index (kg/m2)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.9452700560047307" CI_START="-1.8547299439952696" EFFECT_SIZE="-1.4000000000000001" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-0.2" ORDER="27846" SD_1="1.9" SD_2="1.4" SE="0.23200933669298068" STUDY_ID="STD-McMahon-2000" TOTAL_1="142" TOTAL_2="69" WEIGHT="28.481955539132517"/>
<CONT_DATA CI_END="-1.1196701507720914" CI_START="-1.8803298492279086" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-0.1" ORDER="27847" SD_1="1.6" SD_2="1.2" SE="0.19404940714620364" STUDY_ID="STD-McMahon-2002" TOTAL_1="145" TOTAL_2="72" WEIGHT="40.715154636096244"/>
<CONT_DATA CI_END="-1.3538516877087297" CI_START="-2.44614831229127" EFFECT_SIZE="-1.9" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-0.1" ORDER="27848" SD_1="1.6" SD_2="1.6" SE="0.27865221840769444" STUDY_ID="STD-McNulty-2003" TOTAL_1="68" TOTAL_2="64" WEIGHT="19.74493549280279"/>
<CONT_DATA CI_END="-0.09359525679198066" CI_START="-2.1064047432080195" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="-0.6" ORDER="27849" SD_1="2.76" SD_2="1.95" SE="0.5134812430975322" STUDY_ID="STD-Sanchez_x002d_Reyes-2004" TOTAL_1="44" TOTAL_2="42" WEIGHT="5.814756879777502"/>
<CONT_DATA CI_END="-0.7401598960118458" CI_START="-2.859840103988154" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" MEAN_1="-2.4" MEAN_2="-0.6" ORDER="27850" SD_1="4.76" SD_2="4.76" SE="0.5407446832431807" STUDY_ID="STD-Smith-2001" TOTAL_1="153" TOTAL_2="157" WEIGHT="5.243197452190941"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="11.184467135830209" CI_END="-3.592212536196788" CI_START="-4.7253530192955875" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.158782777746188" ESTIMABLE="YES" I2="19.531258032241148" I2_Q="0.0" ID="CMP-006.07" NO="7" P_CHI2="0.26327640120345297" P_Q="0.6550716063828202" P_Z="6.273646091202712E-47" Q="0.199565740383834" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.15907776844060156" TOTALS="YES" TOTAL_1="1362" TOTAL_2="986" UNITS="" WEIGHT="100.0" Z="14.386679472640944">
<NAME>Sibutramine: Sensitivity Analysis According to Baseline CV Risk (Absolute Weight Loss)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.308907018115507" CI_END="-2.947038032752994" CI_START="-5.041067831723588" DF="4.0" EFFECT_SIZE="-3.994052932238291" ESTIMABLE="YES" I2="51.85889081104176" ID="CMP-006.07.01" NO="1" P_CHI2="0.08089596957877143" P_Z="7.622120174653787E-14" STUDIES="5" TAU2="0.7215231492704333" TOTAL_1="852" TOTAL_2="618" WEIGHT="50.76215387501952" Z="7.476684336948713">
<NAME>Change in Weight in Lower Risk Population (kg)</NAME>
<CONT_DATA CI_END="-3.6341357537755714" CI_START="-7.765864246224429" EFFECT_SIZE="-5.7" ESTIMABLE="YES" MEAN_1="-5.2" MEAN_2="0.5" ORDER="27851" SD_1="7.5" SD_2="5.7" SE="1.05403173860321" STUDY_ID="STD-Apfelbaum-1999" TOTAL_1="81" TOTAL_2="78" WEIGHT="6.57940876351331"/>
<CONT_DATA CI_END="-1.4834188859422164" CI_START="-4.516581114057784" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="-8.1" MEAN_2="-5.1" ORDER="27852" SD_1="7.7" SD_2="6.7" SE="0.7737800929100646" STUDY_ID="STD-Hauner-2004" TOTAL_1="174" TOTAL_2="174" WEIGHT="11.026788817153818"/>
<CONT_DATA CI_END="-2.6240996709316615" CI_START="-5.3759003290683385" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="-8.9" MEAN_2="-4.9" ORDER="27853" SD_1="8.1" SD_2="5.9" SE="0.7020028632777258" STUDY_ID="STD-James-2000" TOTAL_1="350" TOTAL_2="114" WEIGHT="12.818577240105789"/>
<CONT_DATA CI_END="0.02525910305607537" CI_START="-4.425259103056074" EFFECT_SIZE="-2.1999999999999993" ESTIMABLE="YES" MEAN_1="-10.7" MEAN_2="-8.5" ORDER="27854" SD_1="7.5" SD_2="8.1" SE="1.1353571395232944" STUDY_ID="STD-Mathus_x002d_Vliegen-2005" TOTAL_1="94" TOTAL_2="95" WEIGHT="5.770437012589614"/>
<CONT_DATA CI_END="-3.5380405735409797" CI_START="-6.061959426459022" EFFECT_SIZE="-4.800000000000001" ESTIMABLE="YES" MEAN_1="-6.4" MEAN_2="-1.6" ORDER="27855" SD_1="6.63" SD_2="4.47" SE="0.6438686814723106" STUDY_ID="STD-Smith-2001" TOTAL_1="153" TOTAL_2="157" WEIGHT="14.566942041656985"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.675994377330869" CI_END="-3.584445170034458" CI_START="-4.965572223077396" DF="4.0" EFFECT_SIZE="-4.275008696555927" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.02" NO="2" P_CHI2="0.6134219574194781" P_Z="7.029546581274854E-34" STUDIES="5" TAU2="0.0" TOTAL_1="510" TOTAL_2="368" WEIGHT="49.23784612498048" Z="12.133370438852223">
<NAME>Change in Weight in Higher Risk Population (kg)</NAME>
<CONT_DATA CI_END="-1.8570723793135264" CI_START="-7.142927620686473" EFFECT_SIZE="-4.5" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-2.6" ORDER="27856" SD_1="10.26" SD_2="10.26" SE="1.348457237752096" STUDY_ID="STD-Kaukua-2003" TOTAL_1="111" TOTAL_2="121" WEIGHT="4.225845176379918"/>
<CONT_DATA CI_END="-2.6721730938904926" CI_START="-5.127826906109508" EFFECT_SIZE="-3.9000000000000004" ESTIMABLE="YES" MEAN_1="-4.4" MEAN_2="-0.5" ORDER="27857" SD_1="5.1" SD_2="3.8" SE="0.6264538102712343" STUDY_ID="STD-McMahon-2000" TOTAL_1="142" TOTAL_2="69" WEIGHT="15.151247161362877"/>
<CONT_DATA CI_END="-2.9918744738751535" CI_START="-5.208125526124846" EFFECT_SIZE="-4.1" ESTIMABLE="YES" MEAN_1="-4.5" MEAN_2="-0.4" ORDER="27858" SD_1="4.5" SD_2="3.6" SE="0.5653805553906087" STUDY_ID="STD-McMahon-2002" TOTAL_1="145" TOTAL_2="72" WEIGHT="17.45492657468327"/>
<CONT_DATA CI_END="-3.7688040779976144" CI_START="-6.831195922002385" EFFECT_SIZE="-5.3" ESTIMABLE="YES" MEAN_1="-5.5" MEAN_2="-0.2" ORDER="27859" SD_1="4.95" SD_2="4.0" SE="0.7812367645937698" STUDY_ID="STD-McNulty-2003" TOTAL_1="68" TOTAL_2="64" WEIGHT="10.860611357667075"/>
<CONT_DATA CI_END="1.7903034388514834" CI_START="-7.190303438851483" EFFECT_SIZE="-2.6999999999999997" ESTIMABLE="YES" MEAN_1="-4.1" MEAN_2="-1.4" ORDER="27860" SD_1="10.45" SD_2="10.78" SE="2.2910132401770764" STUDY_ID="STD-Sanchez_x002d_Reyes-2004" TOTAL_1="44" TOTAL_2="42" WEIGHT="1.5452158548873403"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.386055511392582" CI_END="-3.6711828496600747" CI_START="-5.01107134841025" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.3411270990351625" ESTIMABLE="YES" I2="25.421280627377943" I2_Q="0.0" ID="CMP-006.08" NO="8" P_CHI2="0.22611403718705014" P_Q="0.4912980556188159" P_Z="5.8948637730243556E-37" Q="0.47368225604152236" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.22911711080635908" TOTALS="YES" TOTAL_1="931" TOTAL_2="794" UNITS="" WEIGHT="100.0" Z="12.700240019010984">
<NAME>Sibutramine: Sensitivity Analysis According to Baseline CV Risk (% Weight Loss)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.47491371274392" CI_END="-2.0611659895155254" CI_START="-5.683820669150509" DF="2.0" EFFECT_SIZE="-3.8724933293330173" ESTIMABLE="YES" I2="73.24383829889278" ID="CMP-006.08.01" NO="1" P_CHI2="0.023814683597678132" P_Z="2.786248530979468E-5" STUDIES="3" TAU2="1.8610460060697154" TOTAL_1="421" TOTAL_2="426" WEIGHT="39.1867901760957" Z="4.190268257436604">
<NAME>Change in Weight in Lower Risk Population (%)</NAME>
<CONT_DATA CI_END="-1.8782598139980853" CI_START="-4.921740186001916" EFFECT_SIZE="-3.4000000000000004" ESTIMABLE="YES" MEAN_1="-8.3" MEAN_2="-4.9" ORDER="27861" SD_1="8.3" SD_2="6.0" SE="0.7764123208412029" STUDY_ID="STD-Hauner-2004" TOTAL_1="174" TOTAL_2="174" WEIGHT="14.044060370193206"/>
<CONT_DATA CI_END="-0.36104958542121013" CI_START="-4.438950414578791" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" MEAN_1="-10.3" MEAN_2="-7.9" ORDER="27862" SD_1="7.0" SD_2="7.3" SE="1.0402999395202008" STUDY_ID="STD-Mathus_x002d_Vliegen-2005" TOTAL_1="94" TOTAL_2="95" WEIGHT="8.909749222782214"/>
<CONT_DATA CI_END="-4.127136680104082" CI_START="-6.872863319895918" EFFECT_SIZE="-5.5" ESTIMABLE="YES" MEAN_1="-7.3" MEAN_2="-1.8" ORDER="27863" SD_1="7.26" SD_2="4.79" SE="0.7004533403291535" STUDY_ID="STD-Smith-2001" TOTAL_1="153" TOTAL_2="157" WEIGHT="16.232980583120277"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.4374595426071397" CI_END="-3.832586563913512" CI_START="-5.22577787110001" DF="4.0" EFFECT_SIZE="-4.529182217506761" ESTIMABLE="YES" I2="0.0" ID="CMP-006.08.02" NO="2" P_CHI2="0.8376590105192473" P_Z="3.390493527928108E-37" STUDIES="5" TAU2="0.0" TOTAL_1="510" TOTAL_2="368" WEIGHT="60.8132098239043" Z="12.743453077753374">
<NAME>Change in Weight in Higher Risk Population (%)</NAME>
<CONT_DATA CI_END="-2.020084717419613" CI_START="-7.779915282580388" EFFECT_SIZE="-4.9" ESTIMABLE="YES" MEAN_1="-7.3" MEAN_2="-2.4" ORDER="27864" SD_1="11.18" SD_2="11.18" SE="1.469371531975481" STUDY_ID="STD-Kaukua-2003" TOTAL_1="111" TOTAL_2="121" WEIGHT="4.892332226819471"/>
<CONT_DATA CI_END="-2.647060776572224" CI_START="-5.352939223427776" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="-4.7" MEAN_2="-0.7" ORDER="27865" SD_1="5.6" SD_2="4.2" SE="0.6902877981940422" STUDY_ID="STD-McMahon-2000" TOTAL_1="142" TOTAL_2="69" WEIGHT="16.558223395532757"/>
<CONT_DATA CI_END="-3.403645159257964" CI_START="-5.596354840742036" EFFECT_SIZE="-4.5" ESTIMABLE="YES" MEAN_1="-4.8" MEAN_2="-0.3" ORDER="27866" SD_1="4.7" SD_2="3.4" SE="0.5593749933110725" STUDY_ID="STD-McMahon-2002" TOTAL_1="145" TOTAL_2="72" WEIGHT="21.55598343962913"/>
<CONT_DATA CI_END="-3.72461802592745" CI_START="-6.495381974072549" EFFECT_SIZE="-5.109999999999999" ESTIMABLE="YES" MEAN_1="-5.31" MEAN_2="-0.2" ORDER="27867" SD_1="4.12" SD_2="4.0" SE="0.7068405261526568" STUDY_ID="STD-McNulty-2003" TOTAL_1="68" TOTAL_2="64" WEIGHT="16.032754973069526"/>
<CONT_DATA CI_END="1.241785402865009" CI_START="-8.64178540286501" EFFECT_SIZE="-3.7" ESTIMABLE="YES" MEAN_1="-5.5" MEAN_2="-1.8" ORDER="27868" SD_1="12.9" SD_2="10.4" SE="2.5213654137755497" STUDY_ID="STD-Sanchez_x002d_Reyes-2004" TOTAL_1="44" TOTAL_2="42" WEIGHT="1.7739157888534138"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Sibutramine: Change in Blood Pressure</NAME>
<CONT_OUTCOME CHI2="9.192027975166203" CI_END="3.2751358559004906" CI_START="0.10991844641772408" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.6925271511591073" ESTIMABLE="YES" I2="34.72604722037399" I2_Q="77.20347339028359" ID="CMP-007.01" NO="1" P_CHI2="0.16306317985544205" P_Q="0.036221808584279924" P_Z="0.036074097014394374" Q="4.386633179344861" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="1.5566285886605162" TOTALS="YES" TOTAL_1="1139" TOTAL_2="767" UNITS="" WEIGHT="100.00000000000001" Z="2.0960912505976106">
<NAME>Sibutramine: Change in Systolic Blood Pressure (mm Hg)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.805394795821342" CI_END="2.4306296528397793" CI_START="-0.3932510395005291" DF="5.0" EFFECT_SIZE="1.0186893066696252" ESTIMABLE="YES" I2="0.0" ID="CMP-007.01.01" NO="1" P_CHI2="0.4400890059883117" P_Z="0.15733888298934276" STUDIES="6" TAU2="0.0" TOTAL_1="789" TOTAL_2="653" WEIGHT="81.32950381104668" Z="1.4140784048874628">
<NAME>Weight Loss Studies</NAME>
<CONT_DATA CI_END="1.8548567012485888" CI_START="-4.654856701248589" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="-2.9" MEAN_2="-1.5" ORDER="27869" SD_1="14.8" SD_2="16.15" SE="1.660671689338418" STUDY_ID="STD-Hauner-2004" TOTAL_1="174" TOTAL_2="174" WEIGHT="15.112091242261837"/>
<CONT_DATA CI_END="4.572581450589976" CI_START="-3.572581450589976" EFFECT_SIZE="0.49999999999999956" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="3.6" ORDER="27870" SD_1="15.81" SD_2="15.81" SE="2.077885860512733" STUDY_ID="STD-Kaukua-2003" TOTAL_1="111" TOTAL_2="121" WEIGHT="11.099396408429449"/>
<CONT_DATA CI_END="4.137987627668018" CI_START="-1.737987627668018" EFFECT_SIZE="1.2000000000000002" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="1.5" ORDER="27871" SD_1="11.2" SD_2="9.7" SE="1.4990008239143624" STUDY_ID="STD-McMahon-2000" TOTAL_1="142" TOTAL_2="69" WEIGHT="17.141641934262775"/>
<CONT_DATA CI_END="6.167759991334183" CI_START="-0.7677599913341835" EFFECT_SIZE="2.6999999999999997" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="1.1" ORDER="27872" SD_1="11.8" SD_2="12.5" SE="1.7692978129636214" STUDY_ID="STD-McMahon-2002" TOTAL_1="145" TOTAL_2="72" WEIGHT="13.91079494609381"/>
<CONT_DATA CI_END="10.007161355752235" CI_START="-0.8071613557522328" EFFECT_SIZE="4.6000000000000005" ESTIMABLE="YES" MEAN_1="4.4" MEAN_2="-0.2" ORDER="27873" SD_1="15.67" SD_2="16.0" SE="2.758806487467745" STUDY_ID="STD-McNulty-2003" TOTAL_1="68" TOTAL_2="64" WEIGHT="7.112025104484331"/>
<CONT_DATA CI_END="3.7754469427266466" CI_START="-2.1554469427266465" EFFECT_SIZE="0.81" ESTIMABLE="YES" MEAN_1="0.32" MEAN_2="-0.49" ORDER="27874" SD_1="13.18" SD_2="13.11" SE="1.5130109359752084" STUDY_ID="STD-Smith-2001" TOTAL_1="149" TOTAL_2="153" WEIGHT="16.953554175514473"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.02677332704" CI_START="1.5732266729599997" DF="0.0" EFFECT_SIZE="4.3" ESTIMABLE="YES" I2="0.0" ID="CMP-007.01.02" NO="2" P_CHI2="1.0" P_Z="0.001996342785273009" STUDIES="1" TAU2="0.0" TOTAL_1="350" TOTAL_2="114" WEIGHT="18.670496188953333" Z="3.090775844822763">
<NAME>Weight Maintenance Studies</NAME>
<CONT_DATA CI_END="7.02677332704" CI_START="1.5732266729599997" EFFECT_SIZE="4.3" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="-2.4" ORDER="27875" SD_1="13.5" SD_2="12.7" SE="1.3912364454390183" STUDY_ID="STD-James-2000" TOTAL_1="350" TOTAL_2="114" WEIGHT="18.670496188953333"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.26582698255909" CI_END="3.3230117161734483" CI_START="1.5119167120157235" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.417464214094586" ESTIMABLE="YES" I2="27.411981733225115" I2_Q="62.86756096286669" ID="CMP-007.02" NO="2" P_CHI2="0.21926796077008315" P_Q="0.1007859658967254" P_Z="1.673671367394654E-7" Q="2.6930630627306122" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.40703252995744976" TOTALS="YES" TOTAL_1="1139" TOTAL_2="767" UNITS="" WEIGHT="100.0" Z="5.2323514588273685">
<NAME>Sibutramine: Change in Diastolic Blood Pressure (mm Hg)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.572763919828478" CI_END="3.030308833896452" CI_START="1.261019056581705" DF="5.0" EFFECT_SIZE="2.1456639452390784" ESTIMABLE="YES" I2="10.277914659017302" ID="CMP-007.02.01" NO="1" P_CHI2="0.3500331198864993" P_Z="1.9962943416958778E-6" STUDIES="6" TAU2="0.1263669229292427" TOTAL_1="789" TOTAL_2="653" WEIGHT="84.36351553312996" Z="4.753799077477623">
<NAME>Weight Loss Studies</NAME>
<CONT_DATA CI_END="3.122431999941654" CI_START="-1.122431999941654" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="-1.3" ORDER="27876" SD_1="10.43" SD_2="9.76" SE="1.0828933677777381" STUDY_ID="STD-Hauner-2004" TOTAL_1="174" TOTAL_2="174" WEIGHT="13.513077407343008"/>
<CONT_DATA CI_END="3.8706039277048268" CI_START="-0.07060392770482715" EFFECT_SIZE="1.9" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="-0.2" ORDER="27877" SD_1="7.65" SD_2="7.65" SE="1.0054286421835805" STUDY_ID="STD-Kaukua-2003" TOTAL_1="111" TOTAL_2="121" WEIGHT="15.054792798077058"/>
<CONT_DATA CI_END="5.131418528403853" CI_START="1.4685814715961465" EFFECT_SIZE="3.3" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="-1.3" ORDER="27878" SD_1="6.3" SD_2="6.4" SE="0.9344143784527924" STUDY_ID="STD-McMahon-2000" TOTAL_1="142" TOTAL_2="69" WEIGHT="16.674817991087426"/>
<CONT_DATA CI_END="5.012978376008443" CI_START="1.1870216239915568" EFFECT_SIZE="3.1" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="-0.1" ORDER="27879" SD_1="6.5" SD_2="6.9" SE="0.9760273102453783" STUDY_ID="STD-McMahon-2002" TOTAL_1="145" TOTAL_2="72" WEIGHT="15.699845652435847"/>
<CONT_DATA CI_END="5.848848523008879" CI_START="-0.24884852300887994" EFFECT_SIZE="2.8" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="0.5" ORDER="27880" SD_1="9.07" SD_2="8.8" SE="1.5555635445639857" STUDY_ID="STD-McNulty-2003" TOTAL_1="68" TOTAL_2="64" WEIGHT="7.551436946421776"/>
<CONT_DATA CI_END="2.768323952974888" CI_START="-1.0283239529748878" EFFECT_SIZE="0.87" ESTIMABLE="YES" MEAN_1="-0.05" MEAN_2="-0.92" ORDER="27881" SD_1="8.42" SD_2="8.41" SE="0.9685504264101916" STUDY_ID="STD-Smith-2001" TOTAL_1="149" TOTAL_2="153" WEIGHT="15.86954473776484"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.818502261064697" CI_START="1.9814977389353035" DF="0.0" EFFECT_SIZE="3.9" ESTIMABLE="YES" I2="0.0" ID="CMP-007.02.02" NO="2" P_CHI2="1.0" P_Z="6.768363973996082E-5" STUDIES="1" TAU2="0.0" TOTAL_1="350" TOTAL_2="114" WEIGHT="15.636484466870037" Z="3.98428487411016">
<NAME>Weight Maintenance Studies</NAME>
<CONT_DATA CI_END="5.818502261064697" CI_START="1.9814977389353035" EFFECT_SIZE="3.9" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="-0.5" ORDER="27882" SD_1="9.6" SD_2="8.9" SE="0.9788456707355836" STUDY_ID="STD-James-2000" TOTAL_1="350" TOTAL_2="114" WEIGHT="15.636484466870037"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2008-11-01 16:18:16 +0100" MODIFIED_BY="Gudrun Paletta" NO="8">
<NAME>Sibutramine: Change in Lipid Parameters</NAME>
<CONT_OUTCOME CHI2="8.751626704036507" CI_END="0.07824319052359502" CI_START="0.006718103555729292" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.04248064703966215" ESTIMABLE="YES" I2="54.29421140466283" I2_Q="87.3679426747994" ID="CMP-008.01" MODIFIED="2008-11-01 16:18:16 +0100" MODIFIED_BY="Gudrun Paletta" NO="1" P_CHI2="0.06761652790380523" P_Q="0.004898974854218974" P_Z="0.01990418072852268" Q="7.916366861358582" RANDOM="YES" SCALE="0.5" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="8.179740345768211E-4" TOTALS="YES" TOTAL_1="561" TOTAL_2="416" UNITS="" WEIGHT="100.0" Z="2.328149234550462">
<NAME>Sibutramine: Change in HDL cholesterol (mmol/L)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.8352598426779252" CI_END="0.09851550771235414" CI_START="0.026456878402508918" DF="3.0" EFFECT_SIZE="0.06248619305743153" ESTIMABLE="YES" I2="0.0" ID="CMP-008.01.01" NO="1" P_CHI2="0.8410161411619983" P_Z="6.75843633399135E-4" STUDIES="4" TAU2="0.0" TOTAL_1="480" TOTAL_2="338" WEIGHT="59.79231851903522" Z="3.3991956021525285">
<NAME>Weight Loss Studies</NAME>
<CONT_DATA CI_END="0.1078717022892712" CI_START="-0.007871702289271226" EFFECT_SIZE="0.04999999999999999" ESTIMABLE="YES" MEAN_1="0.15" MEAN_2="0.1" ORDER="27883" SD_1="0.26" SD_2="0.29" SE="0.029526921283123474" STUDY_ID="STD-Hauner-2004" TOTAL_1="174" TOTAL_2="174" WEIGHT="19.702527359876317"/>
<CONT_DATA CI_END="0.1597113614875042" CI_START="2.886385124958313E-4" EFFECT_SIZE="0.08000000000000002" ESTIMABLE="YES" MEAN_1="0.14" MEAN_2="0.06" ORDER="27884" SD_1="0.26" SD_2="0.26" SE="0.04066980930071023" STUDY_ID="STD-McMahon-2000" TOTAL_1="133" TOTAL_2="59" WEIGHT="13.468239949656319"/>
<CONT_DATA CI_END="0.1803763567787439" CI_START="-3.7635677874389706E-4" EFFECT_SIZE="0.09" ESTIMABLE="YES" MEAN_1="0.12" MEAN_2="0.03" ORDER="27885" SD_1="0.3" SD_2="0.3" SE="0.0461112334163388" STUDY_ID="STD-McMahon-2002" TOTAL_1="129" TOTAL_2="63" WEIGHT="11.308119117877926"/>
<CONT_DATA CI_END="0.1221780210233278" CI_START="-0.02217802102332779" EFFECT_SIZE="0.05" ESTIMABLE="YES" MEAN_1="0.02" MEAN_2="-0.03" ORDER="27886" SD_1="0.19" SD_2="0.15" SE="0.03682619762029242" STUDY_ID="STD-Sanchez_x002d_Reyes-2004" TOTAL_1="44" TOTAL_2="42" WEIGHT="15.313432091624655"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.016218517173719624" CI_START="0.003781482826280373" DF="0.0" EFFECT_SIZE="0.009999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-008.01.02" NO="2" P_CHI2="1.0" P_Z="0.0016225688433999252" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="78" WEIGHT="40.20768148096478" Z="3.1518188818761366">
<NAME>Weight Maintenance Studies</NAME>
<CONT_DATA CI_END="0.016218517173719624" CI_START="0.003781482826280373" EFFECT_SIZE="0.009999999999999998" ESTIMABLE="YES" MEAN_1="0.03" MEAN_2="0.02" ORDER="27887" SD_1="0.02" SD_2="0.02" SE="0.0031727711441488183" STUDY_ID="STD-Apfelbaum-1999" TOTAL_1="81" TOTAL_2="78" WEIGHT="40.20768148096478"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1197585763516646" CI_END="-0.06550206567524636" CI_START="-0.29838261645638575" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.18194234106581605" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.02" MODIFIED="2008-11-01 16:18:16 +0100" MODIFIED_BY="Gudrun Paletta" NO="2" P_CHI2="0.7723065894994192" P_Q="0.653333233425881" P_Z="0.0021948329718827343" Q="0.2017235566494613" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="428" TOTAL_2="357" UNITS="" WEIGHT="100.0" Z="3.062517969454947">
<NAME>Sibutramine: Change in Triglycerides (mmol/L)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.9180350197022034" CI_END="-0.03106514941541011" CI_START="-0.397714933191221" DF="2.0" EFFECT_SIZE="-0.21439004130331554" ESTIMABLE="YES" I2="0.0" ID="CMP-008.02.01" NO="1" P_CHI2="0.6319042127914379" P_Z="0.021900573640442723" STUDIES="3" TAU2="0.0" TOTAL_1="347" TOTAL_2="279" WEIGHT="40.342571066366354" Z="2.292087862544513">
<NAME>Weight Loss Studies</NAME>
<CONT_DATA CI_END="0.08812702415578427" CI_START="-0.6881270241557842" EFFECT_SIZE="-0.3" ESTIMABLE="YES" MEAN_1="-0.11" MEAN_2="0.19" ORDER="27888" SD_1="0.85" SD_2="2.47" SE="0.19802763072040133" STUDY_ID="STD-Hauner-2004" TOTAL_1="174" TOTAL_2="174" WEIGHT="9.000335173366272"/>
<CONT_DATA CI_END="-0.001046562827182157" CI_START="-0.4589534371728178" EFFECT_SIZE="-0.22999999999999998" ESTIMABLE="YES" MEAN_1="-0.31" MEAN_2="-0.08" ORDER="27889" SD_1="0.76" SD_2="0.76" SE="0.11681512465472495" STUDY_ID="STD-McMahon-2002" TOTAL_1="129" TOTAL_2="63" WEIGHT="25.864977935610185"/>
<CONT_DATA CI_END="0.49753269620688134" CI_START="-0.49753269620688134" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-0.2" ORDER="27890" SD_1="1.36" SD_2="0.97" SE="0.25384787686475657" STUDY_ID="STD-Sanchez_x002d_Reyes-2004" TOTAL_1="44" TOTAL_2="42" WEIGHT="5.477257957389893"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.009245266387071932" CI_START="-0.31075473361292805" DF="0.0" EFFECT_SIZE="-0.16" ESTIMABLE="YES" I2="0.0" ID="CMP-008.02.02" NO="2" P_CHI2="1.0" P_Z="0.03751069503050038" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="78" WEIGHT="59.65742893363364" Z="2.080161796654299">
<NAME>Weight Maintenance Studies</NAME>
<CONT_DATA CI_END="-0.009245266387071932" CI_START="-0.31075473361292805" EFFECT_SIZE="-0.16" ESTIMABLE="YES" MEAN_1="-0.05" MEAN_2="0.11" ORDER="27891" SD_1="0.42" SD_2="0.54" SE="0.07691709378440735" STUDY_ID="STD-Apfelbaum-1999" TOTAL_1="81" TOTAL_2="78" WEIGHT="59.65742893363364"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>Sibutramine: Subgroup Analysis in Diabetes</NAME>
<CONT_OUTCOME CHI2="0.2943286382501741" CI_END="-3.7778997525979516" CI_START="-6.198728005452603" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.988313879025277" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.01" NO="1" P_CHI2="0.8631521457980631" P_Q="1.0" P_Z="6.619967943689846E-16" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="223" TOTAL_2="227" UNITS="" WEIGHT="100.0" Z="8.077331000199504">
<NAME>Change in Weight (%)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.020084717419613" CI_START="-7.779915282580388" EFFECT_SIZE="-4.9" ESTIMABLE="YES" MEAN_1="-7.3" MEAN_2="-2.4" ORDER="27892" SD_1="11.18" SD_2="11.18" SE="1.469371531975481" STUDY_ID="STD-Kaukua-2003" TOTAL_1="111" TOTAL_2="121" WEIGHT="17.664792576776787"/>
<CONT_DATA CI_END="-3.72461802592745" CI_START="-6.495381974072549" EFFECT_SIZE="-5.109999999999999" ESTIMABLE="YES" MEAN_1="-5.31" MEAN_2="-0.2" ORDER="27893" SD_1="4.12" SD_2="4.0" SE="0.7068405261526568" STUDY_ID="STD-McNulty-2003" TOTAL_1="68" TOTAL_2="64" WEIGHT="76.3359126314863"/>
<CONT_DATA CI_END="1.241785402865009" CI_START="-8.64178540286501" EFFECT_SIZE="-3.7" ESTIMABLE="YES" MEAN_1="-5.5" MEAN_2="-1.8" ORDER="27894" SD_1="12.9" SD_2="10.4" SE="2.5213654137755497" STUDY_ID="STD-Sanchez_x002d_Reyes-2004" TOTAL_1="44" TOTAL_2="42" WEIGHT="5.9992947917369275"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.272160115320551" CI_END="-3.636090502459231" CI_START="-6.17757352903787" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.9068320157485505" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.02" NO="2" P_CHI2="0.529363462957773" P_Q="1.0" P_Z="3.7845831767904775E-14" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="223" TOTAL_2="227" UNITS="" WEIGHT="100.0" Z="7.568190641825368">
<NAME>Change in Weight (kg)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.8570723793135264" CI_START="-7.142927620686473" EFFECT_SIZE="-4.5" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-2.6" ORDER="27895" SD_1="10.26" SD_2="10.26" SE="1.348457237752096" STUDY_ID="STD-Kaukua-2003" TOTAL_1="111" TOTAL_2="121" WEIGHT="23.11766129673556"/>
<CONT_DATA CI_END="-3.7688040779976144" CI_START="-6.831195922002385" EFFECT_SIZE="-5.3" ESTIMABLE="YES" MEAN_1="-5.5" MEAN_2="-0.2" ORDER="27896" SD_1="4.95" SD_2="4.0" SE="0.7812367645937698" STUDY_ID="STD-McNulty-2003" TOTAL_1="68" TOTAL_2="64" WEIGHT="68.8736197079735"/>
<CONT_DATA CI_END="1.7903034388514834" CI_START="-7.190303438851483" EFFECT_SIZE="-2.6999999999999997" ESTIMABLE="YES" MEAN_1="-4.1" MEAN_2="-1.4" ORDER="27897" SD_1="10.45" SD_2="10.78" SE="2.2910132401770764" STUDY_ID="STD-Sanchez_x002d_Reyes-2004" TOTAL_1="44" TOTAL_2="42" WEIGHT="8.008718995290945"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" NO="10">
<NAME>Sibutramine: Change in Heart Rate</NAME>
<CONT_OUTCOME CHI2="5.386911470124203" CI_END="5.573876037360762" CI_START="3.489427666981035" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="MD" EFFECT_SIZE="4.531651852170898" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.01" NO="1" P_CHI2="0.4952291353817795" P_Q="0.3351091100692961" P_Z="1.567695303171325E-17" Q="0.9290536303146286" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="951" TOTAL_2="707" UNITS="" WEIGHT="99.99999999999999" Z="8.522038297462043">
<NAME>Change in Heart Rate (beats/min)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.6418584189951035" CI_END="5.448139324641787" CI_START="2.8641975763965823" DF="4.0" EFFECT_SIZE="4.156168450519185" ESTIMABLE="YES" I2="0.0" ID="CMP-010.01.01" NO="1" P_CHI2="0.6194264412639305" P_Z="2.8810157170258785E-10" STUDIES="5" TAU2="0.0" TOTAL_1="520" TOTAL_2="515" WEIGHT="65.07540018915189" Z="6.3050496260074596">
<NAME>Weight Loss Studies</NAME>
<CONT_DATA CI_END="5.384943057990515" CI_START="0.21505694200948478" EFFECT_SIZE="2.8" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="-0.9" ORDER="27898" SD_1="12.5" SD_2="12.1" SE="1.3188727335707269" STUDY_ID="STD-Hauner-2004" TOTAL_1="174" TOTAL_2="174" WEIGHT="16.256248606842593"/>
<CONT_DATA CI_END="6.278793947265092" CI_START="2.121206052734908" EFFECT_SIZE="4.2" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="1.3" ORDER="27899" SD_1="8.07" SD_2="8.07" SE="1.0606286460681693" STUDY_ID="STD-Kaukua-2003" TOTAL_1="111" TOTAL_2="121" WEIGHT="25.136187458078496"/>
<CONT_DATA CI_END="9.226933375848148" CI_START="2.5730666241518514" EFFECT_SIZE="5.8999999999999995" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="-0.8" ORDER="27900" SD_1="9.9" SD_2="9.6" SE="1.6974461786494925" STUDY_ID="STD-McNulty-2003" TOTAL_1="68" TOTAL_2="64" WEIGHT="9.813729564088822"/>
<CONT_DATA CI_END="9.295186851518338" CI_START="1.5048131484816616" EFFECT_SIZE="5.3999999999999995" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="-0.6" ORDER="27901" SD_1="9.85" SD_2="8.56" SE="1.9873767488806298" STUDY_ID="STD-Sanchez_x002d_Reyes-2004" TOTAL_1="44" TOTAL_2="42" WEIGHT="7.159219907683778"/>
<CONT_DATA CI_END="7.423457448439562" CI_START="-0.6234574484395625" EFFECT_SIZE="3.4" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="0.1" ORDER="27902" SD_1="15.79" SD_2="15.79" SE="2.0528221335575965" STUDY_ID="STD-Smith-2001" TOTAL_1="123" TOTAL_2="114" WEIGHT="6.710014652458204"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.815999420814471" CI_END="7.9391342117566115" CI_START="2.9446699227303843" DF="1.0" EFFECT_SIZE="5.441902067243498" ESTIMABLE="YES" I2="44.93390314235328" ID="CMP-010.01.02" NO="2" P_CHI2="0.17779037115199736" P_Z="1.9450981395142796E-5" STUDIES="2" TAU2="1.5187659262115412" TOTAL_1="431" TOTAL_2="192" WEIGHT="34.92459981084809" Z="4.271101540409999">
<NAME>Weight Maintenance Studies</NAME>
<CONT_DATA CI_END="10.118923333322918" CI_START="3.881076666677082" EFFECT_SIZE="7.0" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="1.0" ORDER="27903" SD_1="11.0" SD_2="9.0" SE="1.5913166557776506" STUDY_ID="STD-Apfelbaum-1999" TOTAL_1="81" TOTAL_2="78" WEIGHT="11.166392645498034"/>
<CONT_DATA CI_END="6.538229487476996" CI_START="2.261770512523003" EFFECT_SIZE="4.3999999999999995" ESTIMABLE="YES" MEAN_1="4.6" MEAN_2="0.2" ORDER="27904" SD_1="11.3" SD_2="9.7" SE="1.0909534585038694" STUDY_ID="STD-James-2000" TOTAL_1="350" TOTAL_2="114" WEIGHT="23.758207165350058"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" NO="11">
<NAME>Rimonabant: Anthropometric Outcomes</NAME>
<CONT_OUTCOME CHI2="7.9863211142224735" CI_END="-4.070429794694846" CI_START="-5.2596889231835" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.665059358939173" ESTIMABLE="YES" I2="62.435770399246316" I2_Q="0.0" ID="CMP-011.01" NO="1" P_CHI2="0.04629536559439884" P_Q="1.0" P_Z="2.351655638839914E-53" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.22624120637486872" TOTALS="YES" TOTAL_1="2500" TOTAL_2="1599" UNITS="" WEIGHT="100.0" Z="15.376545128363961">
<NAME>Rimonabant: Change in Weight (kg)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.2266121418827476" CI_START="-4.573387858117252" EFFECT_SIZE="-3.9" ESTIMABLE="YES" MEAN_1="-5.3" MEAN_2="-1.4" ORDER="27905" SD_1="5.2" SD_2="3.6" SE="0.34357154694109177" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="336" TOTAL_2="345" WEIGHT="26.735094399659676"/>
<CONT_DATA CI_END="-3.8789434529486204" CI_START="-5.721056547051379" EFFECT_SIZE="-4.8" ESTIMABLE="YES" MEAN_1="-6.6" MEAN_2="-1.8" ORDER="27906" SD_1="7.2" SD_2="6.4" SE="0.46993544489416944" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="305" WEIGHT="20.587852970951996"/>
<CONT_DATA CI_END="-4.566974337860878" CI_START="-6.233025662139123" EFFECT_SIZE="-5.4" ESTIMABLE="YES" MEAN_1="-6.9" MEAN_2="-1.5" ORDER="27907" SD_1="6.1" SD_2="5.0" SE="0.4250209027869505" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="342" WEIGHT="22.621751595071142"/>
<CONT_DATA CI_END="-4.145608896648428" CI_START="-5.254391103351571" EFFECT_SIZE="-4.699999999999999" ESTIMABLE="YES" MEAN_1="-6.3" MEAN_2="-1.6" ORDER="27908" SD_1="6.98" SD_2="4.93" SE="0.2828578013292783" STUDY_ID="STD-RIO_x002d_North-America" TOTAL_1="1219" TOTAL_2="607" WEIGHT="30.055301034317193"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.169305282278336" CI_END="0.3744086392611832" CI_START="0.285425602318764" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.3299171207899736" ESTIMABLE="YES" EVENTS_1="1265" EVENTS_2="297" I2="58.15494135232823" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="-0.4266541387262085" LOG_CI_START="-0.5445070738034654" LOG_EFFECT_SIZE="-0.4815951464986718" METHOD="MH" NO="2" P_CHI2="0.0666929260755269" P_Q="0.0" P_Z="7.412426776564769E-48" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0011854514891749969" TOTALS="YES" TOTAL_1="2500" TOTAL_2="1599" WEIGHT="100.00000000000001" Z="14.533684100935545">
<NAME>Rimonabant: 5% Responders (absolute % difference)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.4142174726166858" CI_START="0.2840226930147843" EFFECT_SIZE="0.34912008281573503" ESTIMABLE="YES" EVENTS_1="166" EVENTS_2="50" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27909" O_E="0.0" SE="0.033213564287114784" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="336" TOTAL_2="345" VAR="0.0011031408526543068" WEIGHT="22.515927110494026"/>
<DICH_DATA CI_END="0.37547070680736894" CI_START="0.2560079871908246" EFFECT_SIZE="0.3157393469990968" ESTIMABLE="YES" EVENTS_1="305" EVENTS_2="59" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27910" O_E="0.0" SE="0.030475743574588883" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="305" VAR="9.287709464240955E-4" WEIGHT="24.372921924679982"/>
<DICH_DATA CI_END="0.4547443901058973" CI_START="0.32107280220049483" EFFECT_SIZE="0.38790859615319606" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="67" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27911" O_E="0.0" SE="0.03410052147891156" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="342" VAR="0.0011628455651337083" WEIGHT="21.943466760185"/>
<DICH_DATA CI_END="0.32869694763225904" CI_START="0.24390895046932587" EFFECT_SIZE="0.28630294905079245" ESTIMABLE="YES" EVENTS_1="592" EVENTS_2="121" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27912" O_E="0.0" SE="0.021629988569108943" STUDY_ID="STD-RIO_x002d_North-America" TOTAL_1="1219" TOTAL_2="607" VAR="4.678564054997835E-4" WEIGHT="31.167684204641002"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.141795999268203" CI_END="0.229506844203116" CI_START="0.14566961728332395" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.18758823074321998" ESTIMABLE="YES" EVENTS_1="639" EVENTS_2="106" I2="73.07435892564322" I2_Q="0.0" ID="CMP-011.03" LOG_CI_END="-0.6392043586873937" LOG_CI_START="-0.836631020791202" LOG_EFFECT_SIZE="-0.7267944126713154" METHOD="MH" NO="3" P_CHI2="0.010983341173526062" P_Q="0.0" P_Z="1.7716085087705178E-18" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0013169435815629416" TOTALS="YES" TOTAL_1="2500" TOTAL_2="1599" WEIGHT="100.0" Z="8.770952706535738">
<NAME>Rimonabant: 10% Responders (absolute % difference)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.1856671065342823" CI_START="0.10113413570174257" EFFECT_SIZE="0.14340062111801244" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27913" O_E="0.0" SE="0.02156492963629052" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="336" TOTAL_2="345" VAR="4.650461902181612E-4" WEIGHT="25.66920563779334"/>
<DICH_DATA CI_END="0.24768100861294876" CI_START="0.15563599513646972" EFFECT_SIZE="0.20165850187470924" ESTIMABLE="YES" EVENTS_1="164" EVENTS_2="22" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27914" O_E="0.0" SE="0.023481302259255356" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="305" VAR="5.513715557905107E-4" WEIGHT="24.483161850890642"/>
<DICH_DATA CI_END="0.3100835794059827" CI_START="0.1968967809361057" EFFECT_SIZE="0.2534901801710442" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27915" O_E="0.0" SE="0.02887471386277504" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="342" VAR="8.337491006571331E-4" WEIGHT="21.268618373256206"/>
<DICH_DATA CI_END="0.1991858103931294" CI_START="0.1331713084270881" EFFECT_SIZE="0.16617855941010876" ESTIMABLE="YES" EVENTS_1="307" EVENTS_2="52" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27916" O_E="0.0" SE="0.016840743627626643" STUDY_ID="STD-RIO_x002d_North-America" TOTAL_1="1219" TOTAL_2="607" VAR="2.836106459314474E-4" WEIGHT="28.57901413805982"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="5.4159620937516975" CI_END="-3.3047159328985574" CI_START="-4.466310276156593" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.885513104527575" ESTIMABLE="YES" I2="44.6081795243536" I2_Q="0.0" ID="CMP-011.04" NO="4" P_CHI2="0.1437523917660265" P_Q="1.0" P_Z="2.8074721943097486E-39" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.15620389555808503" TOTALS="YES" TOTAL_1="2500" TOTAL_2="1598" UNITS="" WEIGHT="100.0" Z="13.112091653223159">
<NAME>Rimonabant: Change in Waist Circumference (cm)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.4263745653344206" CI_START="-4.1736254346655794" EFFECT_SIZE="-3.3000000000000003" ESTIMABLE="YES" MEAN_1="-5.2" MEAN_2="-1.9" ORDER="27917" SD_1="6.1" SD_2="5.5" SE="0.4457354530780287" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="336" TOTAL_2="344" WEIGHT="24.74379999293699"/>
<CONT_DATA CI_END="-3.1248959695421252" CI_START="-5.075104030457874" EFFECT_SIZE="-4.1" ESTIMABLE="YES" MEAN_1="-6.5" MEAN_2="-2.4" ORDER="27918" SD_1="7.4" SD_2="6.9" SE="0.49751119824107504" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="305" WEIGHT="21.750595581681996"/>
<CONT_DATA CI_END="-3.7628141261449226" CI_START="-5.637185873855076" EFFECT_SIZE="-4.699999999999999" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-2.4" ORDER="27919" SD_1="6.8" SD_2="5.7" SE="0.4781648444805513" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="342" WEIGHT="22.817411508906922"/>
<CONT_DATA CI_END="-2.893493402346917" CI_START="-4.306506597653082" EFFECT_SIZE="-3.5999999999999996" ESTIMABLE="YES" MEAN_1="-6.1" MEAN_2="-2.5" ORDER="27920" SD_1="6.98" SD_2="7.39" SE="0.36046917352865493" STUDY_ID="STD-RIO_x002d_North-America" TOTAL_1="1219" TOTAL_2="607" WEIGHT="30.68819291647409"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" NO="12">
<NAME>Rimonabant: Change in Blood Pressure</NAME>
<CONT_OUTCOME CHI2="0.6921071336885565" CI_END="-0.7642001911004948" CI_START="-2.805341284122516" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.7847707376115054" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.01" NO="1" P_CHI2="0.7074746760852064" P_Q="1.0" P_Z="6.089886580578379E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1281" TOTAL_2="992" UNITS="" WEIGHT="100.0" Z="3.427579189246961">
<NAME>Rimonabant: Change in Systolic Blood Pressure (mm Hg)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.4472398467774088" CI_START="-4.352760153222592" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="1.6" ORDER="27921" SD_1="12.8" SD_2="13.2" SE="0.9963245083204153" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="336" TOTAL_2="345" WEIGHT="27.3141853348867"/>
<CONT_DATA CI_END="0.4051508757478901" CI_START="-3.00515087574789" EFFECT_SIZE="-1.3" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="0.3" ORDER="27922" SD_1="12.5" SD_2="12.3" SE="0.869990922893432" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="305" WEIGHT="35.82287487956296"/>
<CONT_DATA CI_END="-0.11907611974918053" CI_START="-3.4809238802508196" EFFECT_SIZE="-1.8" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="-0.3" ORDER="27923" SD_1="12.3" SD_2="10.1" SE="0.8576299837699736" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="342" WEIGHT="36.86293978555034"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.34537720125065147" CI_END="-0.5372978894169279" CI_START="-1.928883074215352" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.23309048181614" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.02" NO="2" P_CHI2="0.8413996171320657" P_Q="1.0" P_Z="5.137796439379402E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1281" TOTAL_2="992" UNITS="" WEIGHT="100.0" Z="3.4734674678055883">
<NAME>Rimonabant: Change in Diastolic Blood Pressure (mm Hg)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.04676016918708559" CI_START="-2.4467601691870855" EFFECT_SIZE="-1.2" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-0.7" ORDER="27924" SD_1="8.2" SD_2="8.4" SE="0.6361138158769093" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="336" TOTAL_2="345" WEIGHT="31.145389264393962"/>
<CONT_DATA CI_END="0.18126794702439253" CI_START="-2.1812679470243923" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="0.1" ORDER="27925" SD_1="8.7" SD_2="8.5" SE="0.6026988028056043" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="305" WEIGHT="34.69467007813561"/>
<CONT_DATA CI_END="-0.30952234821125413" CI_START="-2.690477651788746" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="-0.2" ORDER="27926" SD_1="8.5" SD_2="7.4" SE="0.6073977181106804" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="342" WEIGHT="34.159940657470415"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" NO="13">
<NAME>Rimonabant: Change in Lipid Parameters</NAME>
<CONT_OUTCOME CHI2="0.12197912965429868" CI_END="0.0265795037566375" CI_START="-0.10849008346709668" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.040955289855229594" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.01" NO="1" P_CHI2="0.9408330641644127" P_Q="1.0" P_Z="0.23460274068615194" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1262" TOTAL_2="961" UNITS="" WEIGHT="99.99999999999999" Z="1.1885857466890013">
<NAME>Rimonabant: Change in Total Cholesterol (mmol/L)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.07274871928395718" CI_START="-0.19274871928395718" EFFECT_SIZE="-0.060000000000000005" ESTIMABLE="YES" MEAN_1="0.04" MEAN_2="0.1" ORDER="27927" SD_1="0.82" SD_2="0.88" SE="0.06773018296818825" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="317" TOTAL_2="314" WEIGHT="25.881799844292114"/>
<CONT_DATA CI_END="0.0739480373924843" CI_START="-0.1339480373924843" EFFECT_SIZE="-0.03" ESTIMABLE="YES" MEAN_1="0.05" MEAN_2="0.08" ORDER="27928" SD_1="0.7" SD_2="0.78" SE="0.0530356874985526" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="305" WEIGHT="42.21070113628824"/>
<CONT_DATA CI_END="0.0795587029003128" CI_START="-0.15955870290031282" EFFECT_SIZE="-0.04000000000000001" ESTIMABLE="YES" MEAN_1="0.09" MEAN_2="0.13" ORDER="27929" SD_1="0.8" SD_2="0.8" SE="0.061000459112196245" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="342" WEIGHT="31.907499019419635"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.2497437788017993" CI_END="0.010053070834812862" CI_START="-0.11929086868354005" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.05461889892436359" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.02" NO="2" P_CHI2="0.5353303370443621" P_Q="1.0" P_Z="0.09786502824094784" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1262" TOTAL_2="961" UNITS="" WEIGHT="100.0" Z="1.6552932462954157">
<NAME>Rimonabant: Change in LDL Cholesterol (mmol/L)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.08095153819035936" CI_START="-0.16095153819035937" EFFECT_SIZE="-0.04000000000000001" ESTIMABLE="YES" MEAN_1="0.09" MEAN_2="0.13" ORDER="27930" SD_1="0.79" SD_2="0.76" SE="0.06171110242045755" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="317" TOTAL_2="314" WEIGHT="28.589686020489857"/>
<CONT_DATA CI_END="0.00336429347304279" CI_START="-0.1833642934730428" EFFECT_SIZE="-0.09000000000000001" ESTIMABLE="YES" MEAN_1="0.08" MEAN_2="0.17" ORDER="27931" SD_1="0.63" SD_2="0.7" SE="0.04763571892620907" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="305" WEIGHT="47.981138351297375"/>
<CONT_DATA CI_END="0.13360957569387227" CI_START="-0.13360957569387227" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.25" MEAN_2="0.25" ORDER="27932" SD_1="0.98" SD_2="0.8" SE="0.06816940349300679" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="342" WEIGHT="23.42917562821276"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.2167835287578794" CI_END="0.10917910637101882" CI_START="0.08222027950865801" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.09569969293983842" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.03" NO="3" P_CHI2="0.7489818781403715" P_Q="1.0" P_Z="5.125805983536855E-44" Q="0.0" RANDOM="YES" SCALE="0.5" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2482" TOTAL_2="1568" UNITS="" WEIGHT="100.0" Z="13.915141964541698">
<NAME>Rimonabant: Change in HDL Cholesterol (mmol/L)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.12754026391270956" CI_START="0.07245973608729045" EFFECT_SIZE="0.1" ESTIMABLE="YES" MEAN_1="0.17" MEAN_2="0.07" ORDER="27933" SD_1="0.2" SD_2="0.15" SE="0.014051413255520834" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="318" TOTAL_2="314" WEIGHT="23.95553047568761"/>
<CONT_DATA CI_END="0.1431632266090892" CI_START="0.07683677339091083" EFFECT_SIZE="0.11000000000000001" ESTIMABLE="YES" MEAN_1="0.26" MEAN_2="0.15" ORDER="27934" SD_1="0.26" SD_2="0.23" SE="0.016920324490999065" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="305" WEIGHT="16.520699461348254"/>
<CONT_DATA CI_END="0.1201982749164458" CI_START="0.05980172508355419" EFFECT_SIZE="0.09" ESTIMABLE="YES" MEAN_1="0.21" MEAN_2="0.12" ORDER="27935" SD_1="0.23" SD_2="0.17" SE="0.01540756623828088" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="342" WEIGHT="19.92405439822194"/>
<CONT_DATA CI_END="0.11142027095354883" CI_START="0.06857972904645117" EFFECT_SIZE="0.09" ESTIMABLE="YES" MEAN_1="0.16" MEAN_2="0.07" ORDER="27936" SD_1="0.22" SD_2="0.22" SE="0.0109289104914729" STUDY_ID="STD-RIO_x002d_North-America" TOTAL_1="1219" TOTAL_2="607" WEIGHT="39.59971566474219"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.148921074750443" CI_END="-0.1670104548364712" CI_START="-0.3043200535555159" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.23566525419599355" ESTIMABLE="YES" I2="41.73536637196553" I2_Q="0.0" ID="CMP-013.04" NO="4" P_CHI2="0.16121185143361239" P_Q="1.0" P_Z="1.7225345550410655E-11" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0020086404652300844" TOTALS="YES" TOTAL_1="2481" TOTAL_2="1568" UNITS="" WEIGHT="100.0" Z="6.727794923889175">
<NAME>Rimonabant: Change in Triglycerides (mmol/L)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.219370936266823" CI_START="-0.5606290637331769" EFFECT_SIZE="-0.38999999999999996" ESTIMABLE="YES" MEAN_1="-0.35" MEAN_2="0.04" ORDER="27937" SD_1="1.28" SD_2="0.87" SE="0.0870572444591213" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="317" TOTAL_2="314" WEIGHT="12.797805985922404"/>
<CONT_DATA CI_END="-0.0980722164818621" CI_START="-0.2819277835181379" EFFECT_SIZE="-0.19" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-0.01" ORDER="27938" SD_1="0.64" SD_2="0.68" SE="0.04690279221621036" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="305" WEIGHT="29.155266340327692"/>
<CONT_DATA CI_END="-0.1458486026526401" CI_START="-0.39415139734735993" EFFECT_SIZE="-0.27" ESTIMABLE="YES" MEAN_1="-0.27" MEAN_2="0.0" ORDER="27939" SD_1="0.87" SD_2="0.79" SE="0.06334371362262281" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="342" WEIGHT="20.378499223962468"/>
<CONT_DATA CI_END="-0.13073981861273815" CI_START="-0.2692601813872619" EFFECT_SIZE="-0.2" ESTIMABLE="YES" MEAN_1="-0.08" MEAN_2="0.12" ORDER="27940" SD_1="0.65" SD_2="0.74" SE="0.03533747657282344" STUDY_ID="STD-RIO_x002d_North-America" TOTAL_1="1219" TOTAL_2="607" WEIGHT="37.668428449787434"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" NO="14">
<NAME>Rimonabant: Adverse Events</NAME>
<DICH_OUTCOME CHI2="2.5986319327191887" CI_END="0.08387721680382497" CI_START="0.04563473055460247" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.06475597367921372" ESTIMABLE="YES" EVENTS_1="350" EVENTS_2="122" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="-1.0763559886358127" LOG_CI_START="-1.340704509371699" LOG_EFFECT_SIZE="-1.188720162130835" METHOD="MH" NO="1" P_CHI2="0.4577294823526251" P_Q="0.0" P_Z="3.1880758790278614E-11" Q="0.0" RANDOM="YES" SCALE="0.5" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2503" TOTAL_2="1602" WEIGHT="100.00000000000001" Z="6.637611130613296">
<NAME>Rimonabant: Discontinuation due to Adverse Event (Absolute % Difference)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.14076787826888115" CI_START="0.05092167518448069" EFFECT_SIZE="0.09584477672668092" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="19" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27941" O_E="0.0" SE="0.02292037093362323" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="339" TOTAL_2="348" VAR="5.253434037348805E-4" WEIGHT="18.117271035588786"/>
<DICH_DATA CI_END="0.09640712381413105" CI_START="0.010470459042542651" EFFECT_SIZE="0.05343879142833685" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="28" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27942" O_E="0.0" SE="0.02192302140484362" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="305" VAR="4.8061886751723165E-4" WEIGHT="19.80319433023993"/>
<DICH_DATA CI_END="0.1205212300079053" CI_START="0.021891642249810293" EFFECT_SIZE="0.0712064361288578" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="31" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27943" O_E="0.0" SE="0.02516107146255559" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="342" VAR="6.330795171438294E-4" WEIGHT="15.0341127369964"/>
<DICH_DATA CI_END="0.08336383688854836" CI_START="0.027608372757460132" EFFECT_SIZE="0.05548610482300424" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="44" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27944" O_E="0.0" SE="0.014223594048380533" STUDY_ID="STD-RIO_x002d_North-America" TOTAL_1="1219" TOTAL_2="607" VAR="2.0231062765312612E-4" WEIGHT="47.0454218971749"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.672570940364094" CI_END="0.028824602916369985" CI_START="0.0026393744464716044" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.015731988681420794" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="67" I2="0.0" I2_Q="0.0" ID="CMP-014.02" LOG_CI_END="-1.5402366667710672" LOG_CI_START="-2.5784989923110464" LOG_EFFECT_SIZE="-1.8032163747208632" METHOD="MH" NO="2" P_CHI2="0.6430490969710916" P_Q="0.0" P_Z="0.018518804791895677" Q="0.0" RANDOM="YES" SCALE="0.5" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2503" TOTAL_2="1602" WEIGHT="100.0" Z="2.355078265306898">
<NAME>Rimonabant: Serious Adverse Event (Absolute % Difference)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.07240259026508217" CI_START="6.825485814237753E-4" EFFECT_SIZE="0.03654256942325297" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27945" O_E="0.0" SE="0.018296265199099812" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="339" TOTAL_2="348" VAR="3.3475332023579087E-4" WEIGHT="13.330046625113638"/>
<DICH_DATA CI_END="0.048638069467586656" CI_START="-0.025835037091221688" EFFECT_SIZE="0.011401516188182484" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27946" O_E="0.0" SE="0.01899859057264386" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="305" VAR="3.6094644374695206E-4" WEIGHT="12.362713205682804"/>
<DICH_DATA CI_END="0.043293790296982604" CI_START="-0.009152560536647269" EFFECT_SIZE="0.017070614880167666" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27947" O_E="0.0" SE="0.01337941698095475" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="342" VAR="1.790087987502603E-4" WEIGHT="24.927698514306687"/>
<DICH_DATA CI_END="0.02915428986678839" CI_START="-0.008109141184407684" EFFECT_SIZE="0.010522574341190354" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="21" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27948" O_E="0.0" SE="0.00950615198675212" STUDY_ID="STD-RIO_x002d_North-America" TOTAL_1="1219" TOTAL_2="607" VAR="9.036692559523127E-5" WEIGHT="49.379541654896876"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.6770033931808888" CI_END="0.04508072565302254" CI_START="0.021527152496367694" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.033303939074695116" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-014.03" LOG_CI_END="-1.3460091018413918" LOG_CI_START="-1.6670134126707241" LOG_EFFECT_SIZE="-1.477504396606864" METHOD="MH" NO="3" P_CHI2="0.4441495448394869" P_Q="0.0" P_Z="2.97940278565257E-8" Q="0.0" RANDOM="YES" SCALE="0.5" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2503" TOTAL_2="1602" WEIGHT="100.0" Z="5.542642782526263">
<NAME>Rimonabant: Psychiatric Disorders (Absolute % Difference)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.05235982201826207" CI_START="0.007094963863133512" EFFECT_SIZE="0.029727392940697792" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27949" O_E="0.0" SE="0.011547369878266127" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="339" TOTAL_2="348" VAR="1.3334175110548785E-4" WEIGHT="27.076421942310024"/>
<DICH_DATA CI_END="0.0481594010843079" CI_START="-0.016182609163346726" EFFECT_SIZE="0.015988395960480586" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27950" O_E="0.0" SE="0.016414079736968686" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="305" VAR="2.69422013611566E-4" WEIGHT="13.40060326571504"/>
<DICH_DATA CI_END="0.08199143716522884" CI_START="0.021649167235947498" EFFECT_SIZE="0.05182030220058817" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27951" O_E="0.0" SE="0.015393719069649613" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="342" VAR="2.3696658679529413E-4" WEIGHT="15.235977207949437"/>
<DICH_DATA CI_END="0.05205642089611469" CI_START="0.01666331453939096" EFFECT_SIZE="0.034359867717752825" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="14" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27952" O_E="0.0" SE="0.009029019572782978" STUDY_ID="STD-RIO_x002d_North-America" TOTAL_1="1219" TOTAL_2="607" VAR="8.152319444569812E-5" WEIGHT="44.28699758402549"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>QUOROM statement.</P>
<P>This QUOROM (quality of reporting of meta-analyses) diagram reflects the updated search only (December 2002 to December 2006)</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAkwAAAHFCAIAAACPUTEZAAAmzUlEQVR42u3dK7AdubWAYcMDDwgw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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-02" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Orlistat funnel plot.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAAAAAFUAAKoAAP8AJAAA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-11-01 16:48:50 +0100" MODIFIED_BY="Gudrun Paletta">
<APPENDIX ID="APP-01" MODIFIED="2008-11-01 15:59:36 +0100" MODIFIED_BY="Gudrun Paletta" NO="1">
<TITLE MODIFIED="2008-11-01 15:59:21 +0100" MODIFIED_BY="Gudrun Paletta">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-01 15:59:36 +0100" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD>
<P>Unless otherwise stated, search terms were free text terms; exp = exploded MeSH; the dollar sign ($) stands for any character(s); the question mark (?) = substitute for one or no characters; tw = textword; ab = abstract; ti = titel; kf = Keyword Heading Word; ot = original titel; pt = publication type; sh = MeSH: Medical subject heading (MEDLINE medical index term); adj = adjacency.<BR/>
<BR/>Finally searches were limited to January 2003 to December 2006. Later combined with the findings of the first Cochrane review of this study.<BR/>
<BR/>Part I: Drugs<BR/>1 (orlistat or xenical).tw,ot.<BR/>2 ("Ro 18 0647" or Ro 18-0647 or Ro 180647 or Ro18647).tw,ot.<BR/>3 96829-58-2.rn.<BR/>4 (sibutramin$ or arcalion).tw,ot.<BR/>5 (Bts 54 524 or Bts 54524 or Bts54524).tw,ot.<BR/>6 (reductil or medaria or meridia).tw,ot.<BR/>7 106650-56-0.rn.<BR/>8 (rimonabant or acomplia or zimulti).tw,ot.<BR/>9 (Sr 141716 or Sr141716 or Sr 141716a or Sr141716a).tw,ot.<BR/>10 158681-13-1.rn.<BR/>11 or/1-10<BR/>
<BR/>Part II: RCT/CCT (sensitive search)<BR/>12 exp Randomized Controlled Trials as topic/<BR/>13 Randomized Controlled Trial.pt.<BR/>14 exp Controlled Clinical Trials as topic/<BR/>15 Controlled Clinical Trial.pt.<BR/>16 exp Random Allocation/<BR/>17 exp Double-Blind Method/<BR/>18 exp Single-Blind Method/<BR/>19 or/12-18<BR/>20 exp Clinical Trials as topic/<BR/>21 Clinical Trial.pt.<BR/>22 (clinic$ adj25 trial$).tw,ot.<BR/>23 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (mask$ or blind)).tw,ot.<BR/>24 exp Placebos/<BR/>25 (placebo$ or random).tw,ot.<BR/>26 exp Research Design/<BR/>27 (latin adj3 square).tw,ot.<BR/>28 or/20-27<BR/>29 comparative study.pt.<BR/>30 exp Evaluation Studies as topic/<BR/>31 Evaluation Studies.pt.<BR/>32 exp Follow-Up Studies/<BR/>33 exp Prospective Studies/<BR/>34 (control$ or prospectiv$ or volunteer$).tw,ot.<BR/>35 exp Cross-Over Studies/<BR/>36 or/29-35<BR/>37 19 or 28 or 36<BR/>
<BR/>Part III: I and II<BR/>38 11 and 37<BR/>39 limit 38 to animal<BR/>40 limit 38 to humans<BR/>41 39 not 40<BR/>42 38 not 41<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-11-01 16:45:34 +0100" MODIFIED_BY="Gudrun Paletta" NO="2">
<TITLE MODIFIED="2008-11-01 16:21:12 +0100" MODIFIED_BY="Gudrun Paletta">Methodological quality (Orlistat)</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-01 16:45:34 +0100" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="10" ROWS="17">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Randomization OK</P>
</TH>
<TH>
<P>Allocation Conceal</P>
</TH>
<TH>
<P>Baseline Similarity</P>
</TH>
<TH>
<P>Eligib Crit Spec</P>
</TH>
<TH>
<P>Patient Blinded</P>
</TH>
<TH>
<P>Care Provider Blind</P>
</TH>
<TH>
<P>Outcome Assess Blind</P>
</TH>
<TH>
<P>Primary Outcome Rep</P>
</TH>
<TH>
<P>ITT Analysis</P>
</TH>
</TR>
<TR>
<TD>
<P>Bakris</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Berne</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
</TR>
<TR>
<TD>
<P>Broom</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Davidson</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Derosa</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
</TR>
<TR>
<TD>
<P>Lindgarde</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Krempf</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Finer</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Rossner</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Sjostrom</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Hauptman</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Hollander</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Kelley</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Miles</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Torgerson</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Swinburn</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-11-01 16:45:56 +0100" MODIFIED_BY="Gudrun Paletta" NO="3">
<TITLE MODIFIED="2008-11-01 16:21:22 +0100" MODIFIED_BY="Gudrun Paletta">Methodological quality (Sibutramine)</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-01 16:45:56 +0100" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="10" ROWS="11">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Randomization OK</P>
</TH>
<TH>
<P>Alloc Concealment</P>
</TH>
<TH>
<P>Baseline Similarity</P>
</TH>
<TH>
<P>Eligiblity Crit Spec</P>
</TH>
<TH>
<P>Patient Blinded</P>
</TH>
<TH>
<P>Care Provider Blind</P>
</TH>
<TH>
<P>Outcome Assess Blind</P>
</TH>
<TH>
<P>Primary Outcome Rep</P>
</TH>
<TH>
<P>ITT Analysis</P>
</TH>
</TR>
<TR>
<TD>
<P>Apfelbaum</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Hauner</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>James</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Krakua</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
</TR>
<TR>
<TD>
<P>Mathus-Vliegen</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>McNulty</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>McMahon 2000</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>McMahon 2002</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Sanchez-Reyes</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Smith</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2008-11-01 16:46:10 +0100" MODIFIED_BY="Gudrun Paletta" NO="4">
<TITLE MODIFIED="2008-11-01 16:21:39 +0100" MODIFIED_BY="Gudrun Paletta">Methodological quality (Rimonabant)</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-01 16:46:10 +0100" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="10" ROWS="5">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Randomization OK</P>
</TH>
<TH>
<P>Allocation Conceal</P>
</TH>
<TH>
<P>Baseline Similarity</P>
</TH>
<TH>
<P>Eligib Crit Spec</P>
</TH>
<TH>
<P>Patient Blinded</P>
</TH>
<TH>
<P>Care Provider Blind</P>
</TH>
<TH>
<P>Outcome Assess Blind</P>
</TH>
<TH>
<P>Primary Outcome Rep</P>
</TH>
<TH>
<P>ITT Analysis</P>
</TH>
</TR>
<TR>
<TD>
<P>RIO-Diabetes</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>RIO-Europe</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>RIO-Lipids</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>RIO-NA</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2008-11-01 16:46:21 +0100" MODIFIED_BY="Gudrun Paletta" NO="5">
<TITLE MODIFIED="2008-11-01 16:21:49 +0100" MODIFIED_BY="Gudrun Paletta">Practical approach to prescribing antiobesity drugs</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-01 16:46:21 +0100" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="5" ROWS="4">
<TR>
<TH>
<P>Drug</P>
</TH>
<TH>
<P>Dose</P>
</TH>
<TH>
<P>Potential uses</P>
</TH>
<TH>
<P>Avoid in</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<TR>
<TD>
<P>Orlistat</P>
</TD>
<TD>
<P>120 mg three times daily</P>
</TD>
<TD>
<P>Prediabetes, diabetes, elevated LDL cholesterol, hypertension, pre-existing CVD</P>
</TD>
<TD>
<P>Chronic malabsorption or GI disease</P>
</TD>
<TD>
<P>Prescribe concurrent multivitamin. Half-strength available OTC in US.</P>
</TD>
</TR>
<TR>
<TD>
<P>Sibutramine</P>
</TD>
<TD>
<P>10-15 mg once daily</P>
</TD>
<TD>
<P>Lack of satiety major barrier to weight reduction, dyslipidemia (high triglyceride/low HDL)</P>
</TD>
<TD>
<P>Uncontrolled hypertension, tachycardia, pre-existing CVD</P>
</TD>
<TD>
<P>Monitor blood pressure.</P>
</TD>
</TR>
<TR>
<TD>
<P>Rimonabant</P>
</TD>
<TD>
<P>20 mg once daily</P>
</TD>
<TD>
<P>Dyslipidemia (high triglyceride/low HDL), diabetes, metabolic syndrome, hypertension</P>
</TD>
<TD>
<P>History of psychiatric illness, liver impairment</P>
</TD>
<TD>
<P>Monitor for mood disorders.</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2008-11-01 16:48:50 +0100" MODIFIED_BY="Gudrun Paletta" NO="6">
<TITLE MODIFIED="2008-11-01 16:24:51 +0100" MODIFIED_BY="Gudrun Paletta">Major changes to the first published version of this review</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-01 16:48:50 +0100" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="1" ROWS="2">
<TR>
<TD>
<P>
<B>Overview</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>This is an update of the Cochrane review first published in issue 4, 2003. Major changes include:<BR/>
<BR/>The previous search included head-to-head clinical trials but, due to the length of this review and large number of placebo-controlled studies, the decision was made to focus on placebo-controlled trials only.<BR/>
<BR/>In contrast to the previous version of this review we analysed separately published weight loss and weight maintenance trials together.<BR/>
<BR/>From the date of the last search (December 2002) to December 2006, 29 potentially relevant trials were identified and five orlistat, five sibutramine and four rimonabant studies met final inclusion criteria. These were added to the 11 orlistat and five sibutramine trials previously identified. </P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>